Drug, bio-affecting and body treating compositions inventions 02/07

20070041900 - Method and device for radiotherapy: A radiotherapy method, comprising positioning a predetermined amount of a radionuclide selected from the group consisting of Radium-223, Radium-224, Radon-219 and Radon-220, in proximity to and/or within a tumor of a subject, for a predetermined time period. The predetermined amount and the predetermined time period are selected sufficient for the... Agent: Martin Moynihan Prtsi Inc

20070041899 - Radiolabelled substrates: The present invention relates to radiolabelled P-glycoprotein (P-gp) substrates, which are useful for the labeling and diagnostic imaging of P-gp functionality.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070041901 - Stabilized aptamers to psma and their use as prostate cancer therapeutics: The present invention provides stabilized, high affinity nucleic acid ligands to PSMA. Methods for the identification and preparation of novel, stable, high affinity ligands to PSMA using the SELEX™ method with 2′-O-methyl substituted nucleic acids, and cell surface SELEX™ are described herein. Also included are methods and compositions for the... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070041903 - Modified minigastrin analogs for oncology applications: The invention is directed to modified minigastrin analogs. It further relates to labeling such modified minigastrin analogs with metallic radionuclides. The invention further relates to methods for making such novel modified minigastrin analogs, their labeling with metallic radionuclides and their use in oncology applications as in the targeted diagnostic imaging... Agent: George Georgellis

20070041904 - Peptides whose uptake by cells is controllable: A generic structure for the peptides of the present invention includes A-X-B-C, where C is a cargo moiety, the B portion includes basic amino acids, X is a cleavable linker sequence, and the A portion includes acidic amino acids. The intact structure is not significantly taken up by cells; however,... Agent: Townsend And Townsend And Crew, LLP

20070041902 - Somatostatin analogs with inhibitory activity to growth hormone release: Provided are therapeutic and diagnostic somatostatin analogs including radiotherapeutic and radiodiagnostic Reagents, and methods of making and use thereof.... Agent: Buchanan, Ingersoll & Rooney LLP

20070041905 - Method of treating depression using a tnf-alpha antibody: The invention describes methods of treating depression comprising administering a TNFα antibody, such as a human TNFα antibody. The invention also provides a method for treating depression comprising inhibiting TNFα activity in a subject suffering from depression by systemically administering to the subject a human anti-TNFα antibody, or an antigen-binding... Agent: Lahive & Cockfield, LLP

20070041908 - Injectable composite for the magnetocytolysis of bone metastatic cells: The invention relates to a degradable, biocompatible material which is made from a phosphocalcic cement comprising magnetic particles. Said material can be used to treat bone metastases by means of thermolysis and/or to mark cancer cells.... Agent: Foley And Lardner LLP Suite 500

20070041909 - Nanoparticulate probe for in vivo monitoring of tissue oxygenation: A new class of micro- and nano-particulate paramagnetic spin probes useful for magnetic resonance imaging techniques, including electron paramagnetic resonance (EPR) and magnetic resonance imaging (MRI). The probes are lithium phthalocyanine derivative compounds. Also provided are suspensions and emulsions comprising lithium phthalocyanine derivative probes. Also provided are noninvasive methods for... Agent: Joan N. Drew

20070041906 - Bone substitute composition: An injectable bone mineral substitute material composition with the capability of being hardened in a body fluid in vivo, which comprises at least one calcium phosphate component and at least one calcium sulfate component as a dry mixture mixed with an aqueous liquid, and at least one accelerator, the at... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070041907 - Immunoglobulin molecules with improved characteristics: The present invention provides for IgG1 molecules with improved characteristics. In particular, substitution mutations are provided that, in combination, facilitate improved placental transfer, improved serum half-life and improved FcRn binding. Substitution mutations are also provided, that in combination, can be used to block FcRn function and thereby increase the clearance... Agent: Fulbright & Jaworski L.L.P.

20070041911 - Hfc solution formulations containing salbutamol hydrochloride or salbutamol citrate: This invention relates to stabilized aerosol solution formulations containing acid addition salts of salbutamol, which are suitable for administration by metered dose inhalers (MDIs). More particularly, this invention relates to solution formulations containing one of the aforementioned salts of salbutamol, preferably salbutamol hydrochloride or salbutamol citrate, more preferably one of... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070041910 - Pharmaceutical spray compositions comprising a bioactive agent, at least one volatile silicone and a non-volatile oily phase: Sprayable pharmaceutical compositions suited for improved transdermal penetration contain a) at least one bioactive agent, notably at least one derivative of vitamin D, (b) at least one volatile silicone and c) a non-volatile oily phase, formulated into d) a pharmaceutically acceptable vehicle therefor.... Agent: Buchanan, Ingersoll & Rooney PC

20070041912 - Trospium containing compositions: The invention relates to a method for treating a disease characterized by a constrictive airway comprising administering to a patient in need thereof via inhalation a pharmaceutical composition comprising trospium, wherein said patient achieves an effective therapy for at least 10 hours. The trospium composition is preferably a particulate formulation... Agent: Elmore Patent Law Group, PC

20070041914 - Inhibition of bacterial deposition on oral surfaces: one of A and A′ is a hydrogen atom and the other is selected from a hydrogen atom or a group —(X)nRm; wherein n is i\selected from 0 or 1; provided that when n is 0, m is 1, and when n is 1, m is an integer of 1... Agent: Colgate-palmolive Company

20070041913 - Tooth coating composition: The invention provides a tooth coating composition for beauty and appearance and prevention of dental caries and excellent in the quick drying property, durability, color tone, luster, and removal easiness by using shellac and rosin as main components and a pigment, a pigment dispersant, a dye, an efficacious component having... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070041916 - Preparation containing diol: The invention is a cosmetic or dermatological formulation comprising a) at least one polyol in a concentration of from 0.1 to 20% by weight, based on the total weight of the formulation, and b) at least one diol selected from the group consisting of 2-methyl-1,3-propanediol, pentanediol, and hexanediol, in a... Agent: Alston & Bird LLP

20070041917 - Sunless tanning compositions: e

20070041915 - Use of a biguanide derivative for protecting skin against uvb radiation: The invention relates to the use of a bigaunide derivative for protecting skin against UVB radiation harmful effects and/or for protecting skin against undesirable and/or inaesthetic effects of UVB radiation.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070041918 - Enhanced boron nitride composition and polymer-based compositions made therewith: A boron nitride composition having its surface treated with a coating layer comprising a zirconate coupling agent. The boron nitride composition can be used as fillers in polymeric compounds at levels of up to 90 wt. %, giving thermal conductivity of up to 35 W/mK.... Agent: Geam - QuartzIPLegal

20070041919 - Cosmetic composition: b

20070041920 - Lip makeup composition with good staying power comprising a low molecular weight resin: The present disclosure relates to a lip makeup composition comprising at least one resin chosen from rosins, rosin derivatives and hydrocarbon-based resins, and mixtures thereof, wherein the at least one resin has a number-average molecular mass of less than or equal to 10,000 g/mol, and wherein the lip makeup composition... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070041923 - Body recessed portion cleaning agent: A body cavity cleansing agent of the present invention is either poured into or applied to a navel cavity (N) or an ear hole and solidifies after a specified period of time, and the cleansing agent takes a form that can be removed from the navel cavity (N) or the... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070041929 - Hair conditioning composition comprising silicone polymers containing quaternary groups: A hair conditioning composition comprising silicone polymer containing quaternary groups and a gel matrix. The composition of the present invention can provide improved conditioning benefits such as smooth feel and reduced friction to both damaged hair and non-damaged hair, while providing other benefits such as slippery and slick feel on... Agent: The Procter & Gamble Company Intellectual Property Division

20070041928 - Methods for removing make-up compositions from keratin materials: The invention relates to kits and methods for removing a long wearing or transfer resistant make-up composition from keratin materials such as eyelashes, nails, skin or lips, wherein the make-up composition contains at least one oil soluble film-forming agent and at least one coloring agent, including applying to the make-up... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070041930 - Use of quaternary polysiloxanes in cleaning and care compositions: The invention relates to the use of polysiloxanes which comprise a plurality of quaternary ammonium groups in the molecule in cosmetic or pharmaceutical compositions for the cleaning and care of keratin fibers, in particular of human hair. The improvement in the shine and in the color protection of the hair... Agent: Clariant Corporation Intellectual Property Department

20070041924 - Sebum control compositions based on saponins and sapogenins: The present invention discloses compositions based on certain furostanol saponins and sapogenins that reduce sebum production. These compounds are useful for the reduction of excess sebum associated with dermatological disorders such as acne, dandruff, and body malodor.... Agent: Shyam K. Gupta Bioderm Research

20070041925 - Skin and hair care preparation containing a combination of protein hydrolyzates: The invention relates to cosmetic preparations, especially hair care preparations or hair care products, containing protein hydrolysates of silk, pashmina, cashmere wool, merino wool and/or mohair, mussel thread extracts, so-called bysuss threads, and sericin and/or sericin hydrolysates. The preparations are mild for skin and hair and lead to an improvement... Agent: Greenblum & Bernstein, P.L.C

20070041926 - Mixture, comprising a surfactant and a cosurfactant: A mixture comprising a surfactant and a cosurfactant is proposed wherein the cosurfactant used is an amphiphilic comb polymer having a backbone with two or more side chains attached to the backbone, where the side chains differ from one another and/or the side chains differ from the backbone in their... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070041921 - Method for relaxing hair: A method of relaxing naturally curly hair that comprises: A) carrying out a hair treatment session that comprises the steps of: i) applying to the hair, an alkaline hair relaxer comprising an active hydroxide, ii) allowing the relaxer to remain on the hair for a total period of less than... Agent: Unilever Intellectual Property Group

20070041927 - Skin cleansing agent, particularly for removing printing inks and/or soiling caused by ink: b) 30 to 70 wt.-% of at least one polyethylene glycol of general formula H—O—(CH2CH2—O)nH, wherein n is an integer of from 1 to 150, c) 1 to 30 wt.-% of at least one fatty alcohol polyglycol ether, d) 0.1 to 5 wt.-% of at least one complexing agent, e)... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070041922 - Compositions for treating keratinous surfaces: A cosmetic composition comprising a extract having an extract of Acmella Oleracea in a cosmetically acceptable carrier, and use of such cosmetic compositions in improving skin conditions associated with aging such as wrinkles, fine lines, laxity, mottled pigmentation, and sallowness.... Agent: Julie Blackburn Revlon Consumer Products Corporation

20070041931 - Compositions comprising soy products and dioic acids: This invention relates to topical compositions comprising soy products and dioic acids and their use in skin lightening, against hyperpigmentation and, in particular, against skin spots.... Agent: Philip S. Johnson Johnson & Johnson

20070041935 - Conformable solvent-based bandage and coating material: Liquid hemostatic coating materials comprise a cyanoacrylate monomer and a solvent system comprising a volatile, non-reactive liquid that is non-stinging and non-irritating to a user. The material forms a coating or bandage in the form of a film that when applied and adhered to a surface or to the skin... Agent: Akerman Senterfitt

20070041936 - Homogeneous preparations of il-28 and il-29: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity... Agent: Zymogenetics, Inc. Intellectual Property Department

20070041932 - Conjugate for gene transfer comprising oligonucleotide and hydrophilic polymer, polyelectrolyte complex micelles formed from the conjugate, and methods for preparation thereof: Disclosed is a conjugate for gene transfer, which is capable of being used for treatment of incurable diseases, comprising an oligonucleotide intended to be transferred into target cells and a hydrophilic polymer, wherein an end of the oligonucleotide is covalently conjugated to the hydrophilic polymer. Also, the present invention discloses... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070041934 - Dendrimer based compositions and methods of using the same: The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer based compositions and systems for use in disease diagnosis and therapy (e.g., cancer diagnosis and therapy). The compositions and systems comprise one or more components for targeting, imaging, sensing, and/or providing... Agent: Medlen & Carroll, LLP Suite 350

20070041933 - Functionally diverse macromolecules and their synthesis: Functionally diverse macromolecules and synthetic routes for obtaining the same are disclosed. In certain embodiments, the synthesis proceeds in a divergent manner. In other embodiments, the routes rely on the differential reactivity of monomeric electrophilic triazine building blocks that display protected or unprotected groups. This diversity permits the facile introduction... Agent: Fulbright & Jaworski L.L.P.

20070041937 - G-csf derivative for inducing immunological tolerance: The invention relates to a method, composition and use thereof for inducing immunological tolerance, in particular transplantation tolerance in a recipient and self-tolerance in a patient. Tolerance is preferably induced by administering a G-CSF derivative, or biologically active fragment, homolog or variant thereof, in particular peg-G-CSF, to a transplantation donor.... Agent: Leydig Voit & Mayer, Ltd

20070041939 - Modified cytokines for use in cancer therapy: Cytokine derivatives capable of homing the tumoral vessels and the antigen presenting cells and the use thereof as antitumoral agents.... Agent: Foley And Lardner LLP Suite 500

20070041938 - Stable aqueous solutions of granulocyte macrophage colony-stimulating factor: The invention provides formulations of GM-CSF that comprise chelating agents. The chelating agents stabilize the GM-CSF against N-terminal degradation and allow for rapid absorption of GM-CSF upon administration.... Agent: Seed Intellectual Property Law Group PLLC

20070041940 - Methods of treating cancer using il-21: Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a... Agent: Zymogenetics, Inc. Intellectual Property Department

20070041943 - Expression of virus entry inhibitors and recombinant aav thereof: The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver genes encoding human immunodeficiency virus entry inhibitors to target cells in mammals.... Agent: Marshall, Gerstein & Borun LLP

20070041945 - Novel method for down-regulation of amyloid: A method for in vivo down-regulation of amyloid protein in an animal, including a human being, the method comprising effecting presentation to the animal's immune system of an immunogenically effective amount of at least one amyloidogenic polypeptide or subsequence thereof which has been formulated so that immunization of the animal... Agent: Birch Stewart Kolasch & Birch

20070041941 - Nucleic acid sequences encoding and compositions comrpising ige signal peptide and/or il-15 and methods for using the same: Fusion proteins and nucleic acid molecules encoding fusion proteins are disclosed. Fusion proteins comprising non-IL-15 signal peptide linked to IL-15 protein sequences and fusion proteins comprising an IgE signal peptide linked to non-IgE protein sequences are disclosed. Vectors comprising such nucleic acid molecules; and to host cells comprising such vectors... Agent: Cozen O'connor, P.C.

20070041946 - Serotype of adenovirus and uses thereof: Adenovirus serotypes differ in their natural tropism. The adenovirus serotypes 2, 4, 5 and 7 all have a natural affiliation towards lung epithelia and other respiratory tissues. In contrast, serotypes 40 and 41 have a natural affiliation towards the gastrointestinal tract. The serotypes described, differ in at least capsid proteins... Agent: Trask Britt

20070041944 - Treating tumors by enh dislocation of id proteins: The invention provides methods for the therapy of cancer that are directed towards preventing or inhibiting Id function. The present methods are based on contacting neoplastic or tumor cells with agents that can translocate an Id protein to the cytoplasm and/or sequester an Id protein in the cytoplasm, thereby preventing... Agent: Wilmerhale/columbia University

20070041947 - Use of a lentiviral vector in the treatment of pain: Provided is a method for treating and/or preventing pain, in which a vector system is administered such that an EOI is delivered to a DRG of the subject. Also provided is a method for delivering an EOI to the spinal cord using such a vector system. Further provided is a... Agent: Frommer Lawrence & Haug

20070041942 - Use of calcium binding proteins to improve cardiac contractile function: Methods useful in the regulation of myocardial contraction are disclosed. The methods are useful in the regulation of heart function. The invention reveals that sorcin overexpression enhances cardiac contractile performance and establishes the concept of sorcin as a regulator of myocardial contractility. The invention also provides screening assays that allow... Agent: Dla Piper US LLP

20070041957 - Stimulation of cellular regeneration and differentiation in the inner ear: The present invention provides methods for stimulating the formation of inner ear cells, including inner ear sensory hair cells and inner ear support cells. The methods of the present invention damage and/or kill inner ear cells, and stimulate the formation of new, inner ear cells.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20070041954 - Compositions of placentally-derived stem cells for the treatment of cancer: Disclosed are preparations of placentally-derived stem cells and compositions useful for the treatment of cancer. Said stem cells and compositions function through inducing a “guided differentiation” program in cancer cells, thereby reducing malignancy. Further extension of the invention pertains to augmenting ability of administered cells to induce differentiation through the... Agent: Knobbe Martens Olson & Bear LLP

20070041951 - Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof: The present invention relates to a population of insulin producing cells made by a process comprising contacting non-insulin producing cells with a growth factor selected from the group consisting of GLP-1 or Exendin-4, growth factors having amino acid sequences substantially homologous to GLP-1 or Exendin-4, and fragments thereof. The present... Agent: National Institute Of Health C/o Needle & Rosenberg, P.C.

20070041955 - Hedgehog signaling promotes the formation of three dimensional cartilage matrices: The present invention provides methods and compositions for promoting the formation of three dimensional cartilage matrices. The present invention further provides methods of treating diseases and injuries involving cartilage and bone using the three dimensional cartilage matrices provided herein.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070041950 - Method and device for selective addition of a bioactive agent to a multi-phase implant: A method and device for assembling a multi-phase implant for insertion into a patient defect site that spans more than one tissue type. The assembly device comprises a base and cover portion for constructing a two-phase implant separated by a membrane. A repeating intermediate portion that connects the base and... Agent: Greenlee Winner And Sullivan P C

20070041948 - Method for culturing and proliferating hematopoietic stem cells and progenitor cells using human endometrial cells: Disclosed herein is a method for culturing and proliferating hematopoietic stem cells or progenitor cells. The method comprises co-culturing the hematopoietic stem cells or the progenitor cells with human endometrial stromal cells so as to promote the expansion of hematopoietic stem cell-derived CD34+ cells or the growth of the progenitor... Agent: Intellectual Property / Technology Law

20070041953 - Smooth muscle progenitor cells: Purified populations of smooth muscle progenitor cells are provided as well as methods of making and using the cells.... Agent: Fish & Richardson P.C.

20070041952 - Three-dimensional fiber scaffolds for tissue engineering: A tissue restoration implant adapted for use with a pre-determined tissue, and methods of making and using the same. The tissue restoration implant adapted for use with a pre-determined tissue can include a three-dimensional fiber scaffold, the scaffold comprising at least three systems of fibers; wherein two of the three... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070041949 - Ultrasonic modification of soft tissue matrices: The present invention provides a method of, and apparatus for, utilising ultrasonic energy so as to mechanically disrupt the collagenous architecture of biological matrices in a controlled manner so that the tissue can be rapidly recellularised in continuous form. The present invention also provides for the production of tissue matrices... Agent: Myers Bigel Sibley & Sajovec

20070041956 - Vaccine immunotherapy for immune suppressed patients: A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naïve T-cells and restoring T-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naïve T-cells and exposing the naïve T-cells to endogenous or exogenous antigens at an appropriate site.... Agent: Kenneth I. Kohn Kohn & Associates

20070041958 - Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the enzyme peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the enzyme peptides, and methods of identifying... Agent: Celera Genomics Attn: Wayne Montgomery, Vice Pres, Intel Property

20070041959 - Poly-pegylated protease inhibitors: Disclosed are compounds that comprise: (i) a Kunitz domain polypeptide that comprises a Kunitz domain that binds to and inhibits a protease; and (ii) a plurality of polyethylene glycol moieties attached to the Kunitz domain polypeptide. Each accessible primary amine of the Kunitz domain polypeptide can be attached to one... Agent: Fish & Richardson PC

20070041960 - Apparatus and methods for enzymatic debridement of skin lesions: An apparatus for debridement of devitalized tissue in skin lesions, that includes a plurality of height- and angle-adjustable inlet tubes and at least one outlet tube and a member that forms an occlusive seal around a skin lesion. The plurality of inlet tubes is adapted for directing a continuous stream... Agent: Winston & Strawn LLP Patent Department

20070041962 - Method of promoting healing of a tympanic membrane perforation: The present invention relates to the use of plasminogen and plasmin as agents for enhancing healing of tympanic membrane perforations or other wounds, and for reducing scars or necrotic tissue forming during wound healing. The invention also relates to a method for screening of compounds which enhance wound healing by... Agent: Darby & Darby P.C.

20070041961 - Ultrasound target vessel occlusion using microbubbles: Selective occlusion of a blood vessel is achieved by selectively damaging endothelial cells at a target location in the blood vessel, resulting in the formation of a fibrin clot proximate to the damaged endothelial cells. Additional fibrinogen can then be introduced into the blood vessel if occlusion is not achieved,... Agent: Law Offices Of Ronald M Anderson

20070041963 - Human secreted proteins: The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating diseases, disorders, and/or conditions related to said human secreted proteins. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors,... Agent: Human Genome Sciences Inc Intellectual Property Dept.

20070041965 - Novel dermatophagoides nucleic acid molecules, proteins and uses thereof: The present invention relates to high molecular weight Dermatophagoides proteins, nucleic acid molecules encoding such proteins, and therapeutic and diagnostic reagents derived from such proteins.... Agent: Heska Corporation Intellectual Property Dept.

20070041966 - Polypeptides including modified constant regions: Disclosed are processes for producing a variant polypeptide (e.g. antibodies) having increased binding affinity for an FcγR, which processes comprise modifying the polypeptides by substitution of the amino acid at position 268 of a human IgG CH2 region for a non-native polar or charged amino acid e.g. Gin, Asn, Glu,... Agent: Nixon & Vanderhye, PC

20070041964 - Wisp polypeptides and nucleic acids encoding same: Wnt-1-Induced Secreted Proteins (WISPs) are provided, whose genes are induced at least by Wnt-1. Also provided are nucleic acid molecules encoding those polypeptides, as well as vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, antibodies which bind to... Agent: Heller Ehrman LLP

20070041967 - Igg fc fragment for a drug carrier and method for the preparation thereof: Disclosed is an IgG Fc fragment useful as a drug carrier. Also, the present invention discloses a recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment, comprising culturing the transformant. When conjugated to a certain drug,... Agent: Seed Intellectual Property Law Group PLLC

20070041968 - Methods of inducing an immune response: Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene... Agent: Agensys C/o Morrison & Foerster LLP

20070041969 - Apo-2dcr: Novel polypeptides, designated Apo-2DcR, which are capable of binding Apo-2 ligand are provided. Compositions including Apo-2DcR chimeras, nucleic acid encoding Apo-2DcR, and antibodies to Apo-2DcR are also provided.... Agent: Genentech, Inc.

20070041970 - Ns4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders: The present invention is directed to novel polypeptides NS4 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the... Agent: Genentech, Inc.

20070041971 - Methods for predicting development of auto-immune diseases and treatment of same: The present invention provides a new method for the prediction of, or diagnosis of, auto-immune diseases, thereby alerting the subject to the presence of, or propensity to develop, an auto-immune disease so that preventative or therapeutic regiments may be initiated or changed so as to treat, modulate or prevent expansion... Agent: Morgan Lewis & Bockius LLP

20070041972 - Antibodies and fusion proteins that include engineered constant regions: Antibodies and/or fusion proteins contain a region that includes an IgG2-derived portion IgG4-derived portion.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070041973 - Compositions and methods for treating, preventing and/or reversing type-1 diabetes: The present invention relates generally compounds, compositions, combinations, kits, and methods for treatment; prevention, suppression, and/or delaying the onset of type 1 diabetes, or reversal of type 1 diabetes.... Agent: Howrey LLP

20070041974 - Cytokine zalpha11 ligand antibodies: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller... Agent: Zymogenetics, Inc. Intellectual Property Department

20070041975 - Homogeneous preparations of il-28 and il-29: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity... Agent: Zymogenetics, Inc. Intellectual Property Department

20070041976 - Methods and compositions relating to anti-interleukin-4 receptor antibodies: Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 antagonist to a patient afflicted with such a condition. Suitable IL-4 antagonists include, but are not limited to, IL-4 receptors (such as a soluble human IL-4 receptor), antibodies that bind IL-4, antibodies that bind IL-4R, IL-4 muteins that... Agent: Immunex Corporation Law Department

20070041978 - Bispecific antibody substituting for functional proteins: The present inventors succeeded in constructing bispecific antibodies, which bind to both the blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X, and functionally substitute for blood coagulation factor VIII/activated blood coagulation factor VIII which enhances the enzymatic reaction.... Agent: Fish & Richardson PC

20070041979 - Proteolysis resistant antibody preparations: Antibody preparations with substantially homogeneous and unsialylated glycoforms, such as G0 and G2, are prepared by enzymatic treatment, expression under certain conditions, use of particular host cells, and contact with serum. These antibody preparations resist cleavage by proteases, such as papain, ficin, bromolein, pepsin, a matrix metalloproteinase, such as MMP-7,... Agent: Philip S. Johnson Johnson & Johnson

20070041977 - Single-chain antibody acting against 37 kda/67 kda laminin receptor as tools for the diagnosis and therapy of prion diseases and cancer, production and use thereof: Single-chain antibodies are described which specifically recognize both the 37 kDa precursor form of the laminin receptor (37 kDa LRP) and the 67 kDa high-affinity form of the laminin receptor (67 kDa LR), and pharmaceutical and diagnostic compositions which contain these single-chain antibodies.... Agent: Breiner & Breiner, L.L.C.

20070041980 - Ca6 antigen-specific cytotoxic conjugate and methods of using the same: Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the... Agent: Sughrue Mion, PLLC

20070041981 - Compositions and methods for altering immune function: The present invention relates to molecules that stabilize and/or enhance CD154 activity, compositions comprising these molecules, methods for using these molecules and compositions (e.g., pharmaceutical compositions) comprising them. Specifically, the molecules can be used for enhancing immune function (e.g., enhancing Th1 cytokine expression), stimulating immune responses, and/or treating certain disorders... Agent: Medlen & Carroll, LLP

20070041982 - Ilt3 binding molecules and uses therefor: The present invention provides binding molecules that specifically bind to ILT3, e.g., human ILT3 (hILT3), on antigen presenting cells, such as for example, monocytes, macrophages and dendritic cells (DC), e.g., monocyte-derived dendritic cells (MDDC). The binding molecules of the invention are characterized by binding to hILT3 with high affinity and... Agent: Lahive & Cockfield, LLP

20070041983 - Method for treating tumors using anti-osteopontin antibodies: The present invention is directed to compositions of matter useful for the treatment of tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Genentech, Inc.

20070041984 - Novel methods of cancer diagnosis and therapy targeted against a cancer stem line: Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment.... Agent: Jones Day

20070041985 - Modulation of the poliovirus receptor function: The present invention relates to the identification, the isolation and the use of molecules interfering with the function(s) mediated by the poliovirus receptor (PVR) on cells. The molecules can be used for the treatment of cells having a metastatic potential, metastasis and cancer. Further methods are provided that are useful... Agent: David S Resnick Nixon Peabody

20070041986 - Synthetic polysaccharide antigens for immunological intervention in disease: Provided are synthetic polysaccharide antigens (SPAs) with anti-inflammatory or inflammatory immunomodulatory properties, depending on their structure. Also provided are compositions comprising these SPAs, and methods of using these SPAs and compositions to either prevent or treat inflammatory pathologies, or diseases or conditions susceptible to treatment with inflammatory immunomodulators, by using... Agent: Eli Lilly & Company

20070041987 - Fragments or polymers of albumin with tunable vascular residence time for use in therapeutic delivery and vaccine development: An isolated fusion protein is provided which is a conjugate of a therapeutic polypeptide and an albumin fragment, such as a fragment including an individual domain or subdomain of albumin, or a polymer of albumin (e.g., dimers, trimers, etc.) and which is used to optimize the half-life of that therapeutic... Agent: Stites & Harbison PLLC

20070041990 - Circovirus sequences associated with piglet weight loss disease (pwd): The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a... Agent: Bingham, Mccutchen LLP

20070041989 - Circovirus sequences associated with piglet weight loss disease (pwd): The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a... Agent: Bingham, Mccutchen LLP

20070041988 - Nucleic acid and amino acid sequences of infectious salmon anaemia virus and their use as vaccines: The present invention provides the use of nucleic acid sequences and/or amino acid sequences in the preparation of a vaccine for the protection of fish against infectious salmon anaemia virus. Specifically, such vaccines contain at least one nucleic acid sequence which is derived from ISAV or synthetically prepared analogues thereof,... Agent: Novartis Corporate Intellectual Property

20070041991 - Babesia vaccines: The invention relates to Babesia proteins of a 28 kDa protein family and to immunogenic fragments of such proteins, to nucleic acids encoding such proteins or fragments, to cDNA fragments, recombinant DNA molecules, live recombinant carriers, or host cells comprising such nucleic acids, to vaccines, to methods for the preparation... Agent: Intervet Inc. Patent Department

20070041992 - Compositions and methods for inactivating or suppressing inflammatory cells: Methods are provided for reducing the activity or function of an inflammatory cell by contacting a cell with, or administering to a subject in need thereof, an effective amount of a circumsporozoite protein or homolog thereof, or a fragment thereof. Methods of treating an inflammatory disease, or an autoimmune disease... Agent: Klauber & Jackson

20070041993 - Compositions and methods for symptomatic relief: An herbal formula provides symptomatic relief for various diseases and especially for patients diagnosed with AIDS/ARC. Particularly preferred formulae include at least part of at least four plants selected from the group consisting of Panax ginseng, Angelica sinensis, Astralagus membranaceus, Ligustrum lucidum, Sophora flavescens, Trichosanthes kirilowii, Agrimonia pilosa, Ganoderma lucidum,... Agent: Robert D. Fish Rutan & Tucker LLP

20070041994 - Compositions and methods for treating prostate disorders: Compositions and methods are described for the treatment of prostatitis, benign prostatic hypertrophy, and prostate cancer. The compositions contain either aqueous extracts or dried mixtures of selenium- and zinc-enriched cannabis plant material, shiitake mushrooms, and maitake mushrooms. The compositions are effective in treating prostate disorders by alleviating pain and voiding... Agent: Janet M. Kerr

20070041995 - Oral compositions for hiv-infected subjects: The invention relates to oral compositions comprising yeast cells that can produce a healthful benefit in a subject infected with human immunodeficiency virus. The invention also relates to methods for manufacturing the oral compositions, and methods of use thereof.... Agent: John J Byrne Suite 504

20070041996 - Aromatase activating agent: The present invention is directed to an aromatase activating agent containing a plant selected from among mulberry bark, ginseng, cucumber, and phellodendron bark; or chlorella; or an extract of any of these ingredients. The aromatase activating agent of the present invention is highly safe to the human body, and useful... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070041997 - Bacterial virulence factors and uses thereof: The invention relates to, in part, secreted proteins of bacterial pathogens and methods for their use. More specifically, the invention provides in part several new common secreted proteins for A/E pathogens. In some embodiments of the invention, these polypeptides and nucleic acid molecules encoding these polypeptides, or portions thereof, are... Agent: Woodcock Washburn LLP

20070042000 - Porcine reproductive and respiratory syndrome vaccine based on isolate ja-142: Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of... Agent: Erickson & Kleypas, L.L.C.

20070041999 - Production of multivalent virus like particles: The present invention is directed to the production and in vitro assembly of recombinant viral capsid proteins into virus like particles. In particular, the present invention provides rapid, scalable, and cost efficient methods for the production of multivalent virus like particles utilizing separate populations of capsid fusion peptides containing differing... Agent: King & Spalding LLP

20070041998 - Use of alum and a th1 immune response inducing adjuvant for enhancing immune responses: The invention relates to the use of Alum for the preparation of a drug for enhancing an antigen-specific type 1 immune response against an antigen in the presence of a type 1 inducing adjuvant.... Agent: Fulbright & Jaworski L.L.P.

20070042002 - Influenza recombinant subunit vaccine: The invention provides influenza proteins, including subunit proteins and immunogenic compositions that can be utilized, with or without adjuvants, as vaccines to protect against influenza infection in animal models and humans. The recombinant proteins are expressed from transformed insect cells that contain integrated copies of the appropriate expression cassettes in... Agent: Paradise Patent Services, Inc. Attn: George Darby

20070042001 - Influenza recombinant subunit vaccine: The invention provides influenza proteins, including subunit proteins and immunogenic compositions that can be utilized, with or without adjuvants, as vaccines to protect against influenza infection in animal models and humans. The recombinant proteins are expressed from transformed insect cells that contain integrated copies of the appropriate expression cassettes in... Agent: Paradise Patent Services, Inc. Attn: George Darby

20070042003 - Method of effecting a mammalian model of sepsis, severe sepsis, or septic shock: A method of effecting a model of sepsis, severe sepsis, or septic shock in a mammalian subject which utilizes the step of introducing particulate or vesicle associated iNOS into the body of the mammalian subject. Prior to or during such introduction, an innate immune system activator may be introduced into... Agent: Theodore J. Bielen Jr.

20070042004 - Methods of treating a bacterial infection using f. tularensis lipopolysaccharide: The present invention relates to the ability of Francisella tularensis LVS lipopolysaccharide (LPS) to confer protection in a subject against a subsequent bacterial infection. Accordingly, the invention provides methods of treating and preventing bacterial infection in a subject by administering F. tularensis LPS to the subject. The invention also relates... Agent: Castellano Malm PLLC

20070042005 - Pharmaceutical composition comprising fungal cell or fragment thereof: The present invention relates to compositions, methods and uses of such compositions, the compositions comprising a pharmaceutically active compound and a non-encapsulating adjuvant, wherein the adjuvant comprises a fungal cell or a fragment thereof.... Agent: Boyle Fredrickson Newholm Stein & Gratz, S.c.

20070042008 - Compositions containing phosphatidylcholine and essential fatty acids: The invention discloses pharmaneutical compositions comprising a phospholipid formulation that is fluidized with an oil composition containing a pre-determined ratio of omega 6 and omega 3 fatty acids. In particular the invention discloses phosphatidylcholine compositions that are fluidized with a pre-determined ratio of linoleic acid and alpha linolenic acid.... Agent: Law Offices Of Khalilian Sira, LLC

20070042006 - Stable carprofen composition: A stable solvent-based composition is described which is particularly useful in warm blooded animals such as dogs. The composition comprises a therapeutically effective amount of carprofen, one or more polyols, one or more stabilising agents and optionally, one or more co-solvents.... Agent: Sonnenschein Nath & Rosenthal LLP

20070042007 - Topical composition for delivery of salicylate esters: The present invention provides a self-emulsifiable composition and a stable topical emulsion comprising same, which comprises salicylate esters, oils and surfactants and which does not require organic solvents. The invention also provides methods for manufacturing the compositions. The topical compositions of the invention can be used to enhance delivery of... Agent: Mccarthy Tetrault LLP

20070042009 - Topical composition for delivery of salicylates: The present invention provides a self-emulsifiable composition and a stable topical emulsion comprising same, which comprises salicylate, oils and surfactants and which does not require organic solvents. The invention also provides methods for manufacturing the compositions. The topical compositions of the invention can be used to enhance delivery of salicylates... Agent: Mccarthy Tetrault LLP

20070042010 - Compositions containing amines and use thereof to treat acne or reduce the appearance of oil or pores on the skin: e

20070042012 - Game attracting substance and a method for applying: A Game Attracting Substance and a Method for Applying such substance comprised of a container, a solution of game attractant scent in a non-liquid sprayable foam or gel and a release mechanism whereby the contents of the container, the non-liquid foam or get containing the game attracting scent solution can... Agent: Walter A. Reiter, Iii

20070042013 - Long acting injectable formulations: The application relates to long acting injectable (LAI) formulations for combating ectoparasites and endoparasites in mammals. In particular, this invention provides for a LAI formulation comprising a subcutaneously volatile solvent, a biologically acceptable polymer, a bioactive agents and optionally one or more anti-ectoparasitically or anti-endoparasitically acceptable additive or excipient. Surprisingly,... Agent: Judy Jarecki-black,ph.d,j.d. Merial Ltd.

20070042011 - Soil-fumigant-containing solid material: A soil-fumigant-containing solid material containing not less than 60 and not more than 85 weight % of a soil fumigant, not less than 0.5 and not more than 15 weight % of gelatin, not less than 0 and not more than 10 weight % of an inorganic mineral, not less... Agent: Buchanan, Ingersoll & Rooney PC

20070042014 - Combination of a serotonin reuptake inhibitor and loxapine: The present invention relates to the use of a combination of Loxapine and a serotonin reuptake inhibitor (SRI), for the treatment of depression and other affective disorders.... Agent: Darby & Darby P.C.

20070042015 - Coating composition for polymeric surfaces comprising serpin or serpin derivatives: The invention relates generally to a coating composition for a polymeric surface, methods for coating a polymeric surface, methods for preparing coated medical devices, polymeric surfaces coated with the coating composition, and medical devices comprising the coating composition. In particular, a coating composition for association with a polymeric surface, preferably... Agent: Millen, White, Zelano & Branigan, P.C.

20070042017 - Medical device with coating that promotes endothelial cell adherence and differentiation: Compositions and methods are provided for producing a medical device such as a stent, a stent graft, a synthetic vascular graft, heart valves, coated with a biocompatible matrix which incorporates antibodies, antibody fragments, or small molecules, which recognize, bind to and/or interact with a progenitor cell surface antigen to immobilize... Agent: Kelley Drye & Warren LLP

20070042016 - Methods and systems for treating injured cardiac tissue: Methods and systems are disclosed for treating injury to cardiac tissue by delivering a composition which provides structural support to the cardiac tissue. The composition helps to prevent chamber remodeling by providing structural reinforcement of the tissue or structural reinforcement of the tissue combined with biological therapy. The structurally reinforcing... Agent: Medtronic Vascular, Inc.IPLegal Department

20070042018 - Absorbable endo-urological devices and applications therefor: This invention deals with an absorbable/disintegratable endo-urological stent and applicators for introduction into biological conduits, including such as urethras and ureters, with said stent comprising a fiber-reinforced, multicomponent tube made of polyesters having a range of physicochemical properties.... Agent: Leigh P. Gregory Attorney At Law

20070042020 - Composition for the treatment of dysfunctional energy metabolism syndrome: A nutritional composition for the treatment of syndromes related to dysfunctional energy metabolism is provided. The composition comprises a combination of L-carnitine, acetyl-L-carnitine, pantothenate and niacinamide. Methods of treatment of dysfunctional energy metabolism are also disclosed.... Agent: The Webb Law Firm, P.C.

20070042019 - Method of treating or preventing chronic wounds and a complete nutritional composition comprising glycine and/or leucine for use therein: The invention relates to a method for the treatment and/or prevention of chronic wounds, said method comprising enterally administering to a patient a composition wherein protein represents between 10 and 40% of the total caloric content of the composition; carbohydrate represents between 15 and 90% of the total caloric content... Agent: The Webb Law Firm, P.C.

20070042021 - Nutritional composition against side effects of chemotherapy of radiotherapy: The present invention relates to a nutritional composition suitable for patients undergoing chemotherapy and/or radiation such as cancer patients. The composition, which may be in powder or liquid form, comprises casein and whey proteins, TGF-β and free glutamine.... Agent: Bell, Boyd & Lloyd LLC

20070042022 - Liquid formulations of ractopamine: Described is a soluble stable liquid formulation, process for preparing, and a method of using the soluble stable liquid formulation comprising ractopamine or a physiologically acceptable salt thereof, a liquid nonionic cosolvent, and water.... Agent: Eli Lilly & Company

20070042023 - Dissolvable film: Dissolvable films are described for the administration of an active ingredient. The film comprises degraded pectin and at least one other filming forming ingredient. The film can carry actives such as medicaments, flavors, seasonings, scents and the like.... Agent: National Starch And Chemical Company

20070042025 - Carboxymethylated cellulosic wound dressing garment: A body shaped wound dressing wherein the dressing is a knitted or woven garment comprising a cellulosic yarn, which garment has been carboxymethylated at least in parts of its wound contacting surface.... Agent: Bristol-myers Squibb Company

20070042024 - Wound dressing material: A material for use as a wound dressing, the material being in the form of a roll and comprising gel forming fibers and the material having lines of longitudinal stitching.... Agent: Bristol-myers Squibb Company

20070042026 - Prophylactic and therapeutic treatment of topical and transdermal drug-induced skin reactions: Botanically derived anti-irritants for prophylactic and therapeutic treatment of adverse skin reactions from application of transdermal or topical drug delivery system, permits the effective administration of a drug from a delivery system in which the drug, of a component of the delivery system comprises a skin irritant; and the delivery... Agent: Law Offices Of Nancy A. Bird

20070042027 - Water soluble anesthetic in an oral patch of hydrophilic gums: An oral patch for treating toothaches and oral lesions, including mouth ulcers (canker sores/aphthous ulcers) with water soluble topical anesthetics such as dyclonine hydrochloride. In one embodiment, the patch is made by depositing blobs of wet mixture including anesthetic, muco-adhesive hydrocolloids such as collagen, and bingers onto flat sheets. The... Agent: Graybeal, Jackson, Haley LLP

20070042028 - Plaster causing reduced skin irritation: A plaster containing an active ingredient for the transdermal administration of a pharmaceutical active ingredient, having a removable protective film and an adhesive layer. The plaster includes at least one compound that is contained in the adhesive layer or lies adjacent the adhesive layer between the adhesive layer and the... Agent: Crowell & Moring LLP Intellectual Property Group

20070042029 - Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (vegf-r): The present invention relates to nucleic acid molecules which modulate the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor, such as flt-1 and KDR. Nucleic acid molecules and methods for the inhibition of angiogenesis and treatment of cancer and ocular diseases... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070042030 - Preparation for the application of agents in mini-droplets: The invention relates to a preparation for the application of agents in the form of minuscule droplets of fluid, in particular provided with membrane-like structures consisting of one or several layers of amphiphilic molecules, or an amphiphilic carrier substance, in particular for transporting the agent into and through natural barriers... Agent: Edwards & Angell, LLP

20070042032 - Self forming, thermodynamically stable liposomes and their applications: Certain diacylglycerol-polyethyleneglycol (DAG-PEG) lipids are especially useful for forming thermodynamically stable liposomes. Such liposomes are useful for a variety of purposes, including the delivery of therapeutic agents.... Agent: Thelen Reid & Priest, LLP

20070042031 - Systems and methods for manufacturing liposomes: The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. A therapeutic agent, such as nucleic acid,... Agent: Townsend And Townsend And Crew, LLP

20070042036 - Fat-soluble drug composition: The present invention aims at providing a fat-soluble drug composition having improved absorbability of the fat-soluble component in the living body and being stable as a formulation, specifically a fat-soluble drug composition for capsules. The present invention relates to a fat-soluble drug composition comprising a fat-soluble component and an emulsifier,... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070042034 - High drug load formulations and dosage forms: The invention relates to high drug load formulations containing (R)-2-(2-fluoro-4-biphenylyl)propionic acid as an active pharmaceutical ingredient.... Agent: Myriad Genetics Inc. Intellecutal Property Department

20070042033 - Pantoprazole multiparticulate formulations: Pantoprazole sodium multiparticulates are described which avoid sticking to nasogastric and gastronomy tubes. The pantoprazole multiparticulates have a spheroid core of pantoprazole or an enantiomer thereof, or a salt thereof, a surfactant, and a disintegrant; a sub coat which is comprised of hydroxypropyl methylcellulose (hypromellose) and water, an enteric coat... Agent: Howson And Howson Cathy A. Kodroff

20070042035 - Soft capsule: It is an object of the present invention to provide a capsule anti-sticking agent which can provide excellent anti-sticking effect on a soft capsule without impairing various properties such as water activity, disintegration property and safety, a coated soft capsule of high quality which is coated with the capsule anti-sticking... Agent: John L. Cordani Carmody & Torrance LLP

20070042037 - Pharmaceutical composition containing levodopa and carbidopa: An oral solid pharmaceutical composition for constant and prolonged release of a levodopa/carbidopa combination, for use in the treatment of Parkinson disease.... Agent: Young & Thompson

20070042039 - Calcium carbonate granulation: Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet... Agent: King & Spalding

20070042038 - Progestin co-micronized with a surfactant, pharmaceutical composition comprising same, methods for making same and uses thereof: The invention concerns a progestin co-micronized with a surfactant and a pharmaceutical composition comprising said gestagenic. The invention also concerns methods for preparing same.... Agent: Foley And Lardner LLP Suite 500

20070042041 - Drug-surfactant complexes for sustained release: The invention involves sustained-release pharmaceutical compositions containing a water-soluble ionic small molecule pharmaceutical agent complexed with an oppositely charged surfactant, particularly a natural bile surfactant. The complexes are sustained-release ionic complexes. The complexes release the ionic pharmaceutical agents into aqueous solution slowly and with zero-order kinetics. Thus, they can be... Agent: Hugh Mctavish Mctavish Patent Firm

20070042042 - Metformin tablet with sustained release and method for preparing the same: The present invention relates to a metformin tablet with sustained release and a method for preparing the same, more particularly to an improved metformin tablet with sustained release prepared by manufacturing a composition comprising metformin, which is an active ingredient for treatment of insulin-independent diabetes, and a matrix capable of... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20070042040 - Methods and compositions using gonadotropin hormone releasing hormone: The present invention relates to compositions comprising two sustained release formulations, the first being capable of releasing a gonadotropin releasing hormone composition and the second an estrogenic composition. The compositions of the invention can be employed for an improved androgen deprivation therapy of prostate cancer, in which therapy loss of... Agent: Nixon & Vanderhye, PC

20070042043 - Pellet formulations of acid-labile benzimidazonle compounds: They comprise insert granules of sugar/starch which are: initially coated with a non-alkaline active layer having the benzimidazole compound (omeprazole, lansoprazole, pantoprazole, rabeprazole, etc.), sodium and/potassium salts of acids of formula R—O—SO3H wherein R is an alkyl radical of a (C6-C20)-fatty acid (preferably sodium lauryl sulfate), (C6-C20)-fatty acids (preferably oleic... Agent: Hensley Kim & Edgington, LLC

20070042044 - Matrix compositions for controlled delivery of drug substances: A novel matrix composition for pharmaceutical use. The matrix composition has been designed so that it is especially suitable in those situation where an improved bioavailability is desired and/or in those situation where a slightly or insoluble active substance is employed. Accordingly, a controlled release pharmaceutical composition for oral use... Agent: Foley And Lardner LLP Suite 500

20070042045 - Multilayer dosage form comprising a matrix that influences release of a modulatory substance: d) an outer controlling layer comprising at least 60% by weight of one or a mixture of a plurality of (meth)acrylate copolymers composed of 98 to 85 C1 to C4 alkyl esters of (meth)acrylic acid and 2 to 15% by weight of methacrylate monomers with a quaternary ammonium group in... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070042046 - Methods for the treatment of cancer: The invention provides the use of a pharmaceutical compositions comprising a cytotoxic drug and a porous carrier material in methods for the treatment of cancer by chemo-brachytherapy, in particular intra-tumoural administration.... Agent: Nixon & Vanderhye, PC

20070042048 - Devices, compositions and methods for the pulmonary delivery of aerosolized medicaments: According to the subject invention, dispersible dry powder pharmaceutical-based compositions are provided, including methods for their manufacture and dry powder dispersion devices. A dispersible dry powder pharmaceutical-based composition is one having a moisture content of less than about 10% by weight (% w) water, usually below about 5% w and... Agent: Fish & Richardson P.C.

20070042049 - Nanoparticulate benidipine compositions: The present invention relates to nanoparticulate benidipine compositions having improved bioavailability. The compositions comprise benidipine particles having an effective average particle size of less than about 2000 nm and may be useful in the prevention and treatment of hypertension, renal parenchymal hypertension and angina pectoris.... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner LLP

20070042050 - Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression: Polynucleotides encoding at least one immunizing antigen whose expression is controlled by a promoter derived from a gene encoding a co-stimulatory molecule are provided. The polynucleotides may also encode adjuvants. Compositions comprising at least one immunizing agent and at least one cytokine that enhance dendritic cell stimulation and/or survival are... Agent: Foley And Lardner LLP Suite 500

20070042047 - Vaccines: The present invention relates to the novel nucleic acid constructs, useful in nucleic acid vaccination protocols for the treatment and prophylaxis of MUC-1 expressing tumours. In particular, the construct comprises a fusion between a heat shock protein gene HSP70, typically from Mycobacterium tuberculosis and MUCl-1 or derivative thereof. The invention... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070042051 - Remedy ointment for piles and their manufacturing method: A remedy ointment for piles includes the following steps; forming a base-mixture which include collecting a spawn of a swellfish and a starfish and powdering the same; forming a mixture which is obtained by mixing the powder of a starfish and a swellfish spawn obtained by the above step with... Agent: Jordan And Hamburg LLP

20070042052 - Inorganic antibacterial agents containing high valent silver and preparation method thereof: The present invention provides inorganic antibacterial agents containing high valent silver, which are characterized by containing 2-6% by weight divalent silver, trivalent silver or tetravalent silver based on the total weight of the antibacterial agents, wherein said high valent silver is introduced onto the solid carriers by ion exchanges.... Agent: Raymond Y Chan

20070042054 - Functional aphrodisiac rolled herbal bidis and cigarettes: An herbal formulation comprising the synergistic combination of fiber/powder/granules of the aerial parts of at least two plants selected from the group comprising Marticaria chamomilla, Hygrophila auriculata, Aquilaria agallocha, Valeriana wallichii, Nordostachys jatamansi, Artemisia pallen, Papaver somniferum(mainlyleaf), Evolvulus alsinoides, Ficus benghalensis, Echinops echinatus, Lobelia nicotianaefolia, Mucuna pruriens, Tribulus terrestris and... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP

20070042055 - Herbal formulations and cigarettes containing same useful in controlling body weight: The present invention relates to the an herbal formulation comprising a combination of fiber, powder, and/or granules of aerial parts of plants selected from Hemedesmus indicus, Acorus calamus, Murraya Koenigii, Alpinia galanga, Papaver somniferum, Amorphophallus campanulatus, Hygrophila auriculata, Hygrophila schulli, Cuminum cyminum, Apium graveolens, Colocasia esculenta. The present invention further... Agent: Kenyon & Kenyon LLP

20070042053 - Medicinal herbal composition for treating infection: Herbal compositions derived from Kenyan plants are provided for the treatment of HIV and other infectious diseases. The herbal compositions can include the extracts of up to 14 plants, including the root of Dovyalis abyssinica and Clutia robusta. Also provided are methods for extracting alkaloids and other compounds from the... Agent: Foley & Lardner LLP

20070042056 - Anti-stress agent: The present invention provides an anti-stress agent which can effectively prevent or alleviate various symptoms caused by stress and which is safe and easily taken or ingested. The anti-stress agent comprises an aroma component of coffee or teas as an active ingredient.... Agent: Drinker Biddle & Reath (dc)

20070042057 - Compositions for the treatment and prevention of diabetes mellitus: Compositions comprising a catechin as found in green tea, e.g., epigallocatechin gallate, and ligand which activates the peroxisome proliferatoractivated receptor gamma (PPAR-gamma are useful for the treatment and prevention of diabetes mellitus).... Agent: Stephen M Haracz Bryan Cave

20070042058 - Delivery system for appetite suppressant: The invention relates to a topical delivery system suitable for application to the lips, comprising at least one naturally occurring oil, at least one naturally occurring wax, and at least one naturally occurring diet aid. The invention also relates to a method for controlling weight in an individual by applying... Agent: The Estee Lauder Cos, Inc

20070042059 - Methods for modulating eicosanoid metabolism: The inventive subject matter relates to methods for modulating an eicosanoid metabolic process in cells of an animal in need thereof, which comprises administering to the animal an amount of the inventive compositions effective for regulating the activity of an eicosanoid oxygenase. In particular, the inventive subject matter relates to... Agent: Nath & Associates

20070042060 - Methods to treat one or all of the defined etiologies of female sexual dysfunction: The U.S. Food and Drug Administration defines the four separate components of Female Sexual Dysfunction (FSD) to be decreased sexual desire, decreased sexual arousal, dyspareunia (pain with intercourse), and persistent difficulty in achieving or inability to achieve orgasm (anorgasmia). To establish a diagnosis of FSD, these components must be associated... Agent: Donald N. Halgren

20070042061 - Anti-inflammatory activity of phenethylisothiocyanate (peitc) and the barbarea verna seed preparation containing this compound: The subject of this invention is the anti-inflammatory activity of a formulation of Barbarea verna (upland cress, early winter cress, or winter cress) seed preparation (BSP) containing phenethylisothiocyanate as its main active ingredient. BSP is a promising anti-inflammatory agent, which can be used for treatment of many inflammation-related conditions, including... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20070042062 - Novel anti-diabetic herbal formulation: The invention provides a novel herbal preparation comprises of Glycine max active fraction containing 7S globulin protein extract, Curcuma longa and Zingiber officinale Linn. rhizome extract used in treatment of diabetes and diabetic related diseases.... Agent: Ladas & Parry

20070042063 - Protein kinase modulation by hops and acacia products: Botanical compounds to modulate kinase activity are disclosed. The compounds and methods disclosed also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively. The compositions contain at least one fraction isolated or derived from hops or Acacia.... Agent: Mcdermott Will & Emery LLP Attn: Intellectual Property Deptartment

20070042064 - Extracts of durian fruit for use in skin care compositions: The present invention relates to compositions comprising extracts of Durio zibethinus. The compositions of the present invention are useful for improving the appearance, texture, and/or moisture of mammalian skin. In particular, the compositions of the present invention decrease inflammation in the skin, inhibit matrix metalloprotease-9, which degrades skin proteins such... Agent: In Re: Alticor Inc. 28533 Brinks, Hofer, Gilson & Lione

20070036717 - Chemoradiotherapy with ts-1/camptothecins: An antitumor agent for chemoradiotherapy of rectal cancer comprising a combination of TS-1 (a combination drug of tegafur, gimeracil, and oteracil potassium at a 1:0.4:1 molar ratio) and CPT-11 (irinotecan hydrochloride). The antitumor agent of the invention can achieve marked tumor volume reduction without causing major side effects, especially by... Agent: Sughrue Mion, PLLC

20070036716 - Methods of making radiolabeled tracers and precursors thereof: The present disclosure relates to a solid-phase process for the production of radiolabeled tracers, in particular for the production of 18F-labeled compounds which may be used as Positron Emission Tomography (PET) radiolabeled tracers. The disclosure also relates to radiopharmaceutical kits comprising precursors to the radiolabeled tracers, which can be converted... Agent: Louis J. Wille Bristol-myers Squibb Company

20070036714 - Porphyrin derivatives, methods for obtaining same, and use thereof in radioimmunotherapy: The invention concerns compounds of general formula (I), wherein: when A forms a chain with C, called A-C chain, of formula (1): —X—Y—C6H4-(CH2)n1-C(Z,W)—(CH2)n2-C6H4-Y—X—, then B forms a chain with D, the chain of above formula (1), called A-C and B-D chains located independently of each other, above (position alpha )... Agent: Young & Thompson

20070036718 - Radiolabelled phenylethyl imidazole carboxylic acid ester derivatives: Halogenated carboxylic ester derivatives of phenylethyl imidazole, and their method of preparation are disclosed. Radio-halogenated forms of these compounds are ideally suited for positron-imaging of the adrenal glands, as it is known that these compounds demonstrate a selective and high rate of accumulation in the adrenals. The method of preparing... Agent: Lerner Greenberg Stemer LLP

20070036715 - Tc-labeled arylpiperazine derivatives for imaging serotonin receptor: l

20070036719 - Prostate cancer diagnosis and treatment: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting,... Agent: Bereskin And Parr

20070036720 - Radiolabelled metal transport protein as imaging agent: A 99mcTc labeled metal transport protein, products and uses thereof in imaging and especially detecting the presence of high energy/iron uptake tissues such as a tumour within a mammalian body are provided.... Agent: Myers Bigel Sibley & Sajovec

20070036721 - Methods and compositions for in vivo inflammation monitoring: Disclosed are methods and materials for detecting inflammation using in vivo and in vitro monitoring, as well as methods of reducing inflammation. Also disclosed are composition related to in vivo monitoring of inflammation, as well as transgenic animals and cell lines useful for such.... Agent: Needle & Rosenberg, P.C.

20070036727 - Adducts between magnetic resonance shift reagents and substrates containing exchangeable protons for \"cest\" applications: Disclosed are CEST paramagnetic agents comprising a substrate (SH) containing mobile protons bonded to a para-magnetic chelate (SR) containing a metal selected from iron (11) (high-spin configuration), iron (111), cobalt (11), rhodium (11), copper (11), nickel (11), cerium (111), praseodymium (111), neodymium (111), dysprosium (111), erbium (111), terbium (111), holmium... Agent: Kramer Levin Naftalis & Frankel LLP

20070036728 - A method of transdermal drug delivery using hyaluronic acid nanoparticles: The present invention relates to the development of a hyaluronic acid and hyaluronic acid hybrid nanoparticle systems for the administration of active molecules, peptides, DNA and/or other hydrophilic or hydrophobic molecules, the composition of hyaluronic acid and hyaluronic acid hybrid nanoparticle systems, and the procedure for their development and use.... Agent: Smith Hopen, Pa

20070036729 - Compositions containing magnetic iron oxide particles, and use of said compositions in imaging methods: The present invention relates to complexes which contain magnetic iron oxide particles in a pharmaceutically acceptable shell, said particles having a diameter of 20 nm to 1 μm with an overall particle diameter/core diameter ratio of less than 6, and to the use of these complexes in magnetic particle imaging... Agent: Millen, White, Zelano & Branigan, P.C.

20070036722 - Separation processes: Separation of target material from a liquid sample is achieved by coupling the target to targetable encapsulated gas microbubbles, allowing the microbubbles and coupled target to float to the surface of the sample to form a floating microbubble/target layer, and separating this layer from the sample. In a positive separation... Agent: Ge Healthcare, IncIPDepartment

20070036726 - Eye treatment: The invention relates to a method of diagnosing the eye and to methods for subsequent treatment following such diagnosis. The method involves diagnosing a deficiency in the anatomy and performance of the upper eyelid recognizing the impact of this deficiency during blinking on problems such as dry eye, contact lens... Agent: Robert G. Rosenthal

20070036725 - Imaging of protease activity in live cells using activity based probes: Methods and materials for the imaging of cells containing active proteases such as cathepsin are disclosed. The present materials include activity based probes that bind to an enzyme and are subsequently cleaved. Cleavage results in a fluorescent signal due to removal of a quenching group which, when present on the... Agent: Peters Verny Jones & Schmitt, L.L.P.

20070036723 - Kinematic adhesive fluorescence measurement patch: A kinematic adhesive fluorescence measurement patch for use with a fluorescent light-emitting bead implanted within a user's body includes an adhesive plate for removable adhesion to the user's body and an optical plate. The optical plate includes a rigid member with a light emitter and light detectors attached thereto. The... Agent: Philip S. Johnson Johnson & Johnson

20070036724 - Non-isotopic detection of osteoblastic activity in vivo using modified bisphosphonates: The present invention is directed to a non-isotopic methods for the in vitro and in vivo detection of hydroxyapatite-positive cells and structures.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070036730 - Cellulose derivatives: Stable microdispersed polyanhydroglucuronic acid and salts thereof contain in their polymeric chain from 8 to 30 percent by weight of carboxyl groups, at least 80 percent by weight of these groups being of the uronic type, at most 5 percent by weight of carbonyl groups including intra- and inter-molecular 2,6... Agent: Jacobson Holman PLLC

20070036731 - Topical delivery with a carrier fluid: Aerosol spray formulations capable of delivering high concentrations of active agent-containing materials and/or excipient are described herein. The formulation contains a carrier fluid, a propellant, and a therapeutic, prophylactic, consmeticeutical and/or inert solid suspended, dissolved, or dispersed in the formulation. The active ingredient may be any pharmaceutically active agent, but... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070036733 - Sensation masking composition: The present invention provides masking compositions that include a lower alkyl carboxylic acid, e.g. acetic acid. Also provided is a masking composition that includes (a) a lower alkyl carboxylic acid (e.g. acetic acid), a warming sensate (e.g. vanillin or vanillyl butyl ether) and/or a cooling sensate (e.g. menthol or isopulegol).... Agent: Darby & Darby P.C.

20070036732 - Stable topiramate formulations: Bi- or multi-phasic tablets comprising an effective amount of a moisture sensitive active ingredient, which in particular is topiramate, wherein at least one of the phases comprises hygroscopic gum material, which preferably is xanthan gum, and wherein none of the phases contains both moisture sensitive active ingredient and hygroscopic gum... Agent: Philip S. Johnson Johnson & Johnson

20070036734 - Therapeutic agent for periodontal disease: The present invention provides a human monoclonal antibody that has both activity of inhibiting the aggregation of pathogenic bacteria involved in periodontal diseases and activity of promoting sterilization by leukocytes, that is preferably a monoclonal antibody against 40-kDa OMP, which inhibits the binding of hemin, and that causes no concerns... Agent: Foley And Lardner LLP Suite 500

20070036736 - Hollow silica particles, compositions comprising them, and methods for making same: Methods for making and compositions comprising hollow silica particle are disclosed, said particles made from a composition comprising a silicon-containing compound selected from the group consisting of tetraalkoxysilanes, trialkyloxysilanes and derivatives thereof, dialkoxysilanes and derivatives thereof, alkoxysilanes and derivatives thereof, silicone oligomers, oligomeric silsesquioxanes and silicone polymers distributed over a... Agent: The Procter & Gamble Company Intellectual Property Division

20070036735 - Skin external preparation: A skin external preparation comprises, as an effective component, the powdered of calcareous algae globes into which calcareous algae belonging to corallinaceae of red algae have grown globularly.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070036737 - Products for topical application comprising lysophospholipids and fatty acids: Described is a product containing at least one lysophospholipid and at least one fatty acid, as a combined preparation for simultaneous, separate or sequential use, to be topically applied, in order to temporarily and reversibly inhibit a neuromuscular junction or the release of acetylcholine from autonomic nerve endings; this product... Agent: Lucas & Mercanti, LLP

20070036738 - Spray compositions: Spray compositions and particularly anhydrous aerosol compositions containing particulate antiperspirant actives exhibit a tendency for nozzle blockage, impeding discharge of the contents when a polyol humectant, such as glycerol, is blended into its base composition. The problem is overcome or at least ameliorated by preparation of a base composition, suitable... Agent: Unilever Intellectual Property Group

20070036740 - Modulation of hair growth: The present invention provides methods and compositions including RNAi agents for modulating the growth, development, or maintenance of hair or hair follicles in vertebrate animals.... Agent: Patton Boggs LLP

20070036741 - Thickening agents: Invert water-in-silicone emulsions and a process of production thereof are disclosed. The invert water-in-silicone emulsion is based on polymerizing or copolymerizing one of an ionic, anionic, and/or cationic monomer, or a non-ionic monomer in the presence of a cross-linking agent and transfer agent. The emulsion comprises: a continuous phase having... Agent: Heslin Rothenberg Farley & Mesiti PC

20070036739 - Cosmetic compositions useful for lengthening lashes: Disclosed are mascara compositions containing an aqueous phase, fatty phase, a structuring agent, and a polyurethane/poly(meth)acrylate graft copolymer, and methods of making and using them.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070036742 - Methods and compositions for modulating hair growth or regrowth: The present invention relates to compositions and methods for modulating hair growth or regrowth. The compositions of the present invention comprise extracts of one or more of the following: Boswellia serrata, Undaria pinnatifida, green tea (e.g., Camellia sinensis), shiso, Pureraria mirifica, luteolin (e.g. Perilla ocymoides leaf extract), astilbin, vitamin E,... Agent: In Re: Alticor Inc. 28533 Brinks, Hofer, Gilson & Lione

20070036743 - Antimicrobial polymers: An antimicrobial polymer which is stable to aqueous hydrolysis contains a phenolic antimicrobial agent covalently bounded to one or more polymerized ethylenically unsaturated monomer units preferably through an imide and/or amide group.... Agent: Attn: William J. Davis, Esq. International Specialty Products

20070036745 - Polymeric materials, their preparation and use: Disclosed are highly resilient and cohesive gels formed by the cross-linking of hyaluronan or hylan, their salts or derivatives thereof, using divinyl sulfone (DVS) as the cross-linking agent. Also disclosed are viscoelastic fluids containing alkylsulfone groups covalently attached to the backbone of the polymer, formed by the mono-functionalization of the... Agent: Fish & Richardson PC

20070036744 - Treatment or prevention of respiratory viral infections with alpha thymosin peptides: An alpha thymosin peptide is administered to a patient having, or at risk of a respiratory viral infection, coronavirus infection and/or SARS.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070036746 - Water-degradable fishing lure: A fishing lure that is water-degradable is described. The fishing lure can be a polymeric fishing lure. The fishing lure can have a body that includes at least one hydrophilic polyester or copolyester and at least one plasticizer and wherein the body is degradable upon immersing the body in water... Agent: Kilyk & Bowersox, P.l.l.c.

20070036748 - Combination therapies for cancer: The present invention relates to methods of inducing expression of a polynucleotide encoding a therapeutic polypeptide, e.g., TNF-α, in a cell comprising contacting the cell with a construct comprising an Egr-1 promoter operably linked to a polynucleotide encoding the polypeptide, and at least one chemotherapeutic agent, wherein the chemotherapeutic agent... Agent: Michael Best & Friedrich, LLP

20070036752 - Il-2 fusion proteins with modulated selectivity: The invention provides cytokine fusion proteins with an increased therapeutic index, and methods to increase the therapeutic index of such fusion proteins. The fusion proteins of the invention are able to bind to more than one type of cytokine receptor expressed on cells and also bind to more than one... Agent: Kirkpatrick & Lockhart Nicholson Graham LLP

20070036750 - Mcp1 fusions: The present invention provides polypeptides including MCP1 fused, optionally, by a linker, to an immunoglobulin. Methods for using the polypeptides to treat medical disorders are also covered.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070036749 - Method of determining cytokine dosage for myelosuppressive state: The invention provides kits and methods for evaluating the myelosuppressive state of a patient. These methods and kits provide a useful adjunct for cytotoxic and myelosuppressive therapies. By establishing threshold levels of certain cytokines as a surrogate for myelosuppression, treatment protocols can be optimized to reduce myelotoxicity, while maximizing effective... Agent: Faegre & Benson LLP Patent Docketing

20070036751 - Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies: The invention provides methods for treating tumors and tumor metastases in a mammal comprising administering, to a mammal in need of treatment, a therapeutic amount of an antagonist sufficient to inhibit angiogenesis in combination with a therapeutic amount of anti-tumor immunotherapeutic agent, such as a anti-tumor antigen antibody/cytokine fusion protein... Agent: Olson & Hierl, Ltd.

20070036747 - Pharmaceutical combination useful for stem cell mobilization: Combined pharmaceutical preparation containing G-CSF and P1GF as the active substances, are useful in the mobilization of blood stem cells in a patient or subject in need thereof.... Agent: Birch Stewart Kolasch & Birch

20070036753 - Treatment with anti-vegf antibodies: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.... Agent: Genentech, Inc.

20070036754 - Treatment with anti-vegf antibodies: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.... Agent: Genentech, Inc.

20070036755 - Treatment with anti-vegf antibodies: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.... Agent: Genentech, Inc.

20070036757 - Aav vector for gene therapy: Described are recombinant AAV vectors characterized in that they carry capsid protein modification(s) resulting in a reduced or eliminated heparin binding function. The AAV vectors of the present invention are particularly suitable for gene therapy by systemic application, since (a) transduction of the liver is eliminated or at least drastically... Agent: Howrey LLP

20070036760 - Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor: Sequences of novel adeno-associated virus capsids and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles. AAV-mediated delivery of therapeutic and immunogenic genes using the vectors of the invention is also provided.... Agent: Howson And Howson

20070036763 - Interleukin-17 receptor homologue: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor14.”... Agent: Zymogenetics, Inc. Intellectual Property Department

20070036761 - Lentiviral apoe2 gene therapy: The present invention is a method for inhibiting or reducing disease progression in subjects suffering from conditions or diseases related to the Aβ peptide, including Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like. The method comprises admininstering an apoE2 lentiviral vector to the subject.... Agent: Eli Lilly & Company

20070036756 - Method for treating ischemic diseases: The present invention provides methods for treating ischemic diseases, which comprise the step of administering angiopoietin-1 (Ang1) or an Ang1-encoding vector. The present invention also provides ischemic disease treatment kits which comprise Ang1. Ang1-expressing vectors were prepared, and each was administered alone intramyocardially to rats in the acute phase of... Agent: Clark & Elbing LLP

20070036759 - Method of preparing a proliferation-regulated recombinant adenoviral vector efficiently and kit for preparing the same: Provided is a method of preparing a proliferation-regulated recombinant adenoviral vector effectively, comprising preparing a proliferation-regulated vector plasmid by preparing a restriction enzyme-recognizing sequence in a vector plasmid having a proliferation-regulating unit and having an E1A region, a protein-coding region in a E1B region, a poly(A) signal sequence, and a... Agent: Fish & Richardson PC

20070036758 - Mutants of vaccinia virus as oncolytic agents: The present invention relates to mutant oncolytic vaccinia viruses and their use for selective destruction of cancer cells. The mutant vaccinia viruses of the invention include those having a reduced ability to inhibit the antiviral dsR-NA dependent protein kinase (PKR) and increased sensitivity to interferon. Such mutants include, for example,... Agent: Needle & Rosenberg, P.C.

20070036762 - Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer: A novel gene (designated 85P1B3) and its encoded protein are described. While 85P1B3 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including set forth in Table 1. Consequently, 85P1B3 provides a diagnostic and/or therapeutic target for cancers. The 85P1B3 gene or fragment thereof,... Agent: Agensys C/o Morrison & Foerster LLP

20070036764 - Selective killing of cells by activation of double-stranded rna dependent protein kinase-pkr: Novel methods and compositions for selective killing of cells by activation of PKR are disclosed. In a preferred embodiment, a method is provided for causing cell death in a targeted population of cells that includes the steps of: selecting a nucleotide sequence at a single genetic locus in the targeted... Agent: Martin D. Moynihan Prtsi, Inc.

20070036770 - Biologic device for regulation of gene expression and method therefor: A system and device are provided which include a gene regulatory system controlling expression of one or more expression cassettes present in or released by the device, by emitting one or more stimulations. An expression cassette includes a regulatable transcription control element that is responsive to the emitted stimulations linked... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070036771 - Biologic device for regulation of gene expression and method therefor: A system and device are provided which include a gene regulatory system controlling expression of one or more expression cassettes present in or released by the device, by emitting one or more stimulations. An expression cassette includes a regulatable transcription control element that is responsive to the emitted stimulations linked... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070036769 - Bmp pathway methods and compositions: The present invention relates to mutant BMP intestinal stem cells (ISCs), with these mutant ISCs possessing an inactive Bmpr1a receptor in which BMP binding is substantially inhibited. The present invention relates to vectors which comprise mutant Bmpr1a nucleic acid sequences, whereby the vectors can be used to promote an increase... Agent: Polsinelli Shalton Welte Suelthaus P.C.

20070036772 - Directed in vitro differentiation of marrow stromal cells into neural cell progenitors: The invention relates to methods for inducing marrow stromal cells to differentiate into neural cells by way of increasing intracellular levels of cyclic AMP. The invention also encompasses methods of producing a neural cell by causing a marrow stromal cell to differentiate into a neural cell by increasing intracellular levels... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070036773 - Generation and application of universal t cells for b-all: The present invention is directed to universal T cells and their use in treating diseases and other physiological conditions. More specifically, the present invention is directed to universal T cells and their use in treating treating B-lineage acute lymphoblastic leukemia (B-ALL) in particular and malignancy in general. The universal T... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070036774 - Liver engrafting cells, assays, and uses thereof: A substantially enriched mammalian hepatic liver engrafting cell population is provided. Methods are provided for the isolation and culture of this liver engrafting cell. The progenitor cells are obtained from a variety of sources, including fetal and adult tissues. The cells are useful in transplantation, for experimental evaluation, and as... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070036775 - Method of modulating or examining ku70 levels in cells: A method of predicting whether cells would respond to therapies which are mediated through Bax-regulated apoptosis is disclosed. In one embodiment, the method comprises the step of: (a) examining the intensity of the expression of the Bax protein or mRNA in a cell relative to a control, and (b) based... Agent: Quarles & Brady LLP

20070036776 - Bacterial signaling molecules that down-regulate pathogenic bacterial virulence properties: This invention relates to composition and methods of employing said composition for treating or preventing microbial associated infections and diseases. More particularly the present invention relates to bacterial proteins, peptides and amino acids which are by-products of bacteria, in particular Lactobacillus and more specifically Lactobacillus strains GR-1 and RC-14, in... Agent: Scully Scott Murphy & Presser, PC

20070036767 - Postpartum cells derived from umbilical cord tissue, and methods of making and using the same: Cells derived from human umbilical cords are disclosed along with methods for their therapeutic use. Isolation techniques, culture methods and detailed characterization of the cells with respect to their cell surface markers, gene expression, and their secretion of trophic factors are described.... Agent: Woodcock Washburn LLP

20070036768 - Systems and methods for treating patients with processed lipoaspirate cells: Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are... Agent: Knobbe Martens Olson & Bear LLP

20070036765 - Therapeutic and diagnostic applications of genes differentially expressed in lympho-hematopoietic stem cells: The invention is based at least in part on the discovery of novel group of genes and/or their encoded gene products that are differentially represented in two substantially enriched CD34+/CD38−/Lin− and CD34+/[CD38/Lin]++ hematopoietic cell populations isolated from normal human bone marrow, cord blood, and peripheral blood stem cell preparations.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070036766 - Tissue graft composition comprising autologous bone marrow and purified autologous thrombin: A method for the preparation of an autologous tissue graft composition is disclosed. Bone marrow is harvested from the patient. In one embodiment, the nucleated cells of the bone marrow are subsequently concentrated. Autologous thrombin is purified from a volume of whole blood also taken from the patient. The bone... Agent: Heslin Rothenberg Farley & Mesiti PC

20070036777 - Stabilized pancreas product: The present invention provides stabilized pancreas products useful, for example, as an animal feed additives. The invention also provides for feed additives and feed rations comprising a stabilized pancreas product. Further, the invention provides for methods of making stabilized pancreas products. The present invention also provides for methods of supplementing... Agent: Cargill, Incorporated

20070036780 - Modified proteins, designer toxins, and methods of making thereof: The present invention concerns methods of reducing the antigenicity of a proteinaceous compound while maintaining the compounds biological activity, as well as proteinaceous compositions with biological activity but reduced antigenicity. These methods and compositions have significant benefits to a subject in need of such compounds and compositions. Also included are... Agent: Fulbright & Jaworski L.L.P.

20070036778 - S. epidermidis antigens: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. epidermidis, methods for isolating such antigens and specific uses thereof.... Agent: Fulbright & Jaworski L.L.P.

20070036779 - Stabilising formulation for immunoglobulin g compositions in liquid form and in lyophilised form: This invention is related to a stabilising formulation for immunoglobulins G compositions comprising a sugar alcohol, glycine and a non-ionic detergent, which is suitable for the stabilization of immunoglobulins G compositions in liquid form and in lyophilised form. The invention also relates to an immunoglobulins G composition in liquid form... Agent: Birch Stewart Kolasch & Birch

20070036783 - Antibody complexes: This invention is directed to a soluble complex of ligands that binds to surface molecules of hemopoietic cells and result in their activation or expansion. The complex may be used in the activation and/or expansion of hemopoietic cells, optionally in combination with their transduction. The complex of ligands bind at... Agent: Townsend And Townsend And Crew, LLP

20070036782 - Apo-2 ligand: A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand... Agent: Genentech, Inc.

20070036781 - Ligands: A method of detecting an agent that modulates the activity of CCRL2, the method comprising: (a) contacting a CCRL2 polypeptide with a macrophage inflammatory protein-4 (MIP-4) polypeptide in the presence of a candidate agent under conditions, which in the absence of the test agent, permit the binding of the MIP-4... Agent: Nixon & Vanderhye, PC

20070036784 - Medicament for the protection against thrombotic diseases: A medicament for the protection against thrombotic diseases is described that comprises an active principle which induces irreversible inactivation or degradation of the collagen receptor on thrombocytes. Antibodies, especially the humanized monoclonal antibody JAQ1, are the preferred active principle. Further a diagnostic agent for the determination of the expression rate... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070036785 - Pharmaceutical composition for treatment of diseases caused by il-6 production: Pharmaceutical compositions for prevention or treatment of diseases caused by interleukin-6 production, comprising an antibody to interleukin-6 receptor (IL-6R antibody). As the IL-6R antibody, an antibody of animals other than the human such as mice, rats, etc., a chimeric antibody between these and a human antibody, a reshaped human antibody,... Agent: Foley And Lardner LLP Suite 500

20070036786 - Method of treating autoimmune disease using humanized anti-cd16a antibodies: CD16A binding proteins useful for the reduction of a deleterious immune response are described. In one aspect, humanized anti-CD16A antibodies, optionally lacking effector function, are used for treatment of immune disorders such as idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia.... Agent: Jones Day

20070036792 - Antibodies that specifically bind to reg iv: The present invention relates to antibodies and related molecules that specifically bind to Reg IV. Such antibodies have uses, for example, in the prevention and treatment of gastrointestinal tract cancers, inflammatory bowel disorders, and diabetes. The invention also relates to nucleic acid molecules encoding anti-Reg IV antibodies, vectors and host... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20070036787 - Insulin-induced gene as therapeutic target in diabetes: The present invention relates to the use of a modulator of the expression or activity of the E2IG4 gene for the treatment of diabetes or its complications, obesity or insulin resistance, to a method of screening compounds useful in the treatment of these pathological conditions, and to a method for... Agent: Millen, White, Zelano & Branigan, P.C.

20070036791 - Interleukin-17 receptor homologue: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor14.”... Agent: Zymogenetics, Inc. Intellectual Property Department

20070036789 - Neutralizable epitope of hgf and neutralizing antibody binding to the same: The neutralizing antibody against HGF binding to the inventive neutralizable epitope of HGF is capable of neutralizing HGF as a single agent, and can be effectively used for preventing and treating intractable diseases and cancers that are caused by binding of HGF to its receptor Met.... Agent: Sughrue Mion, PLLC

20070036790 - Treatment with anti-vegf antibodies: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.... Agent: Genentech, Inc.

20070036788 - Use of a compound for reducing the biological effectiveness of il-6: Use of a compound comprising at least a structural entity which binds or is an antagonist for interleukin-6 (IL-6) and/or the IL-6 receptor or parts of it, preferably human IL-6 which compound depletes IL-6 from a solution or blocks at least one or more IL-6 functions on cell surfaces or... Agent: Jacobson Holman PLLC

20070036794 - Agonist anti-trk-c monoclonal antibodies: The invention concerns agonist anti-trkC monoclonal antibodies which mimic certain biological activities of NT-3, the native ligand of trkC. The invention further concerns the use of such antibodies in the prevention and/or treatment of cellular degeneration, including nerve cell damage associated with acute nervous cell system injury and chronic neurodegenerative... Agent: Heller Ehrman LLP

20070036793 - Methods for use of an lkb1/strad7mo25 complex: A method for identifying a compound for use in modulating, for example promoting, the activation or phosphorylation of AMPK (AMP-activated protein kinase) or AMPK subfamily member in a cell, the method comprising the steps of (1) determining whether a test compound modulates, for example promotes, the protein kinase activity of... Agent: Rogalsky & Weyand, LLP

20070036796 - Antibodies against ccr5 and uses thereof: Antibodies that specifically bind to CCR5 are useful for treating immunosuppressive disease.... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20070036799 - Identification and engineering of antibodies with variant fc regions and methods of using same: The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to... Agent: Jones Day

20070036798 - Method and composition for reconforming multi-epitopic antigens to initiate an immune response: The invention concerns methods and compositions for intiating and/or enhancing an immune response by contacting a binding reagent with a soluble antigen, wherein the binding reagent-antigen pair generates an immune response to the antigen.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070036795 - Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular agonist: The present invention relates to methods of inhibiting receptor tyrosine kinases by utilizing a combination of both an extracellular and an intracellular RTK antagonist. The extracellular RTK antagonist is a biological molecule or a small molecule that inhibits activation of the receptor tyrosine kinase by interacting with the extracellular binding... Agent: Kenyon & Kenyon LLP

20070036797 - Methods of treating brain tumors with antibodies: The application is directed toward a method of treating a brain tumor in a patient comprising systemically administering a monoclonal antibody.... Agent: Townsend And Townsend And Crew, LLP

20070036800 - Novel methods of cancer diagnosis and therapy targeted against a cancer stem line: Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment.... Agent: Jones Day

20070036801 - Novel methods of cancer diagnosis and therapy targeted against a cancer stem line: Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment.... Agent: Jones Day

20070036802 - Novel methods of cancer diagnosis and therapy targeted against a cancer stem line: Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment.... Agent: Jones Day

20070036803 - Novel methods of cancer diagnosis and therapy targeted against a cancer stem line: Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment.... Agent: Jones Day

20070036804 - Novel methods of cancer diagnosis and therapy targeted against a cancer stem line: Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer treatment and reduce the likelihood of clinical relapse after treatment.... Agent: Jones Day

20070036805 - Compositions comprising large and small binding fragments of antibodies against the same toxin: A pharmaceutical composition comprising (i) a first specific binding agent selected from an antibody or a large binding fragment of an antibody which specifically binds a target toxin, and (ii) a second specific binding agent which comprises a small binding fragment of an antibody which binds said toxin. The compositions... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20070036806 - Glp-1 analog fusion proteins: The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduce effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or... Agent: Eli Lilly & Company

20070036807 - Compositions comprising structurally stable conjugate molecules: The present invention provides compositions comprising conjugate molecules that are structurally stable at a temperature of between about 2 degrees C. and 8 degrees C. In some examples, a conjugate molecule comprises an antigen, such as an allergen. In some examples, a conjugate molecule comprises the Ragweed antigen Amb a... Agent: Morrison & Foerster LLP

20070036808 - Cancer antigen peptide formulations: Cancer antigen peptides derived from WT1 which have an in vivo efficacy, particularly a clinical usefulness, and cancer vaccines as dosage forms suitable for said cancer antigen peptides, are provided. The invention relates to water-in-oil emulsions which comprise as an effective ingredient either one or both of peptides selected from... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070036810 - Cyclic amp response element activator proteins and uses related thereto: The invention discloses newly identified cyclic AMP response element activator proteins (CREAP proteins). It is contemplated herein that said proteins are suitable drug targets for the development of new therapeutics to prevent, treat or ameliorate pathological conditions related to abnormal activation of CRE-dependent gene expression or abnormal activation of chemokines.... Agent: Novartis Corporate Intellectual Property

20070036812 - Hla-a24 binding cancer antigen peptide derived from livin: The present invention provides a partial peptide consisting of 8-11 contiguous amino acids in the amino acid sequence of livin set forth in SEQ ID NO: 1, which binds to HLA-A24 antigen and is recognized by cytotoxic T cells (CTLs), a polynucleotide encoding the peptide, and cancer vaccine comprising the... Agent: Birch Stewart Kolasch & Birch

20070036811 - Therapeutic cancer vaccine: The present invention relates to polypeptide fragments capable of raising a specific T-cell response, wherein said fragment comprises a peptide consisting of at least 9 consecutive amino acid residues of ML-IAP as well as to said fragments for use as medicaments. The invention furthermore relates to use of said polypeptide... Agent: Knobbe Martens Olson & Bear LLP

20070036809 - Tolerance-induced targeted antibody production: The present invention provides methods for directing the immune response of an animal towards immunologically weak or rare antigens such as tumor antigens. The methods combine subtractive immunization with hyperimmunization and result in the controlled or directed production of target-specific antibodies, helper T cells (CD4+-T lymphocytes) and cytotoxic T cells... Agent: Dilworth & Barrese, LLP

20070036813 - Vegf-related protein: A human VEGF-related protein (VRP) has been identified and isolated that binds to, and stimulates the phosphorylation of, the receptor tyrosine kinase Flt4. The VRP is postulated to be a third member of the VEGF protein family. Also provided are antibodies that bind to VRP and neutralize a biological activity... Agent: Genentech, Inc.

20070036815 - Ricin-like toxins for treatment of cancer: The present invention provides a protein having chain of a ricin-like toxin, a B chain of a ricin-like toxin and a novel heterologous linker amino acid sequence, linking the A and B chains. The linker sequence contains a cleavage recognition site for a specific protease such as those found in... Agent: Bereskin And Parr

20070036814 - S. aureus fibrinogen binding protein gene: The isolation of genes and proteins from Staphylococcus aureus is provided, and the nucleic acids coding for specific regions of the S. aureus CIfA protein are described. The nucleic acids encode proteins that can be useful as vaccines or in pharmaceutical compositions for application to prevent infection, promotion of wound... Agent: Stites & Harbison PLLC

20070036816 - Tuberculosis antigen detection assays and vaccines: The present invention relates to isolated Tuberculosis (TB) antigens that are useful in therapeutic and vaccine compositions for stimulating a TB specific immunological response. The identified antigens are also useful in diagnostic assays to determine the presence of active TB in an individual. Accordingly, the present invention includes polypeptide molecules,... Agent: Antoinette G. Giugliano, P.C.

20070036817 - Immunopotentiating effect of a fomitella fraxinea-derived lectin on chicken immunity and resistance to coccidiosis: This study reports a novel immunopotentiating effect of a lectin (FFrL) extracted from the mushroom Fomitella fraxinea on poultry cell-mediated immunity and poultry coccidiosis. We describe the extraction of FFrL, its in vitro mitogenic activity and in vivo protection against an oral challenge infection with Eimeria acervulina. When tested on... Agent: Usda, Ars, Ott

20070036819 - Malaria vaccines: The invention provides isolated placental P. falciparum polypeptides comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:1-4 and 6-24, and immunogenic derivatives thereof. The invention also provides isolated nucleic acid molecules encoding the placental P. falciparum polypeptides of the invention, compositions comprising one or more... Agent: Seattle Biomedical Research Institute Attn: Karen Blochlinger

20070036818 - Recombinant protein containing a c-terminal fragment of plasmodium msp-1: The present invention provides a recombinant protein comprising a 19 kDa C-terminal fragment of the surface protein 1 of the merozoite form of a Plasmodium type parasite other than Plasmodium vivax which is infectious in man.... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070036820 - Yeast compositions useful as anti-aging dietary supplements: Compositions comprising a plurality of yeast cells, wherein said plurality of yeast cells have been cultured in the presence of an alternating electric field having a specific frequency and a specific field strength for a period of time sufficient to increase the capability of said plurality of yeast cells to... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070036821 - Seaweed extract composition for retardation of cardiovascular disorders and preservation of healthy cardiovascular function: The invention of comprises of a method and composition for retardation of cardiovascular disorder in a mammal comprising the step of administering to a mammal an amount of seaweed extract in effective doses. The invention also comprises a composition and method for preserving cardiovascular health in a mammal comprising the... Agent: Inhouse Co.

20070036823 - Development of a live, attenuated, recombinant vaccine for brucellosis: A recombinant, attenuated strain of Brucella suis with a deficiency in carboxyl-terminal protease (CtpA) activity can be used as a vaccine for the prevention or treatment of Brucellosis. Prior exposure to the Brucella species is identified by detecting a genetic sequence for carboxyl-terminal protease activity in a biological sample.... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20070036822 - Selection system containing non-antibiotic resistance selection marker: A selection system free of antibiotic resistance genes, which is based on the use of an araD gene as a selection marker carried on a vector which is inserted in a bacterial strain deficient of the araD gene. The araD gene from E. coli encodes the L-ribulose-5-phosphate-4-epimerase. A method of... Agent: Buchanan, Ingersoll & Rooney PC

20070036825 - Flavivirus ns5a proteins for the treatment of hiv: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving a-GBV-C NS5A peptide or polypeptide for inhibiting and treating HIV infections.... Agent: Fulbright & Jaworski L.L.P.

20070036826 - Influenza immunogen and vaccine: A chimeric, carboxy-terminal truncated hepatitis B virus nucleocapsid (HBc) protein is disclosed that contains an immunogen for inducing the production of antibodies to the influenza M2 protein. An immunogenic influenza sequence in two to four copies is preferably expressed at or near the N-terminus or in the HBc immunogenic loop... Agent: Edward P. Gamson Suite 2200

20070036824 - Optimized expression of hpv 58 l1 in yeast: Synthetic DNA molecules encoding the HPV58 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV58 L1 protein, wherein said polynucleotides are codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV58 virus-like particles (VLPs), and to produce vaccines and... Agent: Merck And Co., Inc

20070036827 - West nile virus vaccine: A vaccine composition and method of administering same is provided that utilizes an isolated nucleic acid corresponding to substantially an entire Kunjin virus which upon administration to an animal is capable of eliciting a protective immune response to another, more pathogenic flavivirus such as West Nile virus NY 99 strain.... Agent: Leydig Voit & Mayer, Ltd

20070036828 - Group b streptococcus vaccine: This application relates to improved Group B Streptococcus (“GBS”) saccharide-based vaccines comprising combinations of GBS polysaccharides with polypeptide antigens, and vice versa, such that the polypeptide and the saccharide each contribute to the immunological response in a recipient. The combination is particularly advantageous where the saccharide and polypeptide are from... Agent: Novartis Vaccines And Diagnostics Inc.

20070036830 - Container: A container and more specifically a container such as a capsule used to deliver dosages of pharmaceuticals, medicines, vitamins, etc. to an individual is discussed. In one embodiment, the invention includes a container comprising: a cap; a body slidably engagable inside the cap; and a fluid gap positioned between the... Agent: Rosemary M. Miano Attorney For Applicant

20070036831 - Nanoemulsion compositions having anti-inflammatory activity: Nanoemulsion compositions with low toxicity that demonstrate broad spectrum inactivation of microorganisms or prevention of diseases are described. The nanoemulsions contain an aqueous phase, an oil phase comprising an oil and an organic solvent, at least one anti-inflammatory agent, and one or more surfactants. Methods of making nanoemulsions and inactivating... Agent: Foley And Lardner LLP Suite 500

20070036829 - Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye: An ophthalmic composition is self-emulsifying. The composition includes oil globules having an average size of less than 1 micron dispersed in an aqueous phase. These globules include a surfactant component with one or two surfactants and a polar oil component. The surfactant component and the oil component are selected to... Agent: Knobbe Martens Olson & Bear LLP

20070036833 - Mosquito-repellant patch: A mosquito-repellent patch attached to any place desired by the user either on his body, personal belongings, or any other object is comprised of osmosis layer, lemon grass layer, binding layer and strip-off paper in sequence; the strip-off paper being removed for the patch to stick to any place as... Agent: Leong C Lei

20070036832 - Stabilized halopropynyl compositions as preservatives: Preservative compositions are provided with improved stability. The preservative compositions comprise a combination of an amphoteric compound and 3-iodo-2-propynyl butyl carbamate (IPBC). In a particular embodiment, the compositions comprise a combination of a betaine compound and 3-iodo-2-propynyl butyl carbamate. The compositions in some embodiments have surprising stability. The preservative composition... Agent: King & Spalding LLP

20070036835 - Hermetically sealed devices for controlled release or exposure of reservoir contents: Methods are provided for hermetically sealing an opening in a reservoir of a containment device. The method comprises applying a polymeric material to an opening in a reservoir of a containment device, the reservoir comprising reservoir contents (such as a drug or a sensor) to be hermetically isolated within the... Agent: Sutherland Asbill & Brennan LLP

20070036834 - Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome p450 enzymes and membrane efflux systems following vaginal and oral cavity administration: A vaginal or buccal delivery of therapeutic agents having a substrate affinity for metabolic cytochrome P-450 enzymes and membrane efflux transporter systems. A method for augmentation of systemic exposure to the therapeutic agents having a substrate affinity for cytochrome P-450 enzymes and membrane efflux transporter systems, by delivering said agents... Agent: Peters Verny Jones & Schmitt, L.L.P.

20070036836 - Amino acid supplementation for a healthy microbiota ecosystem: The present invention pertains to a nutritional composition for reconstituting an optimal healthy microbiota ecosystem in humans or animals. In particular, the present invention relates to an ingestible carrier containing specific amino acids designed to favor the growth of bacteria favorable to individuals health or for reducing the risk of... Agent: Bell, Boyd & Lloyd LLC

20070036837 - Dietary supplement and method for increasing the colostrum immunoglobulin levels in equine mares and other animals: A novel dietary supplement and methods for the manufacture and administration of the same are disclosed for feeding to equine mares and other animals prior to parturition to boost the colostrum immunoglobulin level in lactating equine mares and other animals and thereby enhance the passive transfer of immunity to neonatal... Agent: Reinhart Boerner Van Deuren S.c. Attn: Linda Kasulke, Docket Coordinator

20070036838 - Methods and compositions for soothing oral and nasal tissues: Use of a salivating agent in the preparation of a medicament for soothing irritated oral and/or nasal tissues is provided. Compositions comprising a salivating agent and a cooling agent are also provided. The use and compositions provided herein provide improved soothing and relief of irritated oral and/or nasal tissues.... Agent: The Procter & Gamble Company Intellectual Property Division

20070036841 - Method of enhancing an ornithine-urea cycle in ruminant gut tissues to detoxify ammonia and increase local urea recycling to the rumen for microbial protein synthesis: A method of stimulating or enhancing an ornithine-urea cycle in ruminant gut tissues, which entails either feeding to a ruminant an effective amount of a ruminant feed or feed supplement containing an effective amount of a compound which stimulates activity of one or more enzymes required in the ornithine-urea cycle.... Agent: Merchant & Gould PC

20070036840 - Phosphorylated glucomannan polysaccharides containing 1-6 and 1-2 linkages increase weight gain in swine: Phosphorylated glucomannans may be purified from naturally occurring sources and used as a supplement to swine feeds for the benefit of swine production.... Agent: Lathrop & Gage Lc

20070036839 - Phosphorylated glucomannane polysaccharides containing 1-6 and 1-2 linkages increase weight gain in poultry: Phosphorylated glucomannans may be purified from naturally occurring sources and used as a supplement to poultry feeds for the benefit of poultry production.... Agent: Lathrop & Gage Lc

20070036843 - Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents: An improved controlled release composition for non-parenteral administration of active agents and other therapeutics, particularly for oral or topical administration, has been developed. The composition is made by dispersing a complex formed of an active agent bound to an ion-exchange resin or to another form of resin or carrier, in... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070036842 - Non-woven scaffold for tissue engineering: Scaffolds for tissue engineering, and methods and systems for manufacturing the same. The starting material used to manufacture the scaffolds may include a needled non-woven sheet, or a batt of fibers. In either case, the starting material includes a bioabsorbable polymer, such as polyglycolic acid or poly-L-lactide. This allows the... Agent: Edwards & Angell, LLP

20070036845 - Packeted body lotion towelette: A packeted towelette impregnated with body lotion is disclosed in the instant application. The towelette is packaged in a leak proof packet and fits easily into a pocket, purse, suitcase, briefcase, golf bag, gym bag or other container. The body lotion contained within the packet is a mixture of many... Agent: Alan R. Thiele Strasburger & Price, LLP

20070036844 - Porous materials having multi-size geometries: A method for forming a porous three-dimensional (3-D) object includes creating a mold from a negative replica of the 3-D object, the 3-D object having a first size and at least one predetermined feature, and then casting a flowable material into and/or onto the mold. The method further includes forming... Agent: Julia Church Dierker Dierker & Associates, P.C.

20070036846 - Wound dressing and method of manufacture thereof: A hydrogel dressing for covering or treating a wound, a surgical incision, a catheter insertion site or the like, comprising a non-fluid sheet material including a structure of cross-linked polymers and/or monomers having suspended therein an agent for controlling infection of the wound, the incision, the catheter insertion site or... Agent: Smith-hill And Bedell, P.C.

20070036847 - Lowly irritative adhesive patch: An adhesive patch for external use which is significantly inhibited from causing a rash, is less irritative to the skin, and sufficiently retains adhesion to the skin. The adhesive patch is characterized by employing a pressure-sensitive adhesive base into which a sucrose fatty acid ester has been incorporated. It does... Agent: Edwards & Angell, LLP

20070036848 - Estrogen compositions and therapeutic methods of use thereof: A pharmaceutical composition comprises at least one estrogenic compound, the composition being adapted for application in a unit dose amount to a vulvovaginal surface and having at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface, wherein the at least... Agent: Harness, Dickey, & Pierce, P.l.c

20070036849 - Use of phospholipid arachidonic acids for increasing muscle mass in humans: This invention discloses a method of increasing muscle mass comprising administering phospholipid arachidonic acid to a human in need thereof.... Agent: Todd S. Parkhurst Holland & Knight LLP

20070036850 - Film-coated tablet or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound: Film-coated tablet, consisting of a tablet core with a film coating, or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound, preferably imatinib or a pharmaceutically acceptable salt of imatinib, preferably imatinib monomethanesulfonate, wherein (i) the tablet cores and the granules have been... Agent: Hoffmann & Baron, LLP

20070036851 - Acid labile drug compositions: A composition and method of making a pharmaceutical dosage form containing an acid labile drug bound to an ion exchange resin is provided. The composition may be coated with a low acid content enteric coating. The binding of the acid labile drug to the exchange resin stabilizes the drug against... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20070036853 - Generally linear effervescent oral fentanyl dosage form and methods of administering: Fentanyl containing dosage forms and methods using same are described. These dosage forms include substantially less fentanyl by weight than know oral formulation and have advantages in terms of cost and side effects. These dosage forms are intended for oral administration of fentanyl across the oral mucosa.... Agent: Cima Lerner, David Et Al

20070036852 - Rapidly dispersing/disintegrating compositions: The present invention relates to a rapidly dispersing/disintegrating, taste masked oral ondansetron dosage forms and a simple and economic process for their manufacture which can be easily scaled up. In particular, the present invention relates to a compressed dosage form for oral administration capable of being rapidly disintegrated comprising a... Agent: Novartis Corporate Intellectual Property

20070036854 - Therapeutic applications of pro-apoptotic benzodiazepines: wherein R1, R2, R3 and R4 are as defined. The invention also includes enantiomers, pharmaceutically acceptable salts, prodrugs or derivatives of the benzodiazepine compounds. Any one or more of these benzodiazepine compounds can be used to treat a variety of dysregulatory disorders related to cellular death. Such disorders include autoimmune... Agent: Medlen & Carroll, LLP

20070036855 - Soft polylactides: Biodegradable polymeric compositions that are liquids or pastes at temperatures below 37° C. are described. Immersion of the compositions in aqueous medium, such as body fluids, increases the viscosity of the composition resulting in the formation of a semisolid material. The polymeric material is a hydroxyalkanoic acid polyester derived from... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070036856 - Diltiazem controlled release formulation and method of manufacture: A controlled release diltiazem dosage formulation comprising a plurality of diltiazem pellets and a gel-forming material where the time of maximum diltiazem blood plasma levels occurs more than 8 hours after administration and preferably more than 10 hours after administration.... Agent: Hedman & Costigan P.C.

20070036857 - Pharmaceutical multiparticulate composition comprising mycophenolic acid or mycophenolate sodium and combination with rapamycin: The present invention relates to a novel composition of mycophenolic acid, a salt or a prodrug thereof and to a fixed combination of mycophenolic acid, a salt or a prodrug thereof and rapamycin or a rapamycin derivative.... Agent: Novartis Corporate Intellectual Property

20070036858 - Drug delivery system for topical administration: This invention is directed to new drug delivery systems (SMS packaging™) and uses thereof, of freshly prepared, effective, high concentrated, hygienic pharmaceutical compositions. The new delivery systems, including sucralfate, is used for treating and preventing oral diseases in mammals. Moreover this invention provides pharmaceutical compositions, methods and kits for topical... Agent: Pearl Cohen Zedek, LLP Pearl Cohen Zedek Latzer, LLP

20070036859 - Sustained release antihistamine and decongestant composition: A controlled-release, non-sedating antihistamine and decongestant composition which provides a 24-hour decongestant dissolution profile using standard ungranulated xanthan gum as the sole controlled-release agent and a process for preparing the same is provided. The pharmaceutical composition of the present invention typically includes: a compressed extended-release core comprising a pharmaceutically effective... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20070036860 - Treatment of allergic conditions: Orally administered sodium cromoglycate has been found to be effective in the treatment of allergic conditions such as asthma, general food allergies, ulcerative colitis, atopic eczema, chronic urticaria and irritable bowel syndrome if it is presented such that the sodium cromoglycate becomes bioavailable within 10 minutes of exposure to intestinal... Agent: Haugen Law Firm

20070036861 - Orally-dispersible multilayer tablet: The present invention relates to a multilayer orodispersible tablet and to the process for preparing it.... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20070036863 - Oxacarbazepine film-coated tablets: The invention relates to formulations, e.g. film-coated tablets containing oxcarbazepine and to processes for the production of said formulations. The film-coated tablets have a tablet core comprising a therapeutically effective dose of oxacarbazepine being in a finely ground form having a mean particle size of from 4 to 12 μm... Agent: Novartis Corporate Intellectual Property

20070036862 - Treatment with azetidinone-based cholesterol absorption inhibitors and omega-3 fatty acids and a combination product thereof: Combinations of one or more azetidinone-based cholesterol absorption inhibitors with mixtures of omega-3 fatty acids, methods of administering such combinations, and unit dosages of such combinations.... Agent: Arent Fox PLLC

20070036866 - Cationic block copolymers: The invention relates to cationic block copolymers of formula A(—X—B)n or C(—Y—D)m, wherein A represents a hydrophilic polymer, B represents polyethyleneimine (PEI), X represents a bridge, n represents 1-200, C represents PEI, D represents the residue of a polyethylene glycol, Y represents a bridge and m represents 1-200. The invention... Agent: Propat, L.L.C.

20070036865 - Endosomolytic polymers: We describe pH-sensitive endosomolytic polymers, delivery particles containing pH-sensitive endosomolytic polymers. The described particles are capable of delivering polynucleotides to cells from the peripheral circulation with subsequent release from endosomes. The endosomolytic polymers are inactive outside the cell but disrupt membranes upon exposure to an acidified endosomal compartment.... Agent: Mirus Corporation

20070036864 - Hygeine product for mouth: An oral hygiene product, such as tooth paste, is described. A methos for controlling undesirable bacterial flora in the oral cavity, as well as the use of the plant Sphagnum, are also described.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070036867 - Controlled and sustained gene transfer mediated by thiol-modified polymers: A delivery system employing nanoparticles of thiolated chitosan which complex with nucleic acids or other drugs. The system utilizes an approximately 33 kDa thiol-modified chitosan derivative resulting in highly effective gene delivery. Thiolation of chitosan resulted in reduced density of positive charges and DNA binding capacity. However, thiolated chitosan carrying... Agent: Smith Hopen, Pa

20070036868 - Particulate vitamin composition: A particulate composition comprising (a) an oil of a vitamin, an oil containing one or more vitamin or a derivative, (b) a gelling agent of vegetable origin, having a glass transition point greater than 20° C., and (c) a protein, except gelatine.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070036869 - Methods for prophylactic and therapeutic nutritional supplementation: The present invention relates to methods for prophylactic nutritional supplementation and therapeutic nutritional supplementation. Specifically, the method involves administering to an individual a composition comprising vitamin A, vitamin E, vitamin D, vitamin C, thiamine, riboflavin, niacin, folic acid, pyridoxine, biotin, pantothenic acid, cobalamin, magnesium, manganese, zinc, selenium, chromium, copper, iron,... Agent: Preston Gates Ellis & Rouvelas Meeds LLP

20070036870 - Aiding of cognitive function: The invention provides the use of a bioavailable iron compound and a bioavailable zinc compound in a weight ratio of at least 2:1, and at least one B vitamin, in the manufacture of an edible composition, for use in aiding the cognitive development or cognitive performance of humans having an... Agent: Unilever Intellectual Property Group

20070036871 - Technique for treatment and prevention of fungal diseases in growing grapes by application of a sodium chlorite, urea sulfuric acid solution: A technique for reducing fungal disease in grape vineyards involves the generation of chlorine dioxide gas by dissolution of sodium chlorite with a urea sulphuric acid (monocarbamide dihydrogen sulphate) activating acid in water, followed by foliar application of the solution/gas to the vines.... Agent: Hogan & Hartson LLP

20070036872 - Alpha-glucosidase activity inhibitor: The present inventors focused on the lotus plant and prepared lotus extracts. When α-glucosidase and its substrate sucrose were reacted with the lotus extracts to examine the effect of adding the extracts on the enzymatic reaction, the lotus extracts were found to have α-glucosidase inhibitory activity. Furthermore, when the lotus... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070036873 - Method of treatment or management of stress: The present invention provides a method of treatment or management of various adaptogenic conditions, such as, stress in mammals, more particularly, humans, comprising administering Withania somnifera plant extract. A high purity extract composition comprising withanolide glycosides, oligosaccharides, withanolide aglycones and a minimum level of polysaccharides, and a pharmaceutically, veterinary or... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20070036874 - Compositions and methods for controlling glucose and lipid uptake from foods: The invention relates to compositions comprising three inhibitors, one pancreatic lipase inhibitor, an alpha glucosidase inhibitor, and a sodium dependent glucose transporter inhibitor. The invention also provides methods of using the compositions for controlling glucose and lipid uptake.... Agent: Morrison & Foerster LLP

20070036875 - Use of allicin as preservative, as disinfectant, as antimicrobial or as biocidal agent: The present invention provides the use of allicin in (i) the treatment of leishmaniasis; (ii) as a disinfectant or biocida treatment of aquatic species; (iii) as an antimicrobial agent for animal feed; (iv) as a preservative agent in foodstuffs; (v) as a water disinfectant or biocide; (vi) as an antiparasitic... Agent: Connolly Bove Lodge & Hutz LLP

20070036876 - Injectable capsaicin: The present invention provides compositions and methods for relieving pain at a site in a human or animal in need thereof by administering at a discrete site in a human or animal in need thereof a dose of capsaicin in an amount effective to denervate a discrete site without eliciting... Agent: Davidson, Davidson & Kappel, LLC

20070036877 - Oral compositions and route of administration for the delivery of a thylakoid extract: The present invention provides a new use for a thylakoid extract, that is for oral route of administration, and a composition comprising the thylakoid extract in adjunction with an acceptable carrier for oral administration. Besides the pharmaceutical use, the thylakoid extract enters the composition of food or food supplements, for... Agent: Marshall, Gerstein & Borun LLP

20070031326 - Compounds that selectively bind to membranes of apoptotic cells: This invention provides new small-molecules capable of selective binding to membranes comprising and exposing phosphatidylserine on their surface and/or membranes which have increased amounts of phosphatidylethanolamine in their outer leaflet.... Agent: Pearl Cohen Zedek, LLP Pearl Cohen Zedek Latzer, LLP

20070031327 - Nanoradiopharmaceuticals and methods of use: The present invention is directed to novel compositions and the use thereof More particularly, the present invention relates to nanoradiophannaceuticals, radioactive nanoparticles, and methods of using them for a range of applications including diagnostic imaging and the treatment of disease.... Agent: Woodcock Washburn LLP

20070031328 - Radiolabeled-pegylation of ligands for use as imaging agents: The present invention is directed to a method of using radiolabeled ethylene glycol (n=1) (EG) or polyethylene glycol (n=from 2 to 10) (PEG) as a labeling group moiety on compounds that can be useful for imaging tissues. Specifically, the EG or PEG moiety preferably contains a radiofluorine (18F), and is... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070031330 - Cancerous disease modifying antibodies: The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can... Agent: Mchale & Slavin, P.A.

20070031329 - Method of obtaining gallium-68 and use thereof and device for carrying out said method: The present invention relates to a method of obtaining from a 68Ge/68Ga generator and a method of producing 68Ga-radiolabelled complexes using the obtained 68Ga. The invention further relates to a kit, which could be used to obtain 68Ga and a kit, which could be used for the production of 68Ga-radiolabelled... Agent: Ge Healthcare, Inc.

20070031331 - Treatment of disorders: The present invention concerns treatment of polychondritis or mononeuritis multiplex in a mammal with an effective amount of an antibody that binds to CD20, optionally also with another agent that treats such disorders in an effective amount.... Agent: Genentech, Inc.

20070031332 - Angiogenic agents from plant extracts, gallic acid, and derivatives: An extract of Chinese blackberry (Rubus suavissimus) has been found to inhibit angiogenesis, and two active fractions isolated. Gallic acid was shown to be one of the active anti-angiogenic compounds by an in vitro human angiogenesis model. Aqueous extracts from other plants either known or found to have gallic acid... Agent: Patent Department Taylor, Porter, Brooks & Phillips, L.l.p

20070031333 - Novel f-18 labeled annexin v, synthesis thereof, and use thereof: A method for noninvasive measurement of apoptosis is described. The method includes the steps of labeling Annexin V with a positron emitter, injecting the labeled Annexin V into a target cell group, obtaining an image of the target cell group using a positron emission tomography scanner, and evaluating the image... Agent: Patent Administrator Katten Muchin Rosenman LLP

20070031334 - Vitamin-targeted imaging agents: for use in such methods. In the compound, V is a vitamin that is a substrate for receptor-mediated transmembrane transport in vivo, or a vitamin receptor binding derivative or analog thereof, L is a divalent linker, R is a side chain of an amino acid of the formula H2NCHRCOOH, M... Agent: Barnes & Thornburg LLP

20070031335 - Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers: Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene... Agent: Kate H. Murashige Morrison & Foerster LLP

20070031339 - Contrast agents: The present invention relates to particles comprising cores of tungsten or tungsten in mixture with other metallic elements as the contrast enhancing material wherein said core are coated, to pharmaceuticals containing such particles, and to the use of such pharmaceuticals specifically as contrast agents in diagnostic imaging, in particular in... Agent: Ge Healthcare, Inc.

20070031336 - 3h-phenoxazine derivatives suitable as near-infrared imaging agents, preparation an use thereof: The present invention provides compounds of formula (I) wherein X and Y represent CH, CH2 or a divalent or trivalent heteroatom under the proviso that X and Y are not simultaneously CH or CH2; m and o represent independently of each other 0 or 1, with the proviso that if... Agent: Novartis Corporate Intellectual Property

20070031338 - Embolized cryoablation for treatment of tumors: An embolized-cryoablation method for treating a tumor of an organ is provided. The method includes inserting a catheter in a vascular pathway connected to a target region adjacent the tumor, and advancing the catheter through the vascular pathway to place a distal end portion of the catheter in the target... Agent: Melvin K. Silverman

20070031337 - Nanoparticle enhanced proton computed tomography and proton therapy: Gold nanoparticles, which have a very high physical density, are bound to a specific antibody for cancer cells and then delivered to areas in which the tumors are believed to be present. The antigens of the cancer cells attract the antibodies bound to the gold nanoparticles so that the gold... Agent: Knobbe Martens Olson & Bear LLP

20070031344 - Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis: Pharmaceutical compositions are described that contain one agent for treatment of sinusitis and a surfactant. The compositions are prepared to have a surface tension that renders the composition effective for treatment of sinusitis.... Agent: Wilson Sonsini Goodrich & Rosati

20070031343 - Flavored medicinal inhalant: A flavored medicinal inhalant includes a medicant, a carrier and an effective amount of a flavoring agent. Carriers such as saline or bacteriostatic water may be utilized. Flavoring agents include natural and artificial flavors chosen from synthetic flavor oils and flavoring aromatics, and/or oils, oleo resins and extracts derived from... Agent: Mark Young, P.A.

20070031345 - Generation of therapeutic microfoam: A method for producing a microfoam suitable for use in scleropathy of blood vessels comprises introducing a physiologically acceptable blood-dispersible gas into a container (I) holding an aqueous sclerosant liquid and releasing the mixture of blood-dispersible gas and sclerosant liquid, whereby upon release of the mixture the components of the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070031346 - Generation of therapeutic microfoam: A method for producing a microfoam suitable for use in scleropathy of blood vessels comprises introducing a physiologically acceptable blood-dispersible gas into a container (1) holding an aqueous sclerosant liquid and releasing the mixture of blood-dispersible gas and sclerosant liquid, whereby upon release of the mixture the components of the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070031341 - Methods of delivering therapeutics to the brain: Intranasal iontophoretic administration of therapeutics such as Reduced Water (RW) or lubeluzole as a means of treating diseases of the CNS involving oxidative stress.... Agent: Philip S. Johnson Johnson & Johnson

20070031342 - Sustained release microparticles for pulmonary delivery: A composition of microparticles for delivery to the pulmonary system provides sustained release of a pharmaceutical agent. The microparticles comprise a lipid structural matrix comprising a multilamellar structure of lipid bilayers having lipid chains ordered in an LβL phase. The lipid matrix at least partially encapsulates the pharmaceutical agent at... Agent: Michael Einschlag Nektar Therapeutics

20070031340 - Thin-film drug delivery article and method of use: An article for use in an aerosol device, for producing an aerosol of a drug composition is disclosed. The article includes a heat-conductive substrate having a surface with a selected surface area, and a drug composition film on the substrate surface having a selected film thickness of between 0.05 and... Agent: Swanson & Bratschun, L.l.c

20070031347 - Powdered medicaments containing a tiotropium salt and salmeterol xinafoate: The invention relates to powdered preparations for inhalation containing a tiotropium salt and salmeterol xinafoate, processes for preparing them and their use in the preparation of a pharmaceutical composition for treating respiratory diseases, particularly for treating COPD (chronic obstructive pulmonary disease) and asthma.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070031348 - Use of oxygen in cosmetic or dermatological preparations: Use of molecular oxygen in cosmetic or dermatological preparations for the prophylaxis and treatment of a flawed appearance of the skin and/or of the cutaneous appendages as can arise through extrinsic and intrinsic and/or age-related or UV-induced disturbances.... Agent: Greenblum & Bernstein, P.L.C

20070031349 - Rapidly absorbing oral formulations of pde 5 inhibitors: e

20070031350 - Screening method for identification of compounds suitable for treatment of oral cavity malodor associated with consumption of garlic: This invention generally relates to a screening method for identifying compositions suitable for use in an oral composition (e.g., a confection or chewing gum product) effective for the treatment of oral cavity malodor associated with the consumption of garlic. In particular, this invention relates to a screening method for determining... Agent: Senniger Powers (wwy)

20070031351 - Dna sequences encoding novel growth/differentiation factors: The invention provides DNA sequences encoding novel members of the TGF-β family of proteins. The. TGF-β family comprises proteins which function as growth and/or differentiation factors and which are useful in medical applications. Accordingly, the invention also describes the isolation of the above-mentioned DNA sequences, the expression of the encoded... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070031356 - Beta-carotene modulation of gene expression: Methods and compositions—particularly compositions containing β-carotene—for modulating the expression of genes that effect or influence cellular health or protect against cellular damage, e.g., skin aging, are provided. More particularly, a method is provided for screening for a compound that modulates an effect of UV irradiation on eukaryotic cells. Methods and... Agent: Stephen M. Haracz, Esq. Bryan Cave LLP

20070031354 - Cosmetic and topical compositions comprising cuphea oil and derivatives thereof: A method for an oxidatively stable cuphea derived emollient composition having a relatively high capric acid concentration is disclosed. Various features and specifications may be controlled, adapted or otherwise modified to improve the application and utilization of cuphea oil and cuphea oil derivatives as emollients. The present invention generally provides... Agent: Noblitt & Gilmore, LLC.

20070031353 - Cosmetic formulations comprising diketo diphenyl pyrrolo-pyrrole pigments: The present invention relates to cosmetic formulations comprising at least one pigment of formula (I) wherein all substituents have the meanings as defined in the claims, and wherein the pigments have a specific surface area (BET) of 15-200 m2/g, as well as to compositions for making up the skin, both... Agent: Ciba Specialty Chemicals Corporation Patent Department

20070031355 - Dermabrasion composition: A dermabrasion composition containing, in a cosmetically acceptable medium, aluminium oxide particles and pumice powder, and optionally a nonionic surfactant chosen from ethoxylated fatty acid esters that are solid at a temperature equal to 45° C., fatty acid esters of sugars, and mixtures thereof. The exfoliant composition can effectively attenuate... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070031357 - High ph compositions: Disclosed is a method for tanning skin comprising applying to the skin a sunless tanning composition comprising dihydroxyacetone (DHA) and a high pH composition, where the high pH composition is applied to the skin after the sunless tanning composition is applied to the skin. The high pH composition can increase... Agent: Fulbright & Jaworski L.L.P.

20070031352 - Powdery preparations containing diethylamino-hydroxybenzoyl-hexyl-benzoate: the method comprising: a) dispersing the benzoyl benzoate of formula I in an aqueous molecularly disperse or colloidally disperse solution of a protective colloid and b) converting the dispersion obtained into a dry powder by removing the water and and drying, wherein the protective colloid used in process step a)... Agent: Connolly Bove Lodge & Hutz LLP

20070031358 - Cosmetic formulations comprising diketo diphenyl pyrrolo-pyrrole pigments: The present invention relates to cosmetic formulations comprising at least one pigment of formula (I) wherein the pigments have a specific surface area (BET) of 6-200 m2/g, and wherein all substituents have the meanings as defined in the claims, as well as to compositions for making up the skin, both... Agent: Ciba Specialty Chemicals Corporation Patent Department

20070031359 - Confectionary lip gloss and method of use: A confectionary lip gloss product is described. The product includes a vessel with a hollow cavity and an edible fluid confectionary housed within the vessel. An applicator for applying the fluid confectionary to a user's lips can also be provided. A method of consuming a confectionary is also described. The... Agent: Ip Group Of Dla Piper US LLP

20070031361 - Cosmetic, pharmaceutical and dermatological preparations comprising homopolymer and/or copolymer waxes of the monomers ethylene and/or propylene: Cosmetic, pharmaceutical or dermatological preparations are described which comprise one or more homopolymer and/or copolymer waxes of the monomers ethylene and/or propylene. The homopolymer and copolymer waxes have a weight-average molecular weight Mw of less than or equal to 25 000 g/mol, a number-average molecular weight Mn of less than... Agent: Clariant Corporation Intellectual Property Department

20070031360 - Stripless depilatory compositions: A depilatory composition that can be applied in liquid form on the surface of the skin, and which is removable by peeling away from the surface of the skin after setting to a pliable film, said composition consisting essentially of (i) a pliable film forming agent, (ii) a hair binding... Agent: Shyam K. Gupta Bioderm Research

20070031365 - Water-based shampoo: There is provided a shampoo capable of exhibiting a smooth feel of hair upon shampooing and rinsing and imparting good luster and manageability to finished hair. The water-based shampoo of the present invention contains silicone oil droplets dispersed therein wherein said oil droplets is composed of at least (A) 50... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070031362 - Cellulose ethers: A cellulose ether which has from 4,000 to 10.000 anhydroglucose repeat units and is substituted with (a) on the average from 0.0003 to 0.08 moles, per mole of anhydroglucose unit, of a substituent comprising an alkyl or arylalkyl group having from 8 to 24 carbon atoms and (b) a substituent... Agent: Union Carbide Chemicals And Plastics Technology Corporation

20070031363 - Epidermal exfoliation method using a topical composition containing vegetable oil, sugar, vinegar, and egg yolk: A method for exfoliating an epidermal skin layer comprising the steps of: applying a dermatological composition to an epidermal layer to be exfoliated, the dermatological composition containing vegetable oil; at least one sugar; dilute acetic acid; and egg yolk; allowing the composition to remain on the area to be exfoliated... Agent: Angus C. Fox, Iii

20070031364 - Keratin gel and the types 2,4 and 6 of collagens of frog protein topical use or for lamina preparation use, such as dressing powdering in food and complements use and in cosmetic mask manufacturing or in solutions used in cosmetic formulation and medical/: is constituted by keratin gel (1) and the types 2, 4 and 6 of collagens, for topical use or for lamina preparation (2) use, such as biological dressing with the gel (1) powdered (3) for food and complements use (4), or with the mentioned gel (1) and powder (3) used... Agent: Laurence B Bond Traskbritt

20070031366 - Process for obtaining a closer shave: A shaving process for obtaining a closer shave and reducing the subsequent appearance of five o'clock shadow involving the steps of: (a) providing an unshaven skin surface; (b) providing a pre-shave composition containing at least one skin-abrading agent; (c) contacting the unshaven skin surface with the pre-shave composition to form... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070031367 - Composition and method for neck skin firming: A topical composition and method for its use for reducing sagging or wrinkles in the neck area of human skin. The composition includes safe and effective amounts of a mild topical astringent (such as Camphor) for skin tightening, a topical antispasmodic (such as benzaldehyde or benzyl cinnamate) for skin smoothing,... Agent: Christie, Parker & Hale, LLP

20070031368 - Chemokine conjugates: Low molecular weight polypeptides with chemokine activity were conjugated to water-soluble polymers and retain biological activity. These conjugated chemokines demonstrate enhanced and unexpected biological properties when compared to unconjugated chemokines.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070031370 - Amine n-oxide based surfactants: w

20070031369 - Quick dispersing hair conditioning composition: Disclosed is a quick dispersing hair conditioning composition comprising (a) an isostearamidopropyl ethyldimethylammonium salt or a dicocodimethylammonium salt; (b) one or more fatty alcohols; (c) dimethicone; and (d) water. The hair conditioning composition of the invention has one or more advantageous properties. For example, an embodiment of the invention has... Agent: Leydig Voit & Mayer, Ltd

20070031371 - Method for preparing branched functionalized polymers using branched polyol cores: A method of preparing a multiarm polymer includes reacting a branched polyol with one or more functionalizing reagents to effect substitution of an ionizable functional group or a protected ionizable functional group, Y, to form a mixture comprising (i) unsubstituted branched polyol containing no Y groups; (ii) a monosubstituted polyol... Agent: Nektar Therapeutics Intellectual Property Department

20070031373 - Reversal of adult onset disorders with granulocyte-colony stimulating factors: A method for treating adult onset neurodegenerative diseases and diabetes by administering an effective dose of Granulocyte-Colony Stimulating Factors.... Agent: Fitch Even Tabin And Flannery

20070031372 - Vaccine immunotherapy for immune suppressed patients: A method of immunotherapy to treat cancer or a synergistic anti-cancer treatment by administering an effective amount of a natural cytokine mixture (NCM), an effective amount of cyclophosphamide (CY), or an effective amount of indomethacin (INDO), wherein the NCM, CY, or INDO are administered singly or in communications thereof. An... Agent: Kohn & Associates PLLC

20070031374 - Combination therapy: The invention provides combination treatments with IL-21, analogues and derivatives thereof.... Agent: Novo Nordisk, Inc. Patent Department

20070031375 - Il-16 antagonist peptides and dna encoding the peptides: The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acid in length. Based on... Agent: Scully Scott Murphy & Presser, PC

20070031376 - Il-6 receptor. il-6 direct fusion protein: The present invention intends to provide an IL-6R•IL-6 fusion protein and the like in which IL-6R and IL-6 are directly linked without a linker. The IL-6 receptor•IL-6 fusion protein of the present invention has a structure in which one amino:acid residue constituting IL-6 receptor and one amino acid residue constituting... Agent: Sughrue Mion, PLLC

20070031377 - Treatment of type 1 immune response-mediated inflammatory lung disease by modulation of ifn-gamma activity: The present invention relates to preventing, or treating and/or reducing the severity or progression of Type 1 immune response-mediated inflammatory lung disease. More particularly, the present invention provides a method for preventing or treating chronic obstructive pulmonary disease (COPD), severe asthma, sarcoidosis, berylliosis or cystic fibrosis by neutralizing or reducing... Agent: Howrey LLP

20070031380 - Integration-site directed vector systems: Some aspects of the application describe materials and methods for making a molecular tether. A molecular tether, in certain embodiments, includes a target-DNA-binding domain having a specific binding affinity for a target-DNA segment in a host chromosome, a carrier-binding domain that specifically binds to a DNA segment on a carrier,... Agent: Dardi & Associates, PLLC

20070031382 - Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same: A method for introducing and expressing genes in animal cells is disclosed comprising infecting the animal cells with live invasive bacteria, wherein the bacteria contain a eukaryotic expression cassette encoding the gene. The gene may encode, e.g., a vaccine antigen, a therapeutic agent, an immunoregulatory agent or an anti-sense RNA... Agent: Sughrue Mion, PLLC

20070031378 - Minicircle vector production: A plasmid is provided comprising comprising the following functional units: a prokaryotic origin of replication, a marker sequence, two specific recombinase recognition sequences and a multiple cloning site, whereby it comprises a gene coding for a sequence specific recombinase, whereby the units are arranged on the plasmid in such a... Agent: Sughrue Mion, PLLC

20070031381 - Recombinant adenoviral vector and method of use: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also... Agent: Townsend And Townsend And Crew, LLP

20070031383 - Recombinant herpes simplex virus useful for treating neoplastic disease: Recombinant herpes simplex viruses comprising DNA encoding cytokines and methods for treating neoplastic diseases using the inventive recombinant viruses are disclosed.... Agent: Marshall, Gerstein & Borun LLP

20070031379 - Therapeutic agent for treatment of cancer comprising human apolipoprotein (a) kringles lk68 or lk8 genes as effective ingredient, and method for treating cancer using the same: The present invention relates to an anticancer or an anti-metastatic agent for gene therapy, more precisely, an anticancer or an anti-metastatic agent for gene therapy containing a gene carrier or cells harboring human apolipoprotein (a) kringle KIV9-KIV10-KV (LK68) or KV (LK8) gene as an effective ingredient, and a treatment method... Agent: Joseph Hyosuk Kim Jhk Law

20070031392 - Delivery vehicle for recombinant proteins: Recombinant nucleic acid molecules are constructed with a first sequence encoding a transgene under the control of regulatory sequences that direct expression of the transgene product in a hematopoietic stem cell, or a progenitor cell therefrom or cell differentiated therefrom. In one embodiment, the cell which expresses the transgene is... Agent: Howson And Howson

20070031390 - Methods and compositions for site-specific genomic expression of nucleic acid sequences: The present invention is directed to methods and compositions for site-specific genomic expression of nucleic acid sequences.... Agent: Viksnins Harris & Padys Pllp

20070031391 - Neural stem cells and use thereof for brain tumor therapy: The present invention is based upon a surprising finding that stem cells, more particularly neural stem cells, can migrate throughout a brain tumor and track metastatic brain tumor cells. The invention provides a method for treating brain tumors by administering genetically engineered neural stem cells in an individual affected by... Agent: David S. Resnick

20070031393 - Methods of use of probiotic bifidobacteria for human beauty benefits: Methods of use in humans of probiotic bacteria of the genus Bifidobacteria for regulating the condition of human keratinous tissue to achieve cosmetic beauty benefits. Said methods include regulation, either prophylactic or therapeutic, of the cosmetic appearance of human keratinous tissue, such as human hair, skin (e.g., scalp), and nails.... Agent: The Procter & Gamble Company Intellectual Property Division

20070031385 - Apparatus and method to treat a wound area: A method is disclosed to treat a patient having a wound area, such as a burn injury. The method provides a plurality of epidermal/dermal cells, and applies that plurality of epidermal/dermal cells to the wound area.... Agent: Dale F. Regelman

20070031388 - Cell-charged multi-layer collagen membrane: A multi-layer sheet of collagen membrane material includes a barrier layer including an outer smooth barrier face and further including a fibrous face opposite the smooth barrier face, and a matrix layer of collagen material adhered to the fibrous face, the matrix layer including collagen I, collagen III, or a... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070031387 - Method for treating and/or preventing spinal cord injury: A method of preventing or treating neurologic function deficit of vertebrates undergone spinal cord injury, comprising administering an effective amount of BM-MNCs to a vertebrate in need thereof through cerebrospinal fluid.... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20070031386 - Modalities for the treatment of degenerative diseases of the retina: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070031384 - Regeneration of pancreatic islets by amniotic fluid stem cell therapy: A method of treating diabetes in a mammalian subject is carried out by: (a) providing mammalian amniotic fluid stem cells, and then (b) administering the cells to the subject in an amount effective to treat diabetes. Optionally, the cells may be differentiated into pancreatic-like cells or at least treated to... Agent: Myers Bigel Sibley & Sajovec

20070031389 - Transplants for myocardial scars: A method is provided for forming a graft in heart tissue which comprises the transplantation of cells chosen from cardiomyocytes, fibroblasts, smooth muscle cells, endothelial cells and skeletal myoblasts. The grafts are especially useful in treating scar tissue on the heart.... Agent: Genzyme Corporation Legal Department

20070031394 - Method of treating neurological disorders: Essential tremor can effectively be treated with high doses of Riboflavin (vitamin B2), either on its own or coupled with one or more other B vitamins and/or coenzyme Q10 (CoQ10). The treatment constitutes a significant improvement over prior treatment methods in that it not only alleviates essential tremor, but results... Agent: Gottlieb Rackman & Reisman PC

20070031395 - Repressor of skeletal muscle differentiation, nucleic acid coding therefor and the use thereof in diagnosis and therapy: Polypeptide sequences which play a part in the regulation of skeletal muscle differentiation, and nucleic acids coding therefor, and the use thereof in diagnosis and therapy are disclosed. Possible uses are also indicated for antibodies which are directed against corresponding epitopes of the GRIM1 polypeptide.... Agent: Heller Ehrman White & Mcauliffe LLP

20070031396 - Method of treating neurological diseases: The invention relates to a method of treating a condition in a subject comprising administering an effective amount of an agent to said subject wherein said agent modulates one or more components of the retinoid signaling pathway.... Agent: Marshall, Gerstein & Borun LLP

20070031397 - Compositions and methods for enhancing axon regeneration: As described below, the present invention generally features compositions and methods for the treatment of CNS disease or injury. In particular, the invention provides methods and compositions for enhancing axonal outgrowth in a subject. In one embodiment, the invention enhances the success of CNS restorative surgery.... Agent: Edwards Angell Palmer & Dodge LLP

20070031398 - One of several enzyme-containing compounds, dietetic food products and drugs produced from and the use therefor for medical purpose: The invention relates to one or several enzyme-containing compounds, i.e. to one or several hydrolyses and to one or several antioxidants which are selected from ubiquinones, carotinoides and antioxidative vitamins. The inventive compounds are used in the form of components for producing food products or drugs which are used, inter... Agent: Joyce Von Natzmer Hall, Vande Sande & Pequigot, LLP

20070031399 - Use of proline specific endoproteases to hydrolyse peptides and proteins: The present invention relates to a process for the proteolytic hydrolysis of a peptide or a polypeptide, said peptide or polypeptide comprising 4 to 40, preferably 5 to 35, amino acid residues and said peptide or polypeptide is not hydrolysable by subtilisin whereby said peptide or polypeptide is hydrolysed by... Agent: Nixon & Vanderhye, PC

20070031400 - Dichloroacetate in combination with clinically high levels of cardioprotective or hemodynamic drugs: The present invention provides compositions and methods for using cardioprotective or hemodynamic drugs in combination with dichloroacetate enabling usage of cardioprotective or hemodynamic drugs at concentrations higher than used in normal clinical practice without increasing deleterious side effects normally associated with the cardioprotective or hemodynamic drug, thereby conferring added clinical... Agent: Pillsbury Winthrop Shaw Pittman LLP

20070031401 - Catalytic domain of adam33 and methods of use thereof: The present invention discloses purified polypeptides that comprise an active ADAM33 catalytic domain. In addition, the present invention discloses nucleic acids that encode the polypeptides of the present invention. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active ADAM33 catalytic domain. In addition,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070031402 - Immunoconjugate formulations: The present invention provides an immunoconjugate formulation that is substantially free of particles, the immunoconjugate formulation comprising: an immunoconjugate and one or more excipients selected from the group consisting of: sucrose, polysorbate 20, polysorbate 80, cyclodextrin, dextrose, glycerol, polyethylene glycol, mannitol, sodium chloride, and an amino acid, wherein the formulation... Agent: Sughrue Mion, PLLC

20070031403 - Interferon-gamma inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use: A human IFN-γ inducing polypeptide and its nucleotide sequence was isolated, purified and characterized. Pharmaceutical compositions containing this novel INF-γ inducing polypeptide or active fragments thereof are formulated and monoclonal antibodies are raised against this polypeptide or antigenic fragments thereof. The polypeptide can be used in a method for treating... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070031404 - Antibodies: Nucleic acids encoding SOC/CRAC calcium channel polypeptides, including fragments and biologically functional variants thereof and encoded polypeptides are provided. The nucleic acids and polypeptides disclosed herein are useful as therapeutic and diagnostic agents. Agents that selectively bind to the foregoing polypeptides and genes also are provided.... Agent: Wolf Greenfield & Sacks, PC

20070031405 - Use of a33 antigens and jam-it: The present invention relates to compositions and methods of treating and diagnosing disorders characterized the by the presence of antigens associated with inflammatory diseases and/or cancer.... Agent: Heller Ehrman LLP

20070031408 - Anti-ccr5 antibody: The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO14O-VK (ATCC Deposit Designation PTA-4097), and (ii) two heavy chains, each heavy chain comprising an expression product of either a plasmid designated pVgl:HuPRO140 HG2-VH (ATCC Deposit... Agent: Cooper & Dunham LLP

20070031406 - Anti-thymocyte antiserum and use thereof to trigger b cell apoptosis: Methods and products are described for inducing B cell apoptosis, using antibody-induced apoptosis. Specifically, polyclonal antiserum or one or more monoclonal antibodies, either alone or in combination, as well as fragments or variants thereof are employed in the methods and products of the present invention. These antibodies, or fragments or... Agent: Nixon Peabody LLP - Patent Group

20070031407 - Peptide or protein containing a c'-d loop of the cd28 receptor family: The invention relates to a protein or peptide comprising the C′-D loop of a member of the CD28 family, uses thereof and mAbs obtainable therefrom.... Agent: Mayer & Williams PC

20070031412 - Direct and indirect effector cell protease receptor-1 (epr-1) inhibitors as antiplatelet agents: Direct and indirect effector cell protease receptor-1 (EPR-1) inhibitors may be used for the treatment of conditions associated with platelet aggregation as antiplatelet agents.... Agent: Moore & Van Allen PLLC

20070031414 - Dr5 antibodies and uses thereof: The invention concerns anti-DR5 antibodies with improved properties, compositions comprising such antibodies, methods and means for making such antibodies, and their therapeutic use, in particular in the treatment of cancer.... Agent: Heller Ehrman LLP

20070031410 - Pop2: nfkb - inhibiting polypeptides, nucleic acids and methods of use: This invention provides a novel pyrin-only protein (POP2), polypeptides, nucleic acids encoding them and methods for making and using them. The polypeptides of this invention have nuclear factor-κB (NF-κB) modulating activity. NF-κB is pivotal for transactivation of cell-cycle regulatory, cytokine and adhesion molecule genes and is dysregulated in many cancers,... Agent: Smith Hopen, Pa

20070031409 - Recombinant dna-molecule complex for the expression of anti-human-interferon-gamma chimeric antibodies or antibody fragments: A method for producing biologically active Fv antibody fragments that have a neutralizing effect on the anti-viral activity of human interferon-gamma (IFN-Γ) by inserting an isolated nucleic acid, having nucleotide sequences that encode the VH and VL domains of the D9D10 monoclonal antibody and a nucleotide sequence that encodes a... Agent: The Webb Law Firm, P.C.

20070031413 - Treatment with anti-vegf antibodies: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.... Agent: Genentech, Inc.

20070031411 - Vaccine comprising a tick cement protein: The invention relates to the use of tick cement proteins in the production of vaccines for protecting animals against the bite of blood-sucking ectoparasites and against the transmission of viruses, bacteria and other pathogens by such ectoparasites. When used as vaccine components, the tick cement proteins of the invention confer... Agent: Klauber & Jackson

20070031417 - Dicer interacting proteins and uses therefor: ABSTRACT Dicer (e.g., DCR-1) interactors are disclosed as are methods to positively or negatively modulate Dicer activity. Uses of Dicer interactors as drug targets are featured. Also featured are uses of Dicer interactors and modulators of same to modulate various Dicer functions in vitro, in cell cultures, and... Agent: Lahive & Cockfield, LLP

20070031421 - Inhibitors targeting osteoclast-associated protein: The present invention relates to a method of detecting metabolic bone disorders using a gene expressed at a high level in osteoclasts, a method of screening for a compound effective for treatment and/or prevention of metabolic bone disorders, and a pharmaceutical composition for treatment and/or prevention of metabolic bone disorders.... Agent: Ip - Seattle Dorsey & Whitney LLP

20070031420 - Masp-2, a complement-fixing enzyme, and uses for it: The invention relates to the discovery and characterization of mannan binding lectin-associated serine protease-2 (MASP-2), a new serine protease that acts in the MBLectin complement fixation pathway.... Agent: Browdy And Neimark, P.l.l.c.

20070031419 - Methods and compositions for treating diseases targeting cdcp1: Methods and compositions for detecting and treating a disease, particularly cancer, associated with differential expression of CDCP1 in disease cells compared to healthy cells. Also provided are antagonists or agonists of CDCP1, and methods for screening agents that modulate the CDCP1 level or activity in vivo or in vitro.... Agent: Celera Genomics Attn: Wayne Montgomery, Vice Pres, Intel Property

20070031418 - Methods for treating lower motor neuron diseases and compositions containing the same: This invention provides methods for the treatment, prevention, and/or amelioration of symptoms relating to lower motor neuron diseases (such as spinal muscular atrophy). The methods comprise administration of an agonist anti-trkC antibody. Compositions and kits are also provided.... Agent: Morrison & Foerster LLP

20070031415 - Regulation of interaction between rapl and rap1: A functional failure of Rap1 as a molecule that regulates integrin adhesion is believed to be related to pathology of inflammation, allergy, autoimmune diseases, cancer immunity, transplantation immunity, and the like that are immune diseases, and therefore elucidation of the mechanism of regulation of integrin adhesion by Rap1 leads to... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070031422 - Selection of cells expressing heteromeric polypeptides: This invention is in the general field of recombinant expression of polypeptides in animal cell culture. More particularly, the invention concerns improved selection in cells of recombinantly engineered vectors designed to express polypeptides.... Agent: Immunex Corporation

20070031416 - Use of antibody: The present invention intended to provide an agent for preventing/treating Alzheimer's disease. More specifically, the present invention provides an agent for preventing/treating Alzheimer's disease, etc., which comprises a monoclonal antibody specifically reacting with a partial peptide at the C-terminal region of a β-amyloid or its derivatives.... Agent: Foley And Lardner LLP Suite 500

20070031438 - Antibodies as chimeric effector cell receptors against tumor antigens: This invention relates to specific antibodies against ganglioside GD3 called MB3.6 and against protein prostate specific membrane antigen (PSMA) called 3D8, 4D4 and 3E11 when prepared as chimeric molecules with signaling molecules of T cells and other effector cells, and the use thereof in the treatment of cancers expressing these... Agent: Clark & Elbing LLP

20070031423 - Antibodies to treat cancer: Compositions and methods for the treatment of cancer, particularly melanoma, myeloma, small cell lung cancer, thymic lymphoma, T-cell lymphoma, B-cell lymphoma, osteosarcoma, and acute T-cell leukemia, are disclosed. Illustrative compositions include one or more anti-ganglioside antibodies and polynucleotides that encode such anti-ganglioside antibodies. These antibodies may be for example, hamster... Agent: Lahive & Cockfield, LLP

20070031429 - Cancerous desease modifying antibodies: The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can... Agent: Mchale & Slavin, P.A.

20070031425 - Cancerous disease modifying antibodies: The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can... Agent: Mchale & Slavin, P.A.

20070031426 - Cancerous disease modifying antibodies: The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can... Agent: Mchale & Slavin, P.A.

20070031427 - Cancerous disease modifying antibodies: The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can... Agent: Mchale & Slavin, P.A.

20070031428 - Cancerous disease modifying antibodies: The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can... Agent: Mchale & Slavin, P.A.

20070031437 - Compositions and methods for modulating vascular development: The present invention provides methods of using EGFL7 antagonist to modulate vascular development. Also provided herein are methods of screening for modulators of EGFL7 activity. Furthermore, methods of treatment using EGFL7 antagonists are provided.... Agent: Genentech, Inc.

20070031424 - Functional heavy chain antibodies, fragments thereof, library thereof and methods of production thereof: The present invention relates to functional heavy chain antibodies, functional single domain heavy chain antibodies, functional VH domains, or functional fragments thereof comprising an amino acid which is neither a charged amino acid nor a C at position 45, and comprising an amino acid at position 103 independently chosen from... Agent: Wolf Greenfield & Sacks, PC

20070031430 - Immunoconjugates: The present invention relates to novel immunoconjugates that are devoid of light chains and comprise at least one variable domain of a heavy chain antibody. The immunoconjugates of the present invention can be used for the preparation of a medicament to treat tumours.... Agent: Wolf Greenfield & Sacks, PC

20070031436 - Multivalent antibody contructs: The present invention relates to a multivalent Fv antibody construct having at least four variable domains which are linked with each over via the peptide linkers 1, 2 and 3. The invention also concerns expression plasmids which code for such an Fv antibody construct and a method of producing the... Agent: Wilson Sonsini Goodrich & Rosati

20070031439 - Novel protein related to melanoma-inhibiting protein and uses thereof: Novel TANGO 130 nucleic acid molecules which encode proteins having homology to melanoma-inhibiting protein are disclosed. In addition to TANGO 130 nucleic acid molecules and proteins, the invention further provides isolated TANGO 130 fusion proteins, antigenic peptides and anti-TANGO 130 antibodies. The invention also provides vectors containing nucleic acid molecules... Agent: Millennium Pharmaceuticals, Inc.

20070031435 - Polypeptide compounds for inhibiting angiogenesis and tumor growth: In certain embodiments, this present invention provides polypeptide compositions, and methods for inhibiting Ephrin B2 or EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070031431 - Tumor antigen: Tumor antigen inducing and/or activating HLA-A2-restricted tumor-specific cytoxic T lymphocytes that is activated by recognizing HLA-A2 and a tumor antigen peptide, and a peptide or polypeptide derived from the tumor antigen, a polynucleotide encoding the peptide or a complementary strand polynucleotide thereof, a transformant comprising a recombinant vector which comprises... Agent: Sughrue Mion, PLLC

20070031432 - Tumor antigen: Tumor antigen inducing and/or activating HLA-A2-restricted tumor-specific cytotoxic T lymphocytes that is activated by recognizing HLA-A2 and a tumor antigen peptide, and a peptide or polypeptide derived from the tumor antigen, a polynucleotide encoding the peptide or a complementary strand polynucleotide thereof, a transformant comprising a recombinant vector which comprises... Agent: Sughrue Mion, PLLC

20070031433 - Tumor antigen: Tumor antigen inducing and/or activating HLA-A2-restricted tumor-specific cytotoxic T lymphocytes that is activated by recognizing HLA-A2 and a tumor antigen peptide, and a peptide or polypeptide derived from the tumor antigen, a polynucleotide encoding the peptide or a complementary strand polynucleotide thereof, a transformant comprising a recombinant vector which comprises... Agent: Sughrue Mion, PLLC

20070031434 - Uses for eph receptor antagonists and agonists: The present application describes methods of inhibiting or stimulating angiogenesis in a mammal comprising administering to the mammal an effective amount of an Eph receptor antagonist or agonist, respectively. Articles of manufacture for use in relation to these methods are also described.... Agent: Heller Ehrman LLP

20070031440 - Modified transferin-antibody fusion proteins: Modified fusion proteins of transferrin and therapeutic proteins or peptides, preferably antibody variable regions, with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.... Agent: Morgan Lewis & Bockius LLP

20070031441 - Immunotherapy based on dendritic cells: Dendritic cells are exposed to at least one bacterial strain in particular bacterial species present in the human commensal flora. The bacterial strain may be a Lactobacillus and/or Bifidobacterium and/or salmonella strain. The exposed dendritic cells or a formulation, pharmaceutical or vaccine comprising such dendritic cells may be used in... Agent: Jacobson Holman PLLC

20070031445 - Compositions and methods for enhancing immune responses mediated by antigen-presenting cells: Molecular adjuvants are disclosed comprising an antigen presenting cell-targeting ligand linked to an immunogen, e.g. tumor associated antigens, bacterial or viral antigens. The ligand and the immunogen are linked via a cleavable linker such as a protease-sensitive oligopeptide, to facilitate processing of the adjuvant by the antigen presenting cell. Methods... Agent: Dann, Dorfman, Herrell & Skillman

20070031444 - Compounds targeted to cellular locations: A soluble derivative of a soluble polypeptide, which comprises two or more heterologous membrane binding elements with low membrane affinity covalently associated with the polypeptide, the elements being soluble in aqueous solution, and the elements being capable of interacting, independently and with themodynamic additivity, with components of cellular or artificial... Agent: Proskauer Rose LLP

20070031442 - Method and compositions for boosting immune response: An antigen presenting molecule is capable of increasing sensitivity of a cytotoxic T lymphocyte to an antigen by interaction with a T cell receptor and CD8 coreceptor thereon, when the antigen presentation molecule displays an increased avidity for the CD8, compared to the molecule encoded by SEQ ID NO. 1... Agent: Bell & Associates

20070031443 - Methods for treating or preventing skin disorders using cd2-binding agents: Methods for treating or preventing an epidermal or dermal disorder, e.g., psoriasis, using a CD2-binding agent, e.g., an inhibitor of the CD2/LFA-3 interaction (e.g., an LFA-3/IgG fusion polypeptide), in combination with an auxiliary agent, e.g., UVB irradiation, are disclosed.... Agent: Leydig Voit & Mayer, Ltd

20070031446 - Hcv vaccines: Disclosed is a Hepatitis C virus (HCV) vaccine comprising at least two epitopes, each from a different hotspot epitope, wherein a hotspot epitope is defined as an epitope containing peptide selected from the group consisting of KFPGGGQIVGGVYLLPRRGPRLGVRATRK, GYKVLVLNPSVAAT, AYAAQGYKVLVLNPSVAAT, DLMGYIP(A/L)VGAPL, GEVQVVSTATQSFLATCINGVCWTV, HMWNFISGIQYLAGLSTLPGNPA, VDYPYRLWHYPCT(V/I)N(F/Y)TIFK(V/I)RMYVGGVEHRL, AAWYELTPAETTVRLR, GQGWRLLAPITAYSQQTRGLLGCIV, IGLGKVLVDILAGYGAGVAGALVAFK, FTDNSSPPAVPQTFQV, LEDRDRSELSPLLLSTTEW, YLVAYQATVCARAQAPPPSWD, MSTNPKPQRKTKRNTNR,... Agent: Fulbright & Jaworski L.L.P.

20070031447 - Method of isolating biologically active fraction containing clinically acceptable native s-lipopolysaccharides obtained from bacteria producing endotoxic lipopolysaccharides: A biologically active fraction (BAF) is presented containing mainly S-lipopolysaccharide (LPS) from gram-negative bacteria producing endotoxic LPSs. These fractions are characterized in that in the lipid A of S-LPS the mole ratio of D-glucosamine and β-hydroxy acids selected from the group comprising β-hydroxydecanoic, β-hydroxydodecanoic, β-hydroxytetradecanoic, β-hydroxyhexadecanoic, is approximately 2:1-4, and... Agent: Ladas & Parry

20070031448 - Method for removing aflatoxins from chinese herbal medicines: A method for removing aflatoxins from Chinese herbal medicines comprises the steps of grinding a predetermined Chinese herbal medicine and submerging it into an amount of alcohol solvent twice as much as the dry weight of the medicine and using water to flush away the alcohol solvent from the medicine... Agent: Ho Shin Huang

20070031449 - Vaccine: The present invention discloses a Gram negative bacterium in which the expression of a protein involved in LPS transport to the outer membrane is functionally downregulated such that the level of LPS in the outer membrane is decreased compared to a wild-type Gram negative bacterium. Down regulation of Imp and... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070031451 - Inactivating pathogens with hydrogen peroxide for vaccine production: The present disclosure provides methods for producing a vaccine composition containing a pathogen that is rendered noninfectious by exposure to hydrogen peroxide. The methods disclosed herein are suitable for the preparation of vaccines for a wide variety of pathogens, including viruses, bacteria and parasites. The disclosure also provides vaccine compositions... Agent: Klarquist Sparkman, LLP

20070031450 - Stabilizers for veterinary vaccines: A formulation for a animal vaccines is provided. The vaccine formulation contains a stabilizer component and a viral immunogen. The stabilizer component includes a substantially TSE/BSE-safe animal-based protein and a vegetable-based protein. The stabilizer component provides for the stabilization of a vaccine throughout its storage and administration.... Agent: Wyeth Patent Law Group

20070031452 - Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes: The invention provides viral material and nucleotide fragments associated with multiple sclerosis and/or rheumatoid arthritis for use in method of diagnosis, prophylaxis, and therapy.... Agent: Oliff & Berridge, PLC

20070031453 - Modified influenza virus for monitoring and improving vaccine efficiency: The immunogenicity of the influenza virus hemagglutinin (HA) molecule may be increased by substitutions of amino acids in the HA sequence. The substitution of specific HA residues, such as asparagine at position 223 of H5 HA, increase the sensitivity of the hemagglutinin inhibition (HI) assay by altering receptor specificity and/or... Agent: Darby & Darby

20070031454 - Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline paraovirus and feline herpes virus: The present invention relates to a vaccine for immunizing a cat against feline viruses. The present invention also relates to a nucleic acid clone that encodes the capsid protein of the isolated feline calicivirus. The present invention further relates to a live or killed vaccine comprising the isolated feline calicivirus,... Agent: Pharmacia & Upjohn

20070031455 - Nipah virus vaccines: The present invention relates to recombinant anti-Nipah virus vaccines and the administration of such vaccines to animals, advantageously pigs. Advantageously, the anti-Nipah virus vaccine may comprise a recombinant avipox virus containing a Nipah virus glycoprotein gene. The invention encompasses methods of vaccinating animals, advantageously pigs, by administration of anti-Nipah virus... Agent: Judy Jarecki-black,ph.d,j.d

20070031456 - Leptospirosis culture process: A process for the culture of Leptospires in a protein-free culture medium and without any fatty acid source in the culture medium, wherein a fatty acid source is fed continuously or intermittently.... Agent: Judy Jarecki-black,ph.d,j.d

20070031457 - Modified bacillus anthracis, vaccine compositions and methods of use thereof: A variety of modified Bacillus anthracis bacteria useful in vaccines are provided. For instance, asporogenic strains of Bacillus anthracis are provided. In addition, Bacillus anthracis strains attenuated in their ability to repair their nucleic acid, such as in their nucleic acid excision repair ability or recombination repair ability, are provided.... Agent: Morrison & Foerster LLP

20070031458 - Recombinant vibrio cholerae strain and vaccine comprising said strain: The present invention relates to a recombinant Vibrio cholerae strain, a vaccine comprising said strain, the use of said strain, and methods for its production. The recombinant strain according to the invention is comprising DNA sequences coding for at least the ETEC pili CFA/1, CS3 and CS6, wherein the DNA... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070031459 - Oral suspension of prednisolone acetate: The present invention relates to novel oral suspension formulation comprising prednisolone acetate, a pharmaceutically acceptable vehicle and a thickening agent. The present invention further provides a method of treating patients in need of prednisolone with the novel formulation.... Agent: Taro Pharmaceuticals U.s.a., Inc. C/o Venable LLP

20070031460 - Pharmaceutical compositions of hydrophobic compounds: This invention concerns novel methods of enhancing the solubility of a compound. Compositions prepared using such methods are also disclosed. Compositions prepared using the methods have various advantages over conventionally known compositions.... Agent: Jones Day

20070031461 - An antimicrobial composition for topical application and a method thereof: The present invention provides an antimicrobial composition for topical application, preferably for treating acne, and a method for using the composition. The composition comprises a photocatalyst mixture comprising a photocatalyst, such as titanium dioxide, and sodium perborate, magnesium silicate, and citric acid. The photocatalyst mixture is in an amount effective... Agent: Baker & Daniels LLP

20070031462 - Powder exfoliating compositions and methods for producing the same: Nighttime dry powder compositions are produced and topically administered externally to skin to enhance the exfoliation of the skin while sleeping.... Agent: Tod R Nissle

20070031463 - Methods and devices for releasing volatile substances: Embodiments of the invention are directed toward devices for emitting a volatile substance, and associated methods of producing such devices. In one embodiment, the delivery device for a volatile substance includes an active layer that is created from a dried polymer solution that contains the volatile substance. A release liner... Agent: Bromberg & Sunstein LLP

20070031464 - Sterilant composition and system: An antimicrobial solution for disinfecting instruments in an automatic sterilization device, the solution comprising: a peracid reaction product formed in situ from combining a liquid acetyl donor with a solid source of peroxide, wherein the in situ reaction takes place in the sterilization device, along with a containment and delivery... Agent: Dinsmore & Shohl, LLP

20070031467 - Composition and method for vascular embolization: A therapeutic composition and a therapeutic method are provided for occlusion of a vascular site. The vascular site may be within a blood vessel or a lymph duct, and may include an aneurysm or an arteriovenous malformation, or may be in a normal section of the vessel or duct. A... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070031469 - Dyed polymethyl methacrylate bone cement and process for its production: A dyed polymethyl methacrylate bone cement is described which is characterised by at least the surface of the polymer particles of the powder component being coated partially or completely with a mixture of one or several dyes and a hydrophobic, low molecular or oligomeric organic coupling agent, such a quantity... Agent: William C. Gerstenzang Norris, Mclaughlin & Marcus P.A.

20070031465 - Implant for regenerating bone or cartilage with the use of transcriptional factor: This invention provides an implant that enable satisfactory bone/cartilage regeneration by allowing sustained release of virus vectors carrying the transcription factor gene in vivo and persistent maintenance of transcription factor activity.... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20070031466 - Method, apparatus and system for preventing or reducing the severity of hemorrhoids: Devices and methods for preventing or reducing the severity of hemorrhoids include a raised portion and a base, where the raised portion extends in a first direction away from the base and is shaped to engage and apply pressure to a region of a patient subject to hemorrhoids. The devices... Agent: Lowe Hauptman Berner, LLP

20070031468 - Modified chitosan for vascular embolization: A therapeutic composition and a method are provided for occlusion of a vascular site. The vascular site may be within a blood vessel or a lymph duct, and may include an aneurysm, an arteriovenous malformation. The composition comprises an acrylated chitosan dissolved in an aqueous medium. The composition is preferably... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070031470 - Nonwoven tissue scaffold: A biocompatible meniscal repair device is disclosed. The tissue repair device includes a scaffold adapted to be placed in contact with a defect in a meniscus, the scaffold comprising a high-density, dry laid nonwoven polymeric material and a biocompatible foam. The scaffold provides increased suture pull-out strength.... Agent: Nutter Mcclennen & Fish LLP

20070031472 - Steroid-containing sustained release intraocular implants and related methods: Biocompatible intraocular implants include a steroid and an auxiliary agent, where the auxiliary agent is present in an amount sufficient to lessen the severity of at least one side effect compared to the use of an otherwise identical implant lacking said auxiliary agent. The steroid and the auxiliary agent may... Agent: Stout, Uxa, Buyan & Mullins LLP

20070031471 - Uses of amniotic membranes as biocompatible devices: Amniotic membranes provided as emulsions to provide desirable features. The emulsion, containing micron or submicron sized particles of amniotic membrane, is formulated to increase absorption and overall bioavailability. In one embodiment, the emulsion is sprayed onto an implantable or insertable medical device. In another embodiment, the emulsion is sprayed onto... Agent: Wood, Herron & Evans, LLP

20070031473 - Drug delivery system and method: A method of introducing a beneficial substance into the body is presented. The method includes the steps of loading biodendrimer with the beneficial substance, and positioning the biodendrimer relative to the body, such that the beneficial substance can be absorbed by the body.... Agent: Bell, Boyd, & Lloyd LLC

20070031474 - Implantable preparations: Implantable preparation comprising a material which can be obtained from globin that has been modified, especially chemically, to be, at least partially, soluble at physiological pH, the material being biocompatible, and biodegradable in the organism. The material may be soluble at physiological pH, or insoluble at that pH. The preparation... Agent: Stites & Harbison PLLC

20070031476 - Agent and method for treating cancer comprising strontium, amino acid(s) and mineral agent(s): The invention relates to the treatment and prophylaxis of cancer. In particular, the invention relates to a pharmaceutical agent comprising strontium, amino acid(s) and mineral element(s), and its use in the preparation of an agent useful for the treatment and prophylaxis of cancer. The invention also relates to a method... Agent: Ladas & Parry

20070031475 - Nutritional composition with unsaturated fatty acids and trace elements: The present invention relates to a powdered nutritional composition, which comprises at least long-chain polyunsaturated fatty acids and trace elements, such as iron, besides optional further constituents, such as macro- and micronutrients. Due to encapsulation of the iron source with or in a fat, wax or mixtures thereof, lipid-oxidation may... Agent: Bell, Boyd & Lloyd LLC

20070031477 - Methods and devices for holding a composition: Methods and devices for holding a composition are described. A first embodiment includes a support substrate that supports an array of film segments having an active agent-containing composition, the film segments being attached to the support substrate by a pattern of adhesive. Another embodiment involves a support substrate supporting film... Agent: Bromberg & Sunstein LLP

20070031478 - Modified peptides and their uses: A modified pro-α chain comprising a triple helix forming domain linked to at least an N-terminal domain, the N-terminal domain containing a polypeptide from at least part of a laminin glycoprotein or secretory leukocyte protease inhibitor. The pro-α chain may form part of a procollagen molecule that has the N-terminal... Agent: Bose Mckinney & Evans LLP James Coles

20070031479 - Bioadhesive gel based on hydroxyethycellulose: Disclosed are compositions in the form of a bioadhesive gel that adheres to the mucous membranes, in particular the vaginal mucosa, for the application of active ingredients and/or principles, comprising hydroxyethylcellulose as the only gelling agent.... Agent: Ostrolenk Faber Gerb & Soffen

20070031483 - Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin: The invention describes combinations of at least three amphipatic substances forming aggregate suspensions in a polar liquid. Judicious choice of system components, which differ at least 2-times to 10-times in solubility, ensures said aggregates to have extended, unusually adaptable surfaces. This is probably due to simultaneous action on said aggregates... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070031480 - Enhanced delivery of sphingolipids: Compositions which comprise delivery vehicles having stably associated therewith at least one organic acid derivative of a sterol are useful in achieving enhanced cellular delivery of physiologically relevant sphingolipids when the compositions are administered.... Agent: Morrison & Foerster LLP

20070031484 - Immunoliposomes that optimize internationalization into target cells: The present invention provides for immunoliposomes that optimizes internalization of a drug into target cells bearing a characteristic cell surface marker. The immunoliposomes comprise an Fab′ domain of an antibody that specifically binds the characteristic marker, an amphipathic vesicle-forming lipid, and a polyethylene glycol derivatized lipid. The invention also provides... Agent: Townsend And Townsend And Crew, LLP

20070031482 - Pdt treatment method for cellulites and cosmetic use: A photosensitizer mixture and a method of treating cellulites by means of a percutaneous application of the mixture into the area of cellulite buildup followed by light illumination are presented. The photosensitizer can be combined with one or more cellular products including adipose cells and/or collagen that have been previously... Agent: Bolesh J. Skutnik Ceramoptec Industries, Inc.

20070031481 - Phospolipid derivative: A phospholipid derivative represented by the following formula (I) wherein R1CO and R2CO independently represent an acyl group; R3 represents hydrogen atom, or a hydrocarbon group; symbol “a” represents an integer of 0 to 4; symbol “b” represents 0 or 1, provided that when a is 0, b is 0;... Agent: Greenblum & Bernstein, P.L.C

20070031486 - Nutritional supplement for use under physiologically stressful conditions: A nutritional supplement to be incorporated into the diet of an individual experiencing physiologically stressful conditions is described.... Agent: Raymond R. Moser Jr., Esq. MoserIPLaw Group

20070031485 - Pharmaceutical composition having a cationic excipient: The invention relates to a pharmaceutical composition comprising a pharmaceutically effective amount of a pharmaceutically active substance and a pharmaceutically acceptable carrier comprising a cationic excipient, wherein said cationic excipient is a labile ester of betaine and a lipophilic alcohol having at least one primary hydroxyl group. The invention also... Agent: Buchanan, Ingersoll & Rooney PC

20070031487 - Nutritional supplement for women: A composition for the nutritional supplementation of women and a method of administering a composition designed for the nutritional supplementation of women is described.... Agent: Raymond R. Moser Jr., Esq. MoserIPLaw Group

20070031488 - Method of administering a partial dose of a segmented pharmaceutical tablet: A drug-containing pharmaceutical tablet adapted for accurate breaking which has two or more segments with at least one segment containing a drug.... Agent: Ted W. Whitlock Accu-break Pharmaceuticals, Inc.

20070031489 - Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness: The present invention relates to methods for reducing the risk associated with the administration of opioid analgesics in patients diagnosed or undiagnosed with respiratory illness by administering an analgesic composition comprising a sub-analgesic dosage of a p-opioid agonist selected from the group consisting of morphine, fentanyl, sufentanil, alfentanil, oxymorphone and... Agent: Dreier LLP

20070031490 - Effervescent powders for inhalation: Effervescent powders comprising inhalable particles are disclosed, as are methods for preparing these powders. The inhalable carrier particles comprise an inorganic or organic carbonate, and an acid, and exhibit effervescence when exposed to water or humid air. The particles have a mass median aerodynamic diameter suitable for nasal, bronchial, or... Agent: Woodcock Washburn LLP

20070031491 - Bioadhesive progressive hydration tablets: A bioadhesive controlled, extended release progressive hydration composition wherein the active ingredient may be protected from water or the surrounding environment, thereby protecting it from metabolism or from other degradation caused by moisture, enzymes, or pH effects, and making it bioavailable only at a controlled rate. The active ingredient may... Agent: Winston & Strawn LLP Patent Department

20070031493 - Pharmaceutical compositions: The present invention relates to pharmaceutical compositions for sustained release comprising a water soluble salt of the HMG-CoA reductase inhibitor fluvastatin as active ingredient, said composition being selected from the group comprising matrix formulations, diffusion-controlled membrane coated formulations; and combinations thereof.... Agent: Novartis Corporate Intellectual Property

20070031492 - Remote controlled synthesis system: A synthesis system and a method for implementing the synthesis system is provided and includes a first synthesis portion and a second synthesis portion. The first synthesis portion includes at least one input device, at least one material collection device, at least one container and at least one configurable flow... Agent: Louis J. Wille Bristol-myers Squibb Company

20070031494 - Method of administering a partial dose using a segmented pharmaceutical tablet: A method for providing partial doses of a drug or drugs is disclosed. The method includes breaking of a tablet configured to have an active layer as a first segment and an inactive support layer or substrate as a second segment, or breaking a layered tablet through a first active... Agent: Ted W. Whitlock Accu-break Pharmaceuticals, Inc.

20070031497 - Gastric acid secretion inhibiting composition: An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on pharmacologically acceptable excipient which causes a delayed release and/or an extended release of the proton pump inhibitor. The H2 receptor antagonist is included in... Agent: Young & Thompson

20070031496 - Osmotic dosage forms comprising semipermeable membranes with polymer blends providing improved properties: Disclosed are osmotic dosage forms including an osmotic core; a semi-permeable membrane that surrounds the osmotic core and comprises a blend of a cellulose acetate polymer and an acrylate copolymer; and an exit formed through the semi-permeable membrane. Also disclosed are methods of making and administering such dosage forms.... Agent: Philip S. Johnson Johnson & Johnson

20070031495 - Permeant delivery system and methods for use thereof: Disclosed is a device for causing the transdermal flux of a per meant into a subject via at least one formed pathway through a skin layer of the subject. The device comprises a delivery reservoir comprising: i) a non-biodegradable matrix having a bottom surface and defining a plurality of conduits... Agent: Needle & Rosenberg, P.C.

20070031498 - Gel composition for cellular adhesion inhibition: The invention includes compositions for inhibiting cellular adhesion, methods of preparation of such compositions, and methods for preventing cell adhesion at a surgical site comprising application of such compositions. The compositions generally comprise a cellular adhesion inhibitory agent, such as dextran sulfate, and a crosslinked hydrogel matrix, preferentially physically entrapping... Agent: Alston & Bird LLP

20070031500 - Long-acting solid formulation comprising triptorelin acetate: The invention relates to a long-acting solid formulation for parenteral administration, comprising a) triptorelin acetate and b) one or more excipients comprising a polymer or copolymer of lactic and/or glycolic acid or a mixture of polymers and/or copolymers of lactic acid and/or glycolic acid, said formulation containing 10 to 99%... Agent: Hunton & Williams LLP Intellectual Property Department

20070031499 - Readily shapeable xerogels having controllably delayed swelling properties: Hydrogels are described which have delayed swelling properties. A hydrogel is formed by reacting a hydrophilic monomer, a first crosslinker, and a second crosslinker. The first crosslinker defines the volume expansion of the hydrogel in an aqueous environment, and the second crosslinker, which is biodegradable, can modulate the swelling rate... Agent: James H. Meadows And Medicus Associates

20070031501 - Use of recombinant or synthetic gelatin-like proteins as stabiliser in lyophilized pharmaceutical compositions: The invention relates to the use of gelatin-like proteins, or polypeptides, with an increased calculated glass transition temperature as stabilisers in lyophilized biological or pharmaceutical compositions.... Agent: Roger Pitt Kirkpatrick & Lockhart Nicholson Graham LLP

20070031502 - Pharmaceutical composition for the treatment of acute disorders: A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active... Agent: Young & Thompson

20070031503 - Hyaluronic acid modification products and drug carrier therefrom: There is provided a drug carrier which has solved the problems of conventional drug carriers, which can encapsulate a low molecular drug efficiently, which can control a sustained release period for a long term, which can control blood residence, which has high dispersibility in an aqueous solution, and which is... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070031505 - Methods for fabricating nano and microparticles for drug delivery: The present invention generally relates to stimuli-responsive drug carriers and methods for making. More specifically, the present invention relates to stimuli-responsive lidded particles that respond to a physiological stimulus and dissolve at a target site inside the body thereby releasing therapeutic agents. The present invention further relates to solid, drug-loaded... Agent: Baker & Botts L.L.P.

20070031504 - Microdevices comprising nanocapsules for controlled delivery of drugs and method of manufacturing same: This application relates to a microdevice for delivering drugs to a target location. The microdevice comprises a plurality of nanocapsules assembled together, each having an outer hydrophobic shell and an inner liquid core contained within the shell. At least one drug is dissolved within the inner liquid core. The liquid... Agent: Oyen, Wiggs, Green & Mutala LLP 480 - The Station

20070031506 - Interleukin-18 inducer: Whey protein is hydrolyzed with hydrolase so that a rate of hydrolysis is preferably 20 to 30%. A fraction, which has molecular weights above 10,000 daltons, is removed from a resultant hydrolysate by means of an ultrafiltration method to obtain a whey protein hydrolysate which is used as an active... Agent: Knobbe Martens Olson & Bear LLP

20070031507 - Bactericide for mrsa: A bactericide for MRSA and a method for making the bactericide are disclosed. The bactericide is characterized in that it comprises a product prepared by pulverizing a shell having a crystalline structure of a calcite structure of calcium carbonate. The bactericide allows a wide variety of articles to be sterilized... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20070031508 - Implantable graft to close a fistula: An implantable graft, which may be inserted into a fistula tract to occlude the primary opening of the fistula, is provided. To prevent unintentional displacement of the graft or extrusion of the graft from the fistula of a patient, the graft may be provided with a cap that extends laterally... Agent: Brinks Hofer Gilson & Lione/chicago/cook

20070031509 - Breakthrough to cure psoriasis, psoriatic arthritis and treatment of other unrelated skin disorders, and external rectal and genital itching: This invention provides a novel method of treating psoriasis in humans by topical administration of a mixture consisting of copper lactate [Cu (C3, H5 O3)2. 2H2O], zinc hydroxide Zn(OH)2, trace amounts of cupric oxide and purified water by blunting the action of T cells present in the bleeding points located... Agent: Laxman S. Sundae

20070031510 - Pharmaceutical combination preparation containing glycyrrhizine, zinc, and a compound comprising a thiol group or a group that is metabolized thereto: The invention relates to the application of a combination including all forms of zinc at least one for the orally applied combination of a free thiol group or a group that is metabolized to a free thiol in a mammal, and as a the only pure plant part, glycyrrhicinic acid... Agent: Roberts, Mlotkowski & Hobbes

20070031511 - Method of treatment: This invention relates to methods and compositions for the treatment of conditions associated with abnormal activity or secretion of the hormone gastrin. In particular the invention relates to the treatment of conditions associated with non-amidated gastrin. In one aspect there is provided a method of treatment or prophylaxis of a... Agent: Needle & Rosenberg, P.C.

20070031512 - Virus-interacting layered phyllosilicates and methods of inactivating viruses: Layered phyllosilicates are useful for adsorbing and/or binding to and, thereby, inactivating viruses. The layered phyllosilicates can be sprayed into a person's nostrils or contained on a face mask to prevent infection; can be suspended in water for skin contact for virus inactivation; can form a portion of an HVAC... Agent: Marshall, Gerstein & Borun LLP

20070031513 - Carbostyril derivatives and mood stabilizers for treating mood disorders: The pharmaceutical composition of the present invention comprises a carbostyril derivative which is a dopamine-sero-tonin system stabilizer and a mood stabilizer in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof. The mood stabilizer may include but is not limited to lithium, valproic acid, divalproex... Agent: Sughrue Mion, PLLC

20070031515 - Inorganic materials for hemostatic modulation and therapeutic wound healing: The invention provides compositions, methods and devices relating to a silaceous oxide that generates a reduced heat of hydration upon contact with blood. By reducing the heat of hydration, the compositions provide a hemostatic agent that attenuates a tissue burning side effect of conventional hemostatic agents without adversely affecting the... Agent: Bozicevic, Field & Francis LLP

20070031514 - Use of isoindolinone derivatives as insecticides: e

20070031516 - Composition for the prevention and treatment of cellulitis: The invention relates to a composition for preventing and treating cellulite, characterized in that it comprises ingredients with lipolytic and venotonic effects, preferably a mixture of caffeine, dry butcher's broom extract (Ruscus Aculeatus), triethanolamine hydroiodide, ivy extract (Hedera helix), L-carnitine and amorphous escine, the tripeptide glycyl-histidyl-lysine, cosmetically acceptable carriers and... Agent: Merchant & Gould PC

20070031517 - Antioxidant producing bacterium and uses thereof: Bacterial strains are provided that can be isolated from the microflora of lowbush blueberry (Vaccinium angustifolium), and that are capable of increasing the antioxidant content of their growth medium. The bacteria can be used, for example, to increase the antioxidant content of various foodstuffs, as probiotics or as additives to... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070031518 - Cytokine modulators and related methods of use: A composition for modulating cytokines to regulate an inflammatory or immunomodulatory response. The composition can include at least one of rosehips, blueberry, blackberry, elderberry, cranberry, rosemary, clove, feverfew, nettle root, artichoke, reishi mushroom, olive extract, green tea extract, grape seed extract, resveratrol, viniferin, Aframomum melegueta, boswellia serrata extract, boswellia forte,... Agent: In Re: Alticor Inc. 28533 Brinks, Hofer, Gilson & Lione

20070031519 - Antibacterial bioactive fraction of cinnamon fruit: This invention relates to a composition comprising a bioactive fraction obtained from fruits of Cinnamomum zeylanicum having moisture 4-6%, Greenish white colour and mild salty flavor optionally along with one or more pharmaceutically acceptable additives, use of the bioactive thus obtained as an antibacterial agent and a process for preparing... Agent: Intellectual Property Group Fredrikson & Byron, P.A.

20070031520 - Method of using ajoene as alcohol dehydrogenase inhibitor, composition for removing hangover comprising ajoene and method of preparing the same: The present invention provides a composition for removing a hangover. In particular, the present invention discloses a method of using ajoene as an alcohol dehydrogenase inhibitor based on the fact that ajoene strongly inhibits alcohol dehydrogenase (ADH) activity. A composition for removing a hangover comprising ajoene suppresses the over-production of... Agent: Cantor Colburn, LLP

20070031521 - Synergistic composition for the treatment of diabetes mellitus: The present invention relates to a synergistic composition for the treatment of diabetes in a subject in need thereof, said composition-comprising Trigonelline of concentration ranging between 20 to 30%, amino acids of concentration ranging between 20 to 60%, and soluble fiber of concentration ranging between 10 to 60%, optionally along... Agent: Merchant & Gould PC

20070031522 - Enriched aqueous components of emblica officinalis: In an extraction process comprising extracting a raw extract from Emblica officinalis the improvement comprising conducting the extraction under conditions of time, temperature and atmosphere, to inhibit the formation of black specks and/or oligomeric and/or polymeric tannins and/or oxidation products thereof.... Agent: Millen, White, Zelano & Branigan, P.C.

20070031523 - Epimeredinoside a, and the pharmaceutics of epimeredinoside a-contained epimeredi indica root extract and its preparatory methods: The invention is involved in epimeredinoside A with its structure showed below, and the preparative methods of the pharmaceutics made from Epimeredi indica root extract containing epimeredinoside A. It includes all kinds of oral pharmaceutics made up with Epimeredi indica root extract and pharmaceutical adjuvant. The root extract is the... Agent: Rabin & Berdo, PC

20070031524 - Food compositions comprising waterleaf leaves and methods of using thereof: This invention relates to and is drawn to food compositions including waterleaf leaves harvested at full bloom. The present invention further relates to and is drawn to methods of reducing the risks of cardiovascular diseases by reducing total plasma cholesterol and plasma LDL-cholesterol and increasing plasma HDL-cholesterol and blood hematocrit... Agent: Larry A. Schemmel Office Of The Attorney General

20070031525 - Food compositions comprising waterleaf leaves and methods of using thereof: This invention relates to and is drawn to food compositions including waterleaf leaves harvested at full bloom. The present invention further relates to and is drawn to methods of reducing the risks of cardiovascular diseases by reducing total plasma cholesterol and plasma LDL-cholesterol and increasing plasma HDL-cholesterol and blood hematocrit... Agent: Larry A. Schemmel Office Of The Attorney General

20070031526 - Topical deodorant compositions based on hydroxycitric acid: This invention relates to the use of Hydroxycitric acid and its derivatives in cosmetic and pharmaceutical compositions for reducing body malodor.... Agent: Shyam K. Gupta Bioderm Research

20070025910 - Anticancer therapy: A subject afflicted with a cancer or precancerous condition is treated by administering an agent that increases expression of somatostatin receptors, and a cytotoxic recognition ligand. In an alternative embodiment, somatostatin analogs, which are radiolabeled are used to treat cancer or precancerous conditions.... Agent: Coleman Sudol Sapone, P.C.

20070025914 - Bronchioalveolar stem cells and uses thereof: The present invention features stems cells from lungs, methods of isolating such stem cells, methods of diagnosing lung diseases, and method of treating lung diseases, including cancer, chronic obstructive pulmonary disease, cystic fibrosis, and emphysema.... Agent: Clark & Elbing LLP

20070025911 - Cancer specific monoclonal antibodies: Novel monoclonal antibodies and binding fragments thereof specific to human breast cancer, lung cancer, colon cancer and other cancers. The monoclonal antibody does not bind to the cell surface of normal human tissues. The corresponding cancer-specific antigen or antigens with an apparent molecular weight of 40-52 130-200 kDa and polynucleotides... Agent: Baker Donelson Bearman Caldwell & Berkowitz, PC

20070025912 - Cytotoxicity mediation of cells evidencing surface expression of cd63: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The... Agent: Mchale & Slavin, P.A.

20070025915 - Determination of am-binding proteins and the association of adrenomedullin (am) therewith: The present invention provides methods for the isolation, identification, and purification of adrenomedullin (AM)-binding proteins. Also, provided are methods for utilizing the purified AM-binding proteins, or functional portions thereof, to diagnose, treat, and monitor AM-related diseases, for example, diseases or disorders associated with abnormally elevated AM levels. In addition, the... Agent: Klarquist Sparkman, LLP

20070025913 - Imaging, diagnosis and treatment of disease: The present invention relates to endothelial cell-specific genes and encoded polypeptides and materials and uses thereof in the imaging, diagnosis and treatment of conditions involving the vascular endothelium.... Agent: Wolf Greenfield & Sacks, PC

20070025916 - Porcine helicobacter infection: Compositions and methods for treating, preventing and diagnosing Helicobacter infection are disclosed. The methods use proteins and/or nucleic acids derived from Helicobacter cerdo, a new pathogen isolated from swine. In addition, porcine models for studying bacterial gastritis and gastric and duodenal ulcer disease caused by Helicobacter pathogens, such as H.... Agent: Judy Jarecki-black,ph.d,j.d

20070025918 - Magnetic resonance imaging (mri) agents: water soluble carbon-13 enriched fullerene and carbon nanotubes for use with dynamic nuclear polarization: The invention relates to carbon-13 enriched fullerene and carbon nanotube (CNT) compositions for improved magnetic resonance imaging (“MRI”). The invention also relates to a dynamic nuclear polarization (DNP) method of MRI utilizing the carbon-13 enriched fullerene and CNTs of the invention.... Agent: Hunton & Williams LLP Intellectual Property Department

20070025917 - Optical imaging based on locally activated bioluminescence: Methods and compositions for detecting and localizing light from a subject are disclosed. Also disclosed are methods for targeting light emission to selected regions, as well as for tracking entities within the subject. Also disclosed are methods for locating a target in a subject, such as by detecting light emission... Agent: General Electric Company Global Research

20070025921 - Inhibition of olfactory neurosensory function to treat eating disorders and obesity: The use of calcium channel blockers administered intra-nasally to inhibit olfactory sensory perception to treat eating disorders, including obesity, is described. Also described is a method of reducing food intake in a subject by administering a pharmaceutical composition comprising an effective amount of a calcium channel blocker to the nasal... Agent: Darby & Darby P.C.

20070025922 - Method of attenuating neurogenic pain: The present invention provides a method of attenuating the formation or reducing the severity of neurogenic pain in the tissue of a patient via applying a composition comprising a hydrophilic foam substrate and a polymeric hydrophilic agent to a portion of the surface of the skin in an amount and... Agent: Leydig Voit & Mayer, Ltd

20070025920 - Stable pharmaceutical solution formulations for pressurized metered dose inhalers: Aerosol solution formulations for use in an aerosol inhaler include 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methyl ethyl]amino]ethyl]-2(1H)-quinolinone or a salt thereof, preferably the hydrochloride thereof, as an active ingredient, a propellant containing a hydrofluoroalkane, and a cosolvent, stabilized by addition of a specific small amount of a high concentrated phosphoric acid and optionally by the... Agent: Holme Roberts & Owen, LLP

20070025919 - Systems and methods for delivery of a therapeutic agent: Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of... Agent: Townsend And Townsend And Crew, LLP

20070025923 - Use of ciclesonide for the treatment of respiratory diseases: The invention relates to new method of treatment of respiratory diseases, in particular the treatment of asthmatic children.... Agent: Nath & Associates PLLC

20070025925 - Method of attenuating neurogenic swelling or neurogenic inflammation: The present invention provides a method of attenuating the formation or reducing the severity of neurogenic swelling and/or neurogenic inflammation in the tissue of a patient via applying a composition comprising a hydrophilic foam substrate and a polymeric hydrophilic agent to a portion of the surface of the skin in... Agent: Leydig Voit & Mayer, Ltd

20070025924 - Method of attenuating swelling or inflammation: The present invention provides a method of attenuating the formation or reducing the severity of swelling and/or inflammation in the tissue of a patient via applying a composition comprising a hydrophilic foam substrate and a polymeric hydrophilic agent to a portion of the surface of the skin in an amount... Agent: Leydig Voit & Mayer, Ltd

20070025927 - Odorless formulation for treating mucosal discontinuities: The present invention includes a method for making a formulation for treating mucosal discontinuities, comprising: providing phenolic compounds and treating the purified phenolic compounds with sulfuric acid to make sulfonic acids and sulfonate salts. The present invention also includes formulations prepared by the method.... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070025926 - Preventing and reversing the formation of advance glycosylation endproducts: The present invention relates to compositions and methods for inhibiting and reversing nonenzymatic cross-linking (protein aging). Accordingly, compositions are disclosed which comprise an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins, and which additionally reverse pre-formed crosslinks in the advanced glycosylation endproducts by cleaving alpha-dicarbonyl-based... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070025928 - Stannous oral care compositions: Disclosed are oral compositions comprising a stannous ion source, a polyvalent cation source and a mineral surface active agent, said compositions providing enhanced therapeutic efficacy derived from stannous fluoride and/or other stannous salt, including antimicrobial effects, control of breath malodor, control of dental plaque growth and metabolism, reduced gingivitis, decreased... Agent: The Procter & Gamble Company Intellectual Property Division

20070025929 - Oral care toothpowder composition with fluoride ion source: A toothpowder oral care composition of fluoride ion source particulate (such as stannous fluoride particulate) dispersed in an oral calcium carbonate abrasive particulate bed is achieved with careful adjustment of the particle sizes of both the fluorinated particulate and the abrasive particulate to achieve a bed of toothpowder where neither... Agent: Colgate-palmolive Company

20070025932 - Applicator glove for application of staining compositions and self-tanning kit including same: A kit for application of self-tanning preparations includes a self-tanning composition and an application glove for applying the composition to the skin which is constructed from fabric including microfibers of 1 denier or less. The inner surface of the glove has a liner of an impermeable flexible material adhered thereto.... Agent: Mchale & Slavin, P.A.

20070025930 - Dibenzoilmethane derivative compounds, the use thereof in the form of photoactivable solar filters and cosmetic compositions containing said compounds: and also to salts or solvates thereof, and to the process for preparing them. The invention also relates to the use of a compound of formula (I) as an agent for protecting the skin or the hair against UV radiation and to a cosmetic and/or dermatological product, characterized in that... Agent: Oliff & Berridge, PLC

20070025933 - Photoprotector and/or photoimmunoprotector compositions of the skin and their uses: The composition comprises of a component A selected from a hydroxylated derivative of benzoic acid or of cinamic acid, their esters, amides or salts, a glycoside of a hexose, and their mixtures; and a component B selected from quinic acid, shikimic acid, their alkaline metal or alkaline earth salts, their... Agent: Law Office Of John C. Mcmahon

20070025931 - Powdery preparations containing 2.4.6-trianilino-p-(carbo-2'-ethylhexyl-1'-oxi)-1.3.5-triazine: by the method comprising: a) dispersing the triazine of formula I in an aqueous molecularly disperse or colloidally disperse solution of a protective colloid and b) converting the dispersion obtained into a dry powder by removing the water and and drying, wherein the protective colloid used in process step a)... Agent: Connolly Bove Lodge & Hutz LLP

20070025936 - Dry nail polish applique and method of manufacturing same: A method of manufacturing a decorative appliqué and the appliqué itself are disclosed. At least two formulations of high viscosity decorative liquid such as liquid nail enamel are provided and heated. A layer of pressure-sensitive adhesive material is applied onto a substrate, and a layer of the formulations are applied... Agent: Peter L. Berger Levisohn, Berger & Langsam, LLP

20070025934 - Nail varnish containing a polyoxyalkylene-chain polymer: A nail varnish composition containing, in a cosmetically acceptable medium comprising an organic solvent medium, at least 0.1% of at least one polymer that is soluble in the organic solvent medium, the polymer containing at least one polyoxyalkylene chain in its main chain or in the form of a graft,... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070025935 - Nail varnish containing a polyoxyethylene/polyoxypropylene block polymer: Nail varnish composition containing, in a cosmetically acceptable medium comprising an organic solvent medium, at least one block copolymer of formula (I) and at least one gelling agent. The invention also relates to a nail varnish composition containing at least one copolymer comprising at least one polyethylene glycol block and... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070025937 - Cosmetic compositions containing hydroquinone: Disclosed are compositions for application to skin, comprising hydroquinone or a derivative thereof, and a cosmetically acceptable vehicle comprising an effective amount of absolute ethanol or an effective amount of an ethanol composition comprising ethanol and methyl alcohol or isopropyl alcohol as a denaturant. Also disclosed are methods of whitening... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070025939 - Cosmetic compositions containing hydroquinone and various sunscreen agents: Disclosed are compositions for application to skin, comprising hydroquinone or a derivative thereof, a stabilizer selected from the group consisting of tetraphthalylidene dicamphor sulfonic acid (Mexoryl SX) and benzophenone-4, and a cosmetically acceptable vehicle. Also disclosed are methods of whitening skin, and methods of reducing discoloration of compositions containing hydroquinone.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070025938 - Depigmentation method and kit: The present invention relates to a cosmetic kit for depigmenting human skin comprising a multi-unit receptacle containing a first unit containing a microdermabrasion composition; a second unit containing a skin depigmenting composition; a third unit containing ascorbic acid in powder form; a fourth unit containing a skin soothing composition; optionally,... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070025940 - Lipstick compositions with enhanced wear: Disclosed are cosmetic compositions for application to the lips, comprising a cosmetically acceptable metal salt of stearic acid, aluminum starch octenyl succinate, an oil and a structuring agent, and methods for making and using them.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070025941 - Liquid lip gloss compositions with enhanced shine: Disclosed are liquid lipgloss compositions comprising an oil, a wax and aluminum starch octenyl succinate, and methods of making and using them.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070025942 - Clear gel antiperspirant or deodorant compositions and related methods: A clear gel emulsion antiperspirant or deodorant composition comprising at least one antiperspirant or deodorant active, a water phase, and an oil phase containing at least one high refractive index oil, wherein the composition is prepared from an oil phase and a water phase that, prior to emulsification, are both... Agent: Julie Blackburn Revlon Consumer Products Corporation

20070025944 - Cosmetic compositions useful for lengthening lashes: Disclosed are cosmetic compositions containing xanthan gum and a non-gelling polysaccharide, and methods of making and using same.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070025945 - Stabilized pharmaceutical and cosmetic composition of catechins or derivatives thereof: A stabilized pharmaceutical and cosmetic composition of catechins is disclosed. The pharmaceutical composition includes antioxidants, metal chelating agents, catechins or derivatives, and water. The pharmaceutical composition disclosed here can inhibit the oxidation of the catechins and derivatives thereof, and therefore extend the shelf life of the pharmaceutical composition of catechins... Agent: Bacon & Thomas, PLLC

20070025946 - Polymers having heterocyclic substituent groups, monomers useful in making such polymers, and compositions containing such polymers: s

20070025947 - Anti-acne method and kit: A cosmetic kit for treating human skin comprising a multi-unit receptacle containing: (a) at least one unit containing a skin preparatory composition containing at least one skin peeling agent; (b) at least one unit containing a keratolytic composition containing at least one anti-acne agent; (c) at least one unit containing... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070025948 - Dilution-type sterilizer composition: The present invention provides a germicidal antiseptic composition for dilution, which is superior in preparation stability, and free of formation of insoluble precipitation even when diluted with water containing an inorganic ion (e.g., tap water etc) when in use, thereby retaining superior germicidal disinfection ability. The present invention relates to... Agent: Birch Stewart Kolasch & Birch

20070025943 - Make-up compositions containing a film forming polyurethane and a film-forming (meth)acrylate copolymer: Disclosed are cosmetic compositions comprising a film forming polyurethane and a film forming (meth)acrylate copolymer, and a cosmetically acceptable carrier, and methods of making and using them.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070025950 - Composition and method for treating cellulite: A composition for reducing the appearance of cellulite is provided that comprises guarana extract and vitamin K. In addition, a method of treating cellulite with a topical composition comprising guarana extract and vitamin K is provided.... Agent: Heidi A. Boehlefeld Renner, Otto, Boisselle & Sklar, LLP

20070025949 - Compositions and kit for alleviating signs of ageing: A cosmetic kit for treating human skin comprising a multi-unit receptacle containing: (a) a unit containing a microdermabrasion composition having at least one type of skin abrading particle; (b) a unit containing a peeling composition having at least one skin peeling agent; (c) a unit containing an anti-ageing composition having... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070025951 - Skin care compositions containing xanthones: Skin care compositions containing xanthones extracted from plants are described. These compositions include lotions, creams, ointments, and the like that reduce wrinkles, give skin a more youthful appearance, provide antioxidant effects, protect the skin, and moisturize the skin. The compositions contain an admixture of a base and a xanthone-containing plant... Agent: Alan J. Howarth

20070025953 - Co-therapy for diabetic conditions: Methods of treating diseases such as diabetes are disclosed. Methods of modulating elevated fructosamine levels, elevated HbA1c levels, impaired glucose tolerance, and impaired fasting glucose are also disclosed. In some embodiments, methods include co-administration of a bile acid sequestrant and two or more additional compounds selected from the group consisting... Agent: Karen M. Whitney Diehl Servilla LLC

20070025954 - Ionene polymers and their use as antimicrobial agents: Disclosed are ionene polymers having antimicrobial activity. “Ionene polymers” as used in this invention are cationic polymers in which a substantial proportion of the atoms providing the positive charge are quaternized nitrogens located in the main polymeric chain or backbone of the polymer rather than in pendant groups. Also disclosed... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070025955 - Tissue adhesive sealant: A tissue adhesive sealant includes a cross-linkable protein in a solution that when combined with a cross-linking agent solution including an aldehyde and amino acid containing species reactive with the aldehyde cross-links to form a seal. The sealant is well suited for bonding tissue alone or in combination with a... Agent: Gifford, Krass, Groh, Sprinkle & Citkowski, P.c

20070025952 - Linear cyclodextrin copolymers: Linear cyclodextrin copolymers and linear oxidized cyclodextrin copolymers containing an unoxidized and/or an oxidized cyclodextrin moiety integrated into the polymer backbone are described. Methods of preparing such copolymers are also described. The linear cyclodextrin copolymer and linear oxidized cyclodextrin copolymer of the invention may be used as a delivery vehicle... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070025956 - Polymer-based compositions and conjugates of non-steroidal anti-inflammatory drugs: Provided herein are water-soluble polymer conjugates and polymer-based compositions of non-steroidal anti-inflammatory drugs. Also provided are methods for synthesizing and administering such conjugates and compositions.... Agent: Nektar Therapeutics

20070025959 - Adjuvant combination formulations: The use of an aminoalkyl glucosamine phosphate compound, or a derivative or analog thereof, in combination with a cytokine or lymphokine such as granulocyte macrophage colony stimulating factor or interleukin-12, is useful as an adjuvant combination in an antigenic composition to enhance the immune response in a vertebrate host to... Agent: Wyeth Patent Law Group

20070025958 - Vaccine immunotherapy: The present invention provides compositions and methods of immunotherapy to treat cancer or other antigen-producing diseases or lesions. According to one embodiment of the invention, a composition is provided for eliciting an immune response to at least one antigen in a patient having an antigen-producing disease or lesion, the composition... Agent: Kohn & Associates PLLC

20070025957 - Vascular targeting of ocular neovascularization: Methods of treating or preventing eye disease in a subject, involving administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a polypeptide having a vascular endothelial targeting amino acid sequence and a cytotoxic amino acid sequence are disclosed. For example, the vascular endothelial targeting amino acid... Agent: Fulbright & Jaworski L.L.P.

20070025960 - Bisphosphonates for prophylaxis and therapy against bioterrorism agents: Disclosed is a method of activating γ/δ T cells to provide temporary protection against a broad spectrum of infectious biological threats to the military and support personnel and exposed persons. γ/δ T cells are activated by administration of high doses of bisphosphonates.... Agent: Intellectual Property / Technology Law

20070025961 - Composition for stabilizing survival of transplanted hematopoietic stem cell, kit for obtaining the composition, method of stabilizing survival of transplanted hematopoietic stem cell, human monoclonal antibody or human polyclonal antibody and method of p: [PROBLEMS] To stabilize the survival of transplanted hematopoietic stem cells by using HLA identical activated lymphocytes. [MEANS FOR RESOLVING PROBLEMS] HLA identical activated lymphocytes in mononuclear cells separated from peripheral blood or umbilical cord blood are proliferated and activated. After separating and collecting, the HLA identical activated lymphocytes are employed... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070025962 - Interleukin-8 homologous polypeptides and therapeutic uses thereof: The present invention is directed to novel polypeptides having structural homology to IL-8 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies... Agent: Sidley Austin LLP Attn: Dc Patent Docketing

20070025964 - Hiv-1 mutations selected for by beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine: The present invention discloses a method for treating HIV that includes administering β-D-D4FC or its pharmaceutically acceptable salt or prodrug to a human in need of therapy in combination or alternation with a drug that induces a mutation in HIV-1 at a location other than the 70(K to N), 90... Agent: King & Spalding LLP

20070025963 - Methods for reduction of scar tissue formation: A method for reducing formation of scar tissue by administering interferon-tau (IFNτ) to a patient is described. Methods for preventing excessive scar formation, such as keloid formation, and for reducing formation of adhesions by administering IFNτ are also described. Interferon-tau is administered systemically or locally in an amount effective to... Agent: Perkins Coie LLP

20070025965 - Therapies for renal failure using interferon-beta: The present invention provides methods for the treatment, and pharmaceuticals for the use in the treatment, of mammalian subjects having, or at risk of developing, glomerulonephritis or chronic renal failure. The methods involve the administration of IFN-β therapeutics.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070025966 - Interferon-alpha polypeptides and conjugates: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the... Agent: Maxygen, Inc. Intellectual Property Department

20070025968 - Methods for selecting and producing t cell peptide epitopes and vaccines incorporating said selected epitopes: The present invention relates to the field of molecular biology and immunology. In particular it relates to vaccines and methods for providing vaccines which elicit immune responses when administered to a mammal, in particular a human. The preferred elicited immune response is a T cell response, elicited by peptide T... Agent: Hoffmann & Baron, LLP

20070025969 - Rnai expression constructs: The present invention provides compositions and methods suitable for expressing 1-x RNAi agents against a gene or genes in cells, tissues or organs of interest in vitro and in vivo so as to treat diseases or disorders.... Agent: Patton Boggs LLP

20070025971 - Substances causing differentiation: A DNA construct is described which contains a fusion gene under the control of a promoter. The fusion gene comprises at least one resistance gene and at least one reporter gene and is slightly toxic to a host cell transfected with that DNA construct. That DNA construct can be encoded... Agent: Knobbe Martens Olson & Bear LLP

20070025970 - Vector system: The present invention relates to retroviral vector genomes and to vector systems comprising such genomes. In particular the present invention relates to a retroviral vector genome comprising two or more NOIs operably linked by one or more Internal Ribosome Entry Site(s); a lentiviral vector genome comprising two or more NOIs... Agent: Frommer Lawrence & Haug

20070025967 - Zap protein and related compositions and methods: This invention provides an isolated ZAP protein and methods and articles of manufacture for increasing resistance to a virus in a subject or mammalian cell. The instant methods and articles are based on the use the ZAP protein to increase such resistance to a virus.... Agent: Cooper & Dunham, LLP

20070025974 - Amylases producing an altered immunogenic response and methods of making and using the same: The present invention provides novel amylase variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides DNA molecules that encode novel amylase variants, host cells comprising DNA encoding novel amylase variants, as well as methods for making amylases less allergenic. In addition, the... Agent: Kamrin T. Macknight Genencor International

20070025975 - Oligodendrocyte determination genes and uses thereof: The invention relates to methods and reagents for promoting the differentiation of oligodendrocytes from stem cells, by co-activating the Olig genes and the Nkx2.2 genes, and the use of the differentiated oligodendrocytes thus obtained in treating diseases, such as Multiple Sclerosis (MS). The invention also relates to the use of... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070025972 - Methods and compositions for smooth muscle reconstruction: This invention also provides a purified or isolated population of ADSCs that can differentiate into a cell of the leiomyogenic lineage, e.g., smooth muscle or skeletal muscle. In yet another aspect, the population additionally can be differentiated into a lineage selected from the group consisting of osteogenic, adipogenic, chondrogenic, myogenic... Agent: Foley & Lardner LLP

20070025973 - Reprogramming of adult or neonic stem cells and methods of use: The present invention relates to methods of reprogramming adult stem cells or stem cells obtained from umbilical or placental cord blood or more preferably, the placeta or umbilical cord tissue itself or the amniotic fluid or amnion. The resulting stem cells and methods of using these stem cells represent additional... Agent: Coleman Sudol Sapone, P.C.

20070025976 - Process for the purification of coenzyme q10: The present invention relates to methods for purifying Coenzyme Q10.... Agent: Cargill, Incorporated

20070025977 - Method of treating steatorrhea in infants: A method for treating steatorrhea in infants in need thereof by administering to the infant an amount of pancrelipase of from about 300 to about 2,500 USP units lipase/kg/meal or from about 1,500 to about 7,500 USP units lipase/kg/day.... Agent: Philip S. Johnson Johnson & Johnson

20070025978 - Bactiophage lysins for enterococcus faecalis, enterococcus faecium and other bacteria: The present disclosure relates to bacteriophage lysins useful for the reduction of certain bacterial populations, including methods and compositions for the treatment of various bacterial infections. For example, bacteriophage lysins were isolated and shown to effectively kill various bacteria, including both E. faecalis and E. faecium (including vancomycin resistant strains),... Agent: Indianapolis Office 27879 Brinks Hofer Gilson & Lione

20070025979 - Coagulation proteins, coagulation-anticoagulation protein complexes, derivatives thereof and their uses: The present invention relates to the use of coagulation proteins and complexes thereof with anticoagulation proteins for the lysis of blood clots or other applications affected by accelerated plasmin production. More specifically, the present invention provides a method for accelerating the dissolution of a blood clot through the administration of... Agent: David S. Resnick

20070025980 - Composition permitting muscle growth while protecting joint health: A composition which helps reduce joint inflammation and structural damage to joints during the growth of muscle structure, whether such growth is for repair of damaged muscle tissue or for development of new and enhanced muscular structure. The composition comprises a combination of edible nutritional protein, and a hyperimmune milk... Agent: Duckor Spradling Metzger

20070025983 - Compounds capable of inhibiting hiv-1 infection: This invention provides an antibody capable of specifically inhibiting the fusion of an HIV-1 envelope glycoprotein+ cell with an appropriate CD4+ cell without cross reacting with the HIV-1 envelope glycoprotein or CD4 and capable of inhibiting infection by one or more strains of HIV-1. This antibody is then used to... Agent: John P. White Cooper & Dunham LLP

20070025982 - Dna vaccines encoding antigen linked to a domain that binds cd40: Vaccines that target one or more antigens to a cell surface receptor improve the antigen-specific humoral and cellular immune response. Antigen(s) linked to a domain that binds to a cell surface receptor are internalized, carrying antigen(s) into an intracellular compartment where the antigen(s) are digested into peptides and loaded onto... Agent: Marshall, Gerstein & Borun LLP

20070025981 - Microorganisms for therapy: Therapeutic methods and microorganisms therefor are provided. The microorganisms are designed to accumulate in immunoprivileged tissues and cells, such as in tumors and other proliferating tissue and in inflamed tissues, compared to other tissues, cells and organs, so that they exhibit relatively low toxicity to host organisms. The microorganisms also... Agent: Stephanie Seidman Fish & Richardson P.C.

20070025985 - Immunoglobulins devoid of light chains: There is provided an isolated immunoglobulin comprising two heavy polypeptide chains sufficient for the formation of a complete antigen binding site or several antigen binding sites, wherein the immunoglobulin is further devoid of light polypeptide chains.... Agent: Wolf Greenfield & Sacks, PC

20070025984 - Treatment of ulcerative colitis with tropomyosin isoforms and monoclonal antibodies to tropomyosin isoforms: This invention pertains to a method for treating ulcerative colitis. Specifically, the method comprises orally or rectally administering to a human having ulcerative colitis a therapeutically effective amount of an antibody which binds to a tropomyosin isoform associated with ulcerative colitis. In another embodiment, the invention pertains to a method... Agent: Licata & Tyrrell P.C.

20070025986 - Modulation of hcn channels by second messengers: The present invention relates to modulation of the activation of hyperpolarization-activated cyclic-nucleotide-sensitive cation non-selective (HCN) channels by second messengers. The present invention provides methods for modulating the activation of HCN channels, methods for the treatment and prevention of disorders associated with abnormality in HCN channel functions, and methods of screening... Agent: Baker & Botts L.L.P.

20070025989 - Administration of agents for the treatment of inflammation: A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the... Agent: Buchanan, Ingersoll & Rooney PC

20070025988 - Method for treating lupus: A method of treating lupus in a subject eligible for treatment is provided involving administering an effective amount of an antibody that binds to a B-cell surface marker to the subject to provide an initial exposure and a subsequent exposure to the antibody within certain dosing regimens and an article... Agent: Genentech, Inc.

20070025987 - Method for treating vasculitis: A method of treating anti-neutrophil cytoplasmic antibodies-associated vasculitis (ANCA-associated vasculitis) in a patient eligible for treatment is provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the patient in a dose of about 400 mg to 1.3 grams at a frequency of... Agent: Genentech, Inc.

20070025990 - Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders: The present invention provides compositions for the prevention or treatment of an autoimmune disorder or an inflammatory disorder in a subject comprising one or more CD2 antagonists. In particular, the invention provides methods for preventing or treating an autoimmune disorder or an inflammatory disorder in a subject comprising administering one... Agent: Jones Day

20070025994 - Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to interleukin 5 (IL-5), which is preferably human IL-5. The invention also relates to human anti-IL-5 antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070025992 - Monoclonal antibody against platelet membrane glycoprotein vi: The present invention provides a human antibody or an active-fragment thereof that specifically binds to human platelet membrane glycoprotein VI and does not induce a human platelet aggregation independently; a cell that produces the antibody or its active-fragment; a pharmaceutical composition that comprises the antibody or its active-fragment as an... Agent: Foley And Lardner LLP Suite 500

20070025993 - Tek antagonists: The present invention provides Tek antagonists and methods of inhibiting angiogenesis in a mammal by administering Tek antagonists. The methods are particularly useful in treating diseases or conditions mediated by angiogenesis, such as solid tumors and diseases or conditions characterized by ocular neovascularization.... Agent: Amgen Inc.

20070025991 - Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation: Methods for treating intestinal inflammation or ghrelin-mediated inflammation by inhibiting the activity of ghrelin or its receptor are described. Also described are methods for identifying ghrelin antagonists and ghrelin receptor antagonists.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070026001 - Apo-2 ligand-anti-her-2 antibody synergism: Methods of using synergistically effective amounts of Apo-2 ligand and anti-Her-2 antibodies to enhance cell death via apoptosis are provided.... Agent: Genentech, Inc.

20070026000 - Apo-2l receptor agonist and cpt-11 synergism: Methods of using synergistically effective amounts of Apo-2L receptor agonists and CPT-11 to induce apoptosis and suppress growth of cancer cells are provided.... Agent: Genentech, Inc.

20070026002 - Inhibitors of angiopoietin-like 4 protein, combinations, and their use: Modulators of angiopoietin-like 4 protein are provided along with methods for their use in the treatment of diseases and pathological conditions. Combinations of ANGPTL4 antagonists and other therapeutics, e.g., anti-cancer agents, and methods of their use in the treatment of mammals susceptible to or diagnosed with cancer, or with relapse... Agent: Genentech, Inc.

20070025998 - Methods for enhancing the efficacy of cancer therapy: The invention concerns the identification of tumor antigens the expression of which is selectively upregulated by retinoid treatment. The invention further concerns improved methods of cancer treatment and, in particular, methods enhancing the efficacy of the treatment of cancers characterized by aberrant Wnt signaling by administration of retinoic acid or... Agent: Merchant & Gould PC

20070025996 - Oculospanin as a tumor specific antigen and methods and compositions utilizing same: The present invention relates to a method of detecting cancer by use of an oncogene, a method of screening for an active compound useful to treat and/or prevent cancer, and a pharmaceutical composition for treatment and/or prevention of cancer. More specifically, the present invention provides a method of detecting cancer... Agent: Paul T. Meiklejohn, Esq. Dorsey & Whitney LLP

20070025995 - Taxoid derivative covalently linked to tumor-specific antibody and a method for preparing the same: To provide a taxoid derivative that has improved solubility in water and acts specifically with respect to tumors, thereby mitigating side effects. The present invention provides an anticancer agent comprises covalent bond compound of an antibody that reacts specifically with respect to cancer cells with a taxoid derivative and a... Agent: Antonelli, Terry, Stout & Kraus, LLP

20070025999 - Treatment with anti-vegf antibodies: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.... Agent: Genentech, Inc.

20070025997 - Use of biomolecular targets in the treatment and visualization of brain tumors: The present invention relates to the use of proteins that are differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as biomolecular targets for brain tumor treatment therapies. Specifically, the present invention relates to the use of therapeutic and imaging agents, which specifically bind to one... Agent: Bozicevic, Field & Francis LLP

20070026003 - Antibodies directed against hepatitis c virus e1e2 complex, compositions of hcv particles, and pharmaceutical compositions: New conformational antibodies are directed against HCV and more particularly to monoclonal antibodies. Described compositions of particles are liable to be recognized by the antibodies, as are pharmaceutical compositions containing them. Also described are HCV enveloped subviral particles or purified HCV enveloped complete viral particles, and the processes for preparing... Agent: Young & Thompson

20070026006 - Method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response: The present invention relates to a delipidation method employing a solvent system useful for extracting lipids from cancer cells, thereby creating a modified cancer cell particle. Upon delipidation of the cancer cells, a portion of the cancer cell antigens remain intact. These exposed antigens, or epitopes, foster and promote antibody... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20070026005 - Vaccine composition comprising il-12 adjuvant encapsulated in controlled-release microsphere: Disclosed is a vaccine composition including a pathogenic antigen and IL-12 encapsulated in controlled release microspheres. Also, the present invention discloses a method of enhancing the adjuvant effect of IL-12 by employing an IL-12 adjuvant encapsulated in controlled release microspheres. IL-12, used as an adjuvant for a co-administered vaccine antigen... Agent: Lucas & Mercanti, LLP

20070026008 - Compositions and methods for wt1 specific immunotherapy: Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that... Agent: Seed Intellectual Property Law Group PLLC

20070026007 - Purposeful movement of human migratory cells away from an agent source: This invention relates to methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention relates to methods and compositions for modulating movement of cells of hematopoietic, neural, epithelial, or mesenchymal origin, in a specific site in a subject. The foregoing are useful, inter alia,... Agent: Edwards & Angell, LLP

20070026009 - Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds: The present invention provides a new class of peptides related to rapid replication and high human mortality, and their use in diagnosing, preventing and treating disease including vaccines and therapeutics for emerging viral diseases and methods of identifying the new class of peptides and related structures.... Agent: Kenyon & Kenyon LLP

20070026012 - Compositions and methods for monitoring and altering protein folding and solubility: The present invention relates to the fields of microbiology, molecular biology and protein biochemistry. More particularly, it relates to compositions and methods for analyzing and altering (e.g., enhancing or inhibiting) protein folding and solubility.... Agent: Medlen & Carroll, LLP

20070026010 - Purification process for bacterial cytolysin: The present invention relates to a method for purifying bacterial cytolysins such as pneumococcal pneumolysin. A single chromatography step produces excellent purification of the cytolysin by binding soluble aggregated cytolysin to a hydrophobic interaction chromatography material in the presence of detergent and high salt.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070026011 - Sdr proteins from staphylococcus capitis and their use in preventing and treating infections: An isolated and/or purified Sdr surface protein from S. capitis and nucleic acids encoding them are provided which includes the SdrX protein which possesses collagen binding activites and the SdrZL protein which possesses SdrZ-like properties. The Sdr surface proteins from S. capitis can be used in pharmaceutical compositions to treat... Agent: Stites & Harbison PLLC

20070026013 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070026014 - Interferon beta in severe acute respiratory syndrome (sars): The us of an interferon (IFN) for the manufacture of a medicament useful for treatment and/or prevention of Severe Acute Respiratory Syndrome (SARS) is described in the present invention.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070026015 - Method: The invention relates to a method of eliciting a T cell response against a T cell epitope in a host mammalian subject, which method comprises: (i) a first immunisation that comprises at least two administrations which are from 1 to 14 days apart to the subject, wherein each administration comprises... Agent: Foley And Lardner LLP Suite 500

20070026016 - Dengue serotype 2 attenuated strain: The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells. The invention further relates to a vaccine composition which comprises a VDV2 strain.... Agent: Stites & Harbison PLLC

20070026017 - Brachyspira pilosicoli 72kda outer-membrane protein and diagnostic and therapeutic uses thereof: The invention relates to Brachyspira pilosicoli 72 kDa outer-membrane protein (Bpmp-72) and its amino acid and neucleotide sequence. The invention also relates to the uses of these sequences in prophylactic (vaccination) and therapeutic treatment of infections with Brachyspira pilosicoli (internal spirochaetosis).... Agent: Novartis Corporate Intellectual Property

20070026018 - Methods for treating, preventing and diagnosing helicobacter infection: Compositions and methods for treating, preventing and diagnosing Helicobacter infection are disclosed. The methods use proteins and/or nucleic acids derived from Helicobacter cerdo, a new pathogen isolated from swine.... Agent: Judy Jarecki-black Merial Limited

20070026019 - Botulinum toxin compositions: A high potency botulinum toxin pharmaceutical composition comprising two excipients (such as albumin and sodium chloride) in a weight to weight ratio of between about 1 and about 100.... Agent: Stephen Donovan Allergan, Inc.

20070026020 - Modified mycobacterium tuberculosis strains and uses thereof: The present invention features modified Mycobacterium tuberculosis strains which lack a functional lspA gene, and vaccine formulations comprising the same. In many embodiments, a modified Mycobacterium tuberculosis strain of the invention comprises deletion or inactivation of the lspA gene and/or one or more non-lspA genes that are involved in Mycobacterium... Agent: Nixon Peabody LLP - Patent Group

20070026021 - Neisseria meningitidis antigens and compositions: This invention provides, among other things, protein, polypeptides, and fragments thereof, derived from bacteria Neisseria meningitidis B. Also provided are nucleic acids encoding for such proteins, polypeptides, and/or fragments, as well as nucleic acids complementary thereto (e.g., antisense nucleic acids). Additionally, this invention provides antibodies which bind to the proteins,... Agent: Morrison & Foerster LLP

20070026022 - Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens: An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070026023 - Coccidial vaccine and methods of making and using same: The present invention relates to a vaccine for coccidiosis in chickens prepared from three attenuated Eimeria species: E. acervulina, E. maxima and E. tenella. The vaccine was similar to or superior to other anticoccidial drugs in stimulating protective immunity against coccidiosis.... Agent: Judy Jarecki-black Merial Limited

20070026024 - Compositions and methods for emulsifying a pefluorocarbon with an oxygen-carrying surfactant: A physiologically acceptable perfluorocarbon emulsion composition that includes perfluorodecalin and an oxygen-carrying fluorinated surfactant forming a stable emulsion in a continuous aqueous phase. The oxygen-carrying fluorinated surfactant may be fractionated to increase its physiological compatibility, and may further include a fatty acid radical perfluorinated to increase its oxygen-carrying capacity. The... Agent: Kunzler & Associates

20070026027 - Human chorionic gonadotropin (hcg) formulations for facilitating weight loss and body contouring: The present invention relates to formulations of hCG for sublingual administration to mammals to facilitate weight loss and/or body contouring. Embodiments of the invention disclose administration of hCG formulations in combination with a low calorie diet and dietary supplements and, in some cases, with an exercise regime. Embodiments of this... Agent: Knobbe Martens Olson & Bear LLP

20070026026 - Oral liquid losartan compositions: The present invention is directed to improved oral liquid compositions that include losartan, or a pharmaceutically acceptable salt or metabolite thereof, and at least one pharmaceutically acceptable carrier in an amount sufficient to provide a pH of about 6 or higher. Processes of preparing such compositions and methods of administering... Agent: Winston & Strawn LLP Patent Department

20070026025 - Topical ointment and method for making and using same: A topical ointment comprises a base material of plasticized hydrocarbon gel and methylcellulose in which are dispersed a plurality of microbubbles containing liquid. The microbubbles containing liquid are encapsulated by the base material to form microencapsulations which are dispersed in the base material to form a hydrogel. Application of the... Agent: Townsend And Townsend And Crew, LLP

20070026028 - Appliance for delivering a composition: Disclosed is an appliance for treating skin or tissue, the appliance comprising a three-layer substrate having a cloth-like appearance and feel. The substrate includes a water-impermeable layer, such as a film, sandwiched between, and attached to, two fibrous layers. The fibrous layer that is adapted to contact skin includes a... Agent: Kimberly-clark Worldwide, Inc.

20070026029 - Apheresis device: The invention relates to an apharesis device for use in the treatment of Alzheimer patients. Said device comprises a solid support with which a flow of blood or plasma can be contacted.... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070026031 - Composite self-cohered web materials: The present invention is directed to implantable bioabsorbable non-woven self-cohered web materials having a high degree of porosity. The web materials are very supple and soft, while exhibiting proportionally increased mechanical strength in one or more directions. The web materials often possess a high degree of loft. The web materials... Agent: Gore Enterprise Holdings, Inc.

20070026033 - Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices: A system and compositions including zotarolimus and paclitaxel are disclosed, as well as methods of delivery, wherein the drugs have effects that complement each other. Medical devices are disclosed which include supporting structures that include at least one pharmaceutically acceptable carrier or excipient, which carrier or excipient can include one... Agent: Dykema Gossett PLLC

20070026034 - Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices: A system and compositions including zotarolimus and paclitaxel are disclosed, as well as methods of delivery, wherein the drugs have effects that complement each other. Medical devices are disclosed which include supporting structures that include at least one pharmaceutically acceptable carrier or excipient, which carrier or excipient can include one... Agent: Dykema Gossett PLLC

20070026035 - Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices: A system and compositions including zotarolimus and paclitaxel are disclosed, as well as methods of delivery, wherein the drugs have effects that complement each other. Medical devices are disclosed which include supporting structures that include at least one pharmaceutically acceptable carrier or excipient, which carrier or excipient can include one... Agent: Dykema Gossett PLLC

20070026037 - Devices, articles, coatings, and methods for controlled active agent release or hemocompatibility: The present invention relates to devices, articles, coatings, and methods for controlled active agent release and/or for providing a hemocompatible surface. More specifically, the present invention relates to copolymer compositions and devices, articles, and methods regarding the same for controlled active agent release. In an embodiment, the present invention includes... Agent: Merchant & Gould PC

20070026036 - Drug/drug delivery systems for the prevention and treatment of vascular disease: A drug and drug delivery system may be utilized in the treatment of vascular disease. A local delivery system is coated with rapamycin or other suitable drug, agent or compound and delivered intraluminally for the treatment and prevention of neointimal hyperplasia following percutaneous transluminal coronary angiography. The local delivery of... Agent: Woodcock Washburn LLP

20070026038 - Method of coating a stent with a polysaccharide layer and associated stents: The invention concerns methods of coating stents and stents produced in accordance therewith. The object of the invention is to provide methods of coating stents with a polysaccharide layer which has improved adhesion capacity on the substrate surface of the implant, and to afford correspondingly functionalized stents. That is achieved... Agent: Hahn Loeser & Parks, LLP

20070026030 - Method of preparing rheological materials for bone and cartilage repair: Methods of mixing delivering biocompatible cement, paste, putty, or gel for bone and cartilage repair are described in this invention. Powder-like solid materials are loaded into a first syringe. Liquids are loaded into one or multiple syringes. The liquids are injected into the first syringe containing the solid materials. To... Agent: Berkeley Advanced Biomaterials, Inc.

20070026032 - Percutaneous access device system facilitating cell growth thereon: A biocompatible implantable portal is provided that has a wall defining a communicative passage through an interior bore. The exterior of the portal has a neck region adapted to promote autologous cell growth on the neck region. A series of channels are provided on the exterior neck region to facilitate... Agent: Gifford, Krass, Groh, Sprinkle & Citkowski, P.c

20070026039 - Composite self-cohered web materials: The present invention is directed to implantable bioabsorbable non-woven self-cohered web materials having a high degree of porosity. The web materials are very supple and soft, while exhibiting proportionally increased mechanical strength in one or more directions. The web materials often possess a high degree of loft. The web materials... Agent: Gore Enterprise Holdings, Inc.

20070026040 - Composite self-cohered web materials: The present invention is directed to implantable bioabsorbable non-woven self-cohered web materials having a high degree of porosity. The web materials are very supple and soft, while exhibiting proportionally increased mechanical strength in one or more directions. The web materials often possess a high degree of loft. The web materials... Agent: Gore Enterprise Holdings, Inc.

20070026043 - Medical devices combined with diblock copolymer compositions: The present invention provides a medical device combined with a polymeric coating material comprising a bioerodable diblock copolymer and optionally a therapeutic agent.... Agent: Seed Intellectual Property Law Group PLLC

20070026041 - Pea-tempo/pea-bz coatings for controlled delivery of drug from implantable medical devices: Provided herein are coating comprising PEA-TEMPO/PEA-BZ for implantable medical devices, the coating being useful for the controlled delivery of bioactive agents into a patient's body.... Agent: Squire, Sanders & Dempsey LLP

20070026045 - Reinforced matrices: A reinforced matrix membrane containing one or more scaffold-forming proteins suitable for cell growth and for use in chondrocyte cell transplantation, and method of making same. The scaffold is incubated with the collagen matrix in solutions, colloidal dispersions, or suspensions of stabilizing proteins. The reinforced matrix may be used in... Agent: Morgan, Lewis & Bockius LLP

20070026042 - System for treating aneurysmal disease: Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed... Agent: Philip S. Johnson Johnson & Johnson

20070026044 - Use of vegf for treating bone defects: The present invention provides pharmaceutical compositions comprising VEGF or variants thereof for promoting bone formation, in vitro and in vivo. Methods of using those compositions are also provided. Compositions and methods of the present invention can be used for promoting and improving the repair process in subjects with bone defects.... Agent: Genentech, Inc.

20070026048 - Implantable drug delivery device: The invention is directed to an implantable device to enable delivery of drugs to the retina. The device minimizes stress to the retina by virtue of its softness and smooth shape that conform to the retina. Drugs are delivered by osmosis or by the device dissolving. It may be connected... Agent: Second Sight Medical Products, Inc.

20070026046 - Neoglycopolymer-cross-linked biopolymer matrix: The present application provides a cross-linked biopolymer matrix, or scaffold, comprising a biopolymer and cross-linked with a neoglycopolymer. A specific example of a biopolymer matrix according to this invention comprises collagen as the biopolymer. Also provided is a method for producing the cross-linked biopolymer matrix and methods of use thereof.... Agent: Foley & Lardner LLP

20070026047 - Thermal effect on crystalinity for drug delivery devices: A drug delivery device for placement in the eye includes a drug core comprising a pharmaceutically active agent, and a holder that holds the drug core. The holder is made of a material impermeable to passage of the active agent and includes an opening for passage of the pharmaceutically agent... Agent: Bausch & Lomb Incorporated

20070026050 - Method for production of arachidonic acid: The present invention relates to a process for producing arachidonic acid. In one embodiment, Mortierella sect. schmuckeri microorganisms are cultured in fermentation medium, preferably containing a component of a complex nitrogen source. Further disclosed is a food product which includes Mortierella sect. schmuckeri microorganisms or lipid isolated from such microorganisms... Agent: Sheridan Ross PC

20070026049 - Method of increasing lean body mass and reducing body fat mass in infants: Disclosed is a method of increasing lean body mass and reducing fat body mass in infants, said method comprising administration to an infant, term or preterm, a nutritional formula comprising a source of DHA and ARA. It has been found that the administration of DHA and ARA, or a source... Agent: Shu-ki Yeung

20070026052 - Hemostatic material: The present invention relates to hemostatic fabric materials, and to the methods for making and using such materials. In particular, the present invention relates to hemostatic fabric materials made from chemically treated plant materials that are soluble on wound surfaces.... Agent: Michael F. Krieger Kirton & Mcconkie

20070026053 - Joint resurfacing orthopaedic implant and associated method: An orthopaedic implant includes a porous structure made of a type I collagen matrix having at least one sheet of a naturally occurring extracellular matrix secured thereto. Methods of making and using such an implant are also disclosed.... Agent: Barnes & Thornburg LLP

20070026051 - Use of tripolidine in providing refreshedness on waking: There is disclosed the use of a consumable film comprising triprolidine for enabling an individual to wake refreshed after sleep and the method of treating such an individual with triprolidine. Use of a consumable film comprising triprolidine as active ingredient in the manufacture of a composition for the treatment of... Agent: Nixon & Vanderhye, PC

20070026054 - Medicament preparations for transdermal application containing active ingredient combinations for treating parkinson's disease: Transdermal pharmaceutical preparations for the treatment of Parkinson's disease containing a combination of at least two active substances selected from the following groups of active substances: dopamine agonists and L-dopa, monoamine oxidase inhibitors, anticholinergics, NMDA-receptor antagonists, sympathomimetics; at least two of the said active substances being members of different active... Agent: D. Peter Hochberg Co. L.p.a.

20070026056 - Antiviral patch: An adhesive patch is provided wherein the patch includes a porous backing having a front side and a back side. The patch also includes a therapeutic formulation located on the front side of the backing. The backing includes a flexible sheet of water insoluble porous material. The therapeutic formulation includes... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070026055 - Production method of nicotine transdermal preparation: The present invention provides a production method of a nicotine transdermal preparation, which includes a step of forming, on a support, an adhesive layer containing an adhesive and a liquid ingredient compatible with the adhesive, and a step of impregnating the adhesive layer with nicotine by continuously applying nicotine to... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070026057 - In vivo targeting of dendritic cells: The invention provides a composition for modulating immunity by the in vivo targeting of an antigen to dendritic cells. The composition comprises: a preparation of antigen-containing membrane vesicles or antigen-containing liposomes which have on their surfaces a plurality of metal chelating groups; and, a ligand for a receptor on the... Agent: Dorsey & Whitney LLP Intellectual Property Department

20070026059 - Ligands for orphan nuclear hormone receptor steroidogenic factor-1 (sf-1): The 1.5 Å crystal structure of the orphan nuclear receptor steroidogenic factor 1 (SF-1) ligand binding domain in complex with an LxxLL motif from a co-regulator protein is disclosed. The structure reveals the presence of a phospholipid ligand in a surprisingly large pocket (˜1600 Å3), with the receptor adopting the... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20070026061 - Liposomal formulation and use thereof: Cationic liposome encapsulated antimonial drugs formulations are provided. The drug-loaded liposome have enhanced efficacy as antileismanial agents and provide improved therapeutic index as compared to the minimal dose of free drug.... Agent: Reed Smith LLP

20070026058 - Method and composition for treating rhinitis: There is provided pharmaceutical compositions for the treatment of rhinitis by, for example, nasal or ocular administration comprising zwitterionic cetirizine, a polar lipid liposome and a pharmaceutical-acceptable aqueous carrier. The compositions are preferably homogeneous in their nature.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070026060 - Method for treating advanced ovarian cancer: A method for treating advanced epithelial ovarian cancer patients who attain a clinically-defined complete response after initial platinum/paclitaxel-based chemotherapy is described. The method involves administering a chemotherapeutic agent, such as doxorubicin, entrapped in liposomes.... Agent: Philip S. Johnson Johnson & Johnson

20070026062 - Tablet comprising a fibrate: Stable tablets and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved or dispersed in an non-aqueous vehicle with improved bioavailability, thereby eliminating the food effect so that the tablet or composition can be administered to a patient irrespective of being in fed or fasted state.... Agent: Cheryl H Agris Phd

20070026063 - Composition for coating comprising low-substituted cellulose ether and coated preparation having unpleasant taste masked: The present invention is a composition for coating comprising a wet-milled product obtained by suspending low-substituted cellulose ether having a molar substitution of from 0.05 to 1.0 per anhydrous glucose unit in water and then applying a shear force to the aqueous dispersion. The present invention is also a coated... Agent: Alston & Bird LLP

20070026064 - Pharmaceutical dosage forms having watermark-type identification and authentication inditia: Oral solid dosage forms having holographic markings or identification marks such as a watermark thereon and methods of preparing the same are disclosed. One preferred method of applying an identification mark on a pharmaceutical dosage form described herein includes applying a film coating having a first color to an oral... Agent: Lucas & Mercanti, LLP

20070026067 - Liquid formulations for controlled delivery of benzisoxazole derivatives: Disclosed are dosage forms including a controlled release dosing structure; and a liquid formulation contained within the controlled release dosing structure; wherein the liquid formulation comprises a benzisoxazole derivative and a liquid carrier. Also disclosed are methods of making and using such dosage forms.... Agent: Philip S. Johnson Johnson & Johnson

20070026066 - Oral pharmaceutical delivery system with improved sustained release: A solid orally ingested delivery system having at least one lipid, dry particles including at least one pharmaceutical, and at least one filler, where the dry particles are continuously coated by the lipid and form a homogeneous suspension with the lipid, and at least part of the pharmaceutical is microencapsulated... Agent: Greensfelder Hemker & Gale PC

20070026065 - Solid, modified-release pharmaceutical dosage forms which can be administered orally: The present invention relates to solid, modified-release pharmaceutical dosage forms which can be administered orally and comprise 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide, and process for their production, their use as medicaments, their use for the prophylaxis, secondary prophylaxis and/or treatment of disorders, and their use for producing a medicament for the prophylaxis, secondary prophylaxis... Agent: Jeffrey M. Greenman

20070026068 - Compartmentalized dosage form: The present invention provides a dosage form that prevents misuse of the medicament contained within. The dosage form contains an inactivating substance in combination with the medicament, wherein the two substances are separated by a permeable or semi-permeable partition. The partition becomes impermeable upon activation by a medical professional, thereby... Agent: Darby & Darby P.C.

20070026073 - Amorphous efavirenz and the production thereof: Efavirenz compositions of enhanced bioavailability are described that contain efavirenz with at least one solubility-enhancing polymer. Described methods to produce the bioenhanced products comprise solvent spray drying. One aspect of the method includes the steps of providing a mixture comprising efavirenz, a solubility-enhancing polymer and a single solvent, a solvent... Agent: International Specialty Products Attn: William J. Davis, Esq.

20070026072 - Benzoquinones of enhanced bioavailability: Benzoquinone compositions of enhanced solubility and bioavailability are described that contain at least one benzoquinone with at least one solubility-enhancing polymer. In one embodiment, the benzoquinone is coenzyme Q1O. Described methods to produce the bioenhanced products comprise dry blending and solvent spray drying. One aspect of the method includes the... Agent: International Specialty Products Attn: William J. Davis, Esq.

20070026069 - Biommetic hierarchies using functionalized nanoparticles as building blocks: The invention provides a three-dimensional construct including a polymeric matrix and a nanoparticle as shown in FIG. 1 having a diameter of about 5 nm to about 10 microns, wherein the nanoparticle is (a) coated with at least two monomolecular layers each carrying biological information and (b) dispersed in the... Agent: Ratnerprestia

20070026070 - Cross-linked polysaccharide composition: The present invention provides a process for making cross-linked polysaccharide gels under basic conditions. More particularly, the present invention provides a process for forming cross-linked hyaluronic acid gels under basic conditions. The resulting gels possess improved degradation characteristics, and are useful in a variety of medical and cosmetic applications.... Agent: Knobbe Martens Olson & Bear LLP

20070026071 - Magnesium salt proton pump inhibitor dosage forms: The present invention concerns oral dosage formulations of sparingly to very slightly water soluble proton pump inhibitors, the oral dosage forms so made, and methods of use thereof. The oral dosage form has a core tablet of compressed particles composed of powder particles of a pharmaceutically acceptable material, having coated... Agent: Richard S. Roberts Roberts & Roberts, L.L.P.

20070026075 - Gelled donepezil compositions and methods for making and using the same: Gelled donepezil compositions and methods for making and using the same are provided. The subject compositions include a donepezil active agent in a gelled oral pharmaceutically acceptable vehicle comprising an emulsion of water and oil. Also provided are kits of the subject compositions.... Agent: Bozicevic, Field & Francis LLP

20070026074 - Vaginal treatment composition: A vaginal treatment composition that rapidly forms a gel when placed into contact with monovalent or polyvalent cations, such as sodium (Na+) and calcium (Ca2+) cations naturally found in vaginal mucosa, is provided. The gel may form in less than about 1 hour, in some embodiments less than about 1... Agent: Dority & Manning, P.A.

20070026079 - Intranasal administration of modulators of hypothalamic atp-sensitive potassium channels: Provided are methods of increasing KATP channel activity in the hypothalamus of a mammal, methods of reducing glucose production in a mammal, methods of reducing peripheral glucose levels in a mammal, methods of reducing triglyceride levels in a mammal, methods of reducing very low density lipoprotein (VLDL) levels in a... Agent: Myers Bigel Sibley & Sajovec

20070026080 - Manufacturing process for tigecycline: Disclosed herein is a manufacturing process for the preparation of tigecycline suitable for intravenous infusion.... Agent: Wyeth Patent Law Group

20070026077 - Method of producing dosage units of a solid drug form containing warfarin sodium salt as active component: The invention relates to a method of producing dosage units of a solid drug form containing as the active substance warfarin sodium salt in an amount of 1 to 10 mg and having high degree of content uniformity satisfying the Bergum criterion, wherein an aqueous solution of warfarin sodium salt... Agent: Buchanan, Ingersoll & Rooney PC

20070026081 - Microparticles: Microparticles comprising or consisting of a therapeutic agent having a particle density of at least 80% of the solid agent and a shape factor of 1 to 5. The microparticles may be produced by spray drying and may be used in needleless injection.... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070026076 - Molecular vaccines employing nucleic acid encoding anti-apoptotic proteins: T cell immune responses are enhanced by presentation of antigen to CD8+ T cells using a chimeric nucleic acid immunogen or vaccine that links DNA encoding an antigen with DNA encoding a polypeptide that targets or translocates the antigenic polypeptide to which it is fused (immunogenicity-potentiating polypeptides or “IPP”). By... Agent: Mckenna Long & Aldridge LLP

20070026078 - Pharmaceutical co-crystal compositions: A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide,... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070026083 - Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced: A method for preparing solid materials is described. One aspect of the method includes the steps of providing a mixture comprising an organic material in a blend of a solvent and non-solvent for the organic material, distributing the mixture into either droplets or granules, and evaporating the solvent and non-solvent... Agent: International Specialty Products Attn: William J. Davis, Esq.

20070026082 - Multiparticle pharmaceutical dosage form containing a mucoadhesively formulated peptide or protein active substances method for producing said pharmaceutical dosage form: The invention relates to an oral, multiparticle pharmaceutical dosage form containing pellets, the size of which ranges from 50 to 2500 μm and which essentially consist of: a) an inner matrix layer containing an active substance which is a peptide or a protein, including the derivatives or conjugates thereof, and... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070026084 - Deer antler extract for promoting angiogenesis: An isolated extract of deer velvet which contains components which have molecular weights that are substantially less than or equal to 10 kDa and which have a proliferative effect on endothelial cells and/or promote angiogenesis.... Agent: Knobbe Martens Olson & Bear LLP

20070026085 - Antimicrobial and antiviral composition: An antimicrobial and antiviral barrier composition for topical application to the proximal anterior nares includes an antiseptic solution in combination with cocos nucifera (coconut oil) and one or more citrus oils such as, for example, citrus sinensis (orange oil). Various embodiments may also include one or more of the following... Agent: Robert M. Downey, P.A.

20070026086 - Method for the isolation of biogically active substances from dairy by-product or waste flows, and biologically active substances obtained therefrom: The present invention relates to method for the isolation of at least one biologically active substance from an industrial dairy by-product or waste flow, comprising—selecting at least one industrial dairy waste or by-product flow containing at least one biologically active substance;—bringing the at least one industrial dairy waste or by-product... Agent: Hoffmann & Baron, LLP

20070026087 - Anti-coronavirus agent: e

20070026088 - Pharmaceutical antidiabetic composition: An antidiabetic composition embodied in the form of a powder extracted from hardened antlers. The powdered extract contains 0.5 ng of insulin and insulin-like growth factor-I in the quantity of 18 ng per 1 g of the composition.... Agent: Smith Hopen, Pa

20070026089 - Touch screen with bacteria inhibition layer and manufacturing method thereof: The present invention is to provide a touch screen having a bacteria inhibition layer for prohibiting bacteria from growing thereon and a method for manufacturing the same comprising uniformly dispersing particles of nano metal material in a solution to be applied to a surface treatment so that the solution can... Agent: Bacon & Thomas, PLLC

20070026090 - Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium: The present invention is of a method for reducing activity of inflammatory immune cells by exposure to selenium. Particularly, the invention relates to a method of short-term, high dose dietary selenium supplementation for treating a subject having an inflammatory disease, particularly inflammatory bowel disease (IBD). An article of manufacture comprising... Agent: Martin D Moynihan Prtsi Inc

20070026091 - Preparation and administration of jojoba product for reducing weight, fat and blood lipid levels and for the prevention and treatment of cancer: A method of orally administering jojoba for fat reduction, blood lipid reduction, and cancer prevention and treatment in humans is disclosed. The method incorporates a sufficient quantity of jojoba, defatted jojoba meal, jojoba extract, defatted jojoba meal extract, naturally derived or synthesized simmondsin, or any naturally derived or synthesized simmondsin... Agent: Quarles & Brady LLP

20070026092 - Supercritical carbon dioxide extract of pharmacologically active components from nerium oleander: A method for the extraction of pharmacologically active components from the oleander plant using supercritical carbon dioxide and combining the extraction with other isolation methods. The extraction is carried out using carbon dioxide at supercritical conditions, with or without the addition of a modifier. The isolated product is recovered in... Agent: Jackson Walker LLP